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Voltage-gated Na+ channels (VGSCs) initiate and propagate action potentials in 
neurones. Functional VGSCs have been found in an increasing number of cancer cells 
and patient biopsies from different tissues. Blocking VGSCs using pharmacological 
agents or suppressing VGSC expression using RNA interference reduces cell 
metastatic behaviour, such as migration and invasion in vitro and metastasis in vivo in 
rodent models. In breast cancer, a high mRNA level of Nav1.5, a VGSC isoform, 
correlates with metastasis and poor prognosis. However, the detailed mechanism(s) 
underlying VGSC-dependent metastatic cell behaviours is not fully understood. 
Depolarised membrane potential (Vm) induces mitotic activity in neurones and 
causes tumourigenesis in Xenopus laevis. Given that VGSCs depolarise the Vm upon 
action potential firing in neurones, using MDA-MB-231 human breast cancer cells 
where VGSCs are endogenously expressed, the present study hypothesised that 
VGSCs increase cell metastatic behaviours by depolarising the Vm. 
This study found that VGSCs depolarise the Vm of MDA-MB-231 cells by ~4 mV. 
Hyperpolarising the Vm by blocking VGSCs with tetrodotoxin (TTX) or activating large 
conductance Ca2+-activated K+ channels using NS-1619 slowed cell migration to a 
similar extent. Rac1 is a small GTPase that potentiates cell migration via facilitating 
actin filament assembly. Both TTX and NS-1619 reduced the active Rac1 level at the 
leading edge of cells, suggesting that Vm controls Rac1 activity/distribution and 
henceforth cell motility in MDA-MB-231 cells. However, MDA-MB-231 cell invasion was 
inhibited by TTX but not NS-1619, suggesting that Na+, rather than Vm, may be the 
factor that underlies VGSC-dependent cell invasion. Finally, this study recorded Na+ 
current carried by VGSCs in tumour cells in tissue slices from mice, suggesting that 
VGSCs are functional in vivo. In summary, the present study provides novel evidence 
elucidating mechanisms underlying VGSC-dependent metastatic cell behaviours. 
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1 Chapter 1: General Introduction 
1.1 The discovery of voltage-gated Na+ channels  
In 1952, during their research on the squid giant axon, Hodgkin and Huxley 
demonstrated that the electrical signals in nerve arise from the activation of a voltage-
dependent Na+ current (INa) at the axon membrane that transports INa into the cell 
(Hodgkin & Huxley, 1952a, b, c, d). The fast inward INa inactivates within 2 ms, and is 
replaced by a voltage-dependent, outward K+ current (IK) that brings the membrane to its 
electrically resting state (Hodgkin & Huxley, 1952a, b). INa and IK result in the all-or-none 
nervous response called the action potential (Hodgkin, 1939; Hodgkin & Huxley, 1952d). 
Not only did their seminal work demonstrate the powerfulness of the voltage-clamp 
technique, which controls the voltage across the cell membrane and measures the 
membrane current (Hodgkin et al., 1952), but it also established the foundation of 
research into electrical signals in modern physiology and neuroscience. 
Together with the first successful intracellular recording of an action potential in the 
giant squid axon, Hodgkin, along with Cole & Curtis’ work implied the existence of 
specialised machineries, later known as ion channels, at the cell membrane that permit 
the increased permeability of Na+ and K+ ions (Hodgkin, 1937; Cole & Curtis, 1939; Cole 
& Hodgkin, 1939). In the 1960s, researchers began to probe the structure of voltage-
gated Na+ channels (VGSCs) by identifying their binding sites with tetrodotoxin (TTX) 
and saxitoxin (STX) (Kao & Nishiyama, 1965; Camougis et al., 1967; Hille, 1968), both 
selective VGSC blockers (Buchwald et al., 1964). In the 1970s, solubilisation and 
purification of VGSCs labelled with TTX or STX was developed (Ritchie & Rogart, 
1977a), which heralded the purification of the VGSC protein in 1980 from scorpion toxin-
labelled N18 neuroblastoma cells (Beneski & Catterall, 1980). Along with a later study, 
which demonstrated a partial purification of a TTX-binding protein from electric eel 




later known as the VGSC α subunit. Two smaller β subunits, namely β1 (36 kDa) and β2 
(33 kDa), were discovered thereafter (Hartshorne et al., 1982). In the 2000s, a splice 
variant of β1, β1B, was reported (Kazen-Gillespie et al., 2000; Qin et al., 2003), and β3 
and β4 were also identified (Morgan et al., 2000; Yu et al., 2003). Recently, the crystal 
structures of bacterial VGSC proteins from Arcobacter butzleri at 2.7–3.2 Å resolution 
(Payandeh et al., 2011; Payandeh et al., 2012), Alphaproteobacterium HIMB114 at 3.05 
Å resolution (Zhang et al., 2012) and Magnetococcus sp. marinus at 4.0 Å resolution 
(McCusker et al., 2012) were solved. 
In mammals, VGSCs are protein complexes that consist of one pore-forming α 
subunit covalently or non-covalently linked with one or more β subunits (Catterall, 2000; 
Isom, 2002; Brackenbury & Isom, 2011). 
 
1.2 VGSC α subunits 
To date, 10 VGSC α subunit proteins, Nav1.1–Nav1.9 and NaX, have been 
identified in humans, and they are encoded by ten different genes (SCN1A–SCN11A, 
Table 1.1) (Goldin, 2001; Catterall, 2012). The α subunits have distinct expression 
profiles in human tissues and show different sensitivity to blockage by TTX (Table 1.1) 
(Offermanns & Rosenthal, 2008; Catterall, 2012). 
 
1.2.1 The structure of VGSC α subunit 
The VGSC α subunit is a transmembrane homotetramer. Each of the four domains 
(I–IV) has six transmembrane segments (S1–S6, Figure 1.1) (Noda et al., 1984). The 
central pore-forming area consists of four S5–S6 segments and their re-entrant pore 
loops (Payandeh et al., 2011), surrounded by the symmetrically distributed S1–S4 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1.1. The structure of the voltage-gated Na+ channel (VGSC).  
The VGSC α subunit contains four domains each with six transmembrane segments. 
Segment 4 (yellow) is the voltage sensor. The inactivation loop between domain III and 
IV is highlighted in red. The drug binding sites at the α subunit are shown (Cestele & 
Catterall, 2000). All VGSC β subunits contain an immunoglobulin (Ig) loop. β1–β4 are 
transmembrane proteins, whereas β1B is a secreted protein (Isom, 2002). There are 
various phosphorylation sites on both the α and β subunits. The binding sites for annexin 
II light chain (p11) (Okuse et al., 2002), ankiryn G (Lemaillet et al., 2003), multicopy 
suppressor of Gsp1 (MOG1) (Wu et al., 2008), Nedd-4 (van Bemmelen et al., 2004), 
syntrophin (Gee et al., 1998), dystrophin (Gee et al., 1998) and protein tyrosine 
phosphatase 1 (PTPH1) (Jespersen et al., 2006) are shown. EF: EF-hand motif. IFM: 
isoleucine-phenylalanine-methionine motif. IQ: isoleucine-glutamine domain. Ѱ: 




to Li+, but 12-fold greater than K+ and many organic cations (Hille, 1971, 1972), and the 
selective Na+ transportation is mediated by the ion selectivity filter formed by the side 
chains of four highly conserved glutamic acid residues on the S1–S2 loop (Heinemann 
et al., 1992; Payandeh et al., 2011). When Na+ with planar waters of hydration approach 
the ion selectivity filter, the negatively charged glutamic acid residues interact with Na+ 
and partially remove its water of hydration. Na+ is hydrated while being transported 
through the pore and interacts with other bound water at the inner shell of the pore 
(Payandeh et al., 2011). Interestingly, in spite of the high degree of structural similarity 
between VGSCs and voltage-gated K+ channels (VGPCs), this mechanism is distinct 
from K+ transportation through VGPCs, in which K+ ions are deprived of water of 
hydration when passing through the channel (Zhou et al., 2001).  
 
1.2.2 Activation and inactivation of VGSC α subunits 
The opening of VGSCs requires a small transmembrane capacitive current (“gating 
current”) carried by “gating charges” (Hodgkin & Huxley, 1952d; Armstrong & Bezanilla, 
1973; Hirschberg et al., 1995). It is now known that the positively charged arginine 
residues at the VGSC S4 segment serve as the gating charges (Bezanilla, 2000; 
Catterall, 2000). When VGSCs are in their resting state, the gating charges are 
electrically neutralised by negatively charged residues in the S2 and S3 segments. Upon 
membrane potential (Vm) depolarisation (i.e. the transmembrane voltage becomes less 
negative, in contrast to Vm hyperpolarisation where the voltage becomes more negative), 
the S4 segment moves towards the extracellular side by rotating, a conformation change 
that leads to the opening of the pore (Yang & Horn, 1995; Yang et al., 1996; Bezanilla, 
2000; Groome, 2014). This allows the fast influx of Na+ within a few milliseconds upon 
channel activation, leading to a fast inward INa.  
Following activation, VGSCs undergo fast inactivation, and thus the inward INa is 




loop between domain III and IV is the key element during fast inactivation (Vassilev et 
al., 1988; Vassilev et al., 1989). The detailed structure of the inactivation loop was later 
probed by nuclear magnetic resonance (NMR) (Rohl et al., 1999). It is proposed that the 
loop contains an α-helix followed by a key hydrophobic sequence containing isoleucine-
phenylalanine-methionine (the IFM motif, Figure 1.1, which can fold at a pair of glycine 
residues and plug to the inner mouth of the pore (West et al., 1992; Kellenberger et al., 
1996; Kellenberger et al., 1997a; Kellenberger et al., 1997b; Rohl et al., 1999). After fast 
channel inactivation, before the channel reaches full inactivation state, a small amount of 
Na+ is still able to flow through the pore. This phenomenon results in a small INa, namely 
persistent INa, whose size comprises only a small percentage of the peak transient INa. 
However, persistent INa does not fully inactivate and can last for hundreds of milliseconds 
(Stafstrom, 2011). In neurones, persistent INa extends the duration of Vm depolarisation 
and together with other types of Vm-depolarising currents, persistent INa can mediate 
sustained neuronal excitability by lowering the threshold of action potential generation 
and therefore support repetitive firing (Stafstrom et al., 1985; French et al., 1990; Beck & 
Yaari, 2008).  
 
1.2.3 Toxin-binding sites on VGSC α subunits 
Many neurotoxins and synthetic compounds can bind to a number of sites on the 
VGSC α subunit and thus modify channel activity. So far, six neurotoxin binding sites 
have been identified (Table 1.2) and these have contributed greatly to the identification 
of VGSC structure-function relationships since the 1970s (Hille, 1975; Cestele & 
Catterall, 2000).  
The binding site of TTX, STX and μ-conotoxin is called site 1 (Figure 1.1). These 
neurotoxins exhibit extracellular pore-blocking mechanism (Hille, 1968), because they 
bind to the re-entrant loop between S5 and S6 where the mouth of the pore is formed 





   
Table 1.2. The neurotoxin binding sites on the voltage-gated Na+ channel α subunit 
Binding site Locations Neurotoxins References 
Site 1 Domain I, II, III and IV S5-S6 TTX, STX, μ-conotoxin 
(Noda et al., 1989; 
Terlau et al., 1991) 
Site 2 Domain I and IV S6 Veratridine, batrachotoxin 
(Ulbricht, 1969; 
Catterall, 1977; 
Ragsdale et al., 1994, 
1996) 
Site 3 Domain I and IV S3-S4 α scorpion toxins, sea-anemone toxins 
(Catterall & Beress, 
1978; Rogers et al., 
1996) 
Site 4 Domain II S1-S2 and S3-S4 β scorpion toxins (Cestele et al., 1998) 
Site 5 Domain I S6, domain IV S5 Brevetoxins and ciguatoxins 
(Benoit et al., 1986; 
Lombet et al., 1987; 
Trainer et al., 1994) 
Site 6 Unknown TxVIA (Hasson et al., 1993) 




extracellular Na+ entry to the pore and therefore reduce Na+ conductance (Narahashi et 
al., 1964; Hille, 1968). It is suggested μ-conotoxin shares an overlapping but not 
identical binding region with TTX and STX. Additional extracellular residues at the S5–
S6 segment in domain II are required for μ-conotoxin binding (Chahine et al., 1998). 
VGSC isoforms show different binding affinity with neurotoxins that bind to site 1. For 
example, Nav1.1–1.4, 1.6 and 1.7 can be blocked by TTX in the nanomolar range, 
whereas Nav1.5, 1.8 and 1.9 are sensitive to TTX at micromolar concentrations (Table 
1.1) (Goldin, 2001). 
Neurotoxin binding site 2 is in the intramembrane region comprising S6 in both 
domain I and IV. Site 2-binding drugs such as veratridine and batrachotoxin have higher 
affinity for activated VGSCs and cause sustained channel activation, meanwhile shifting 
the voltage-dependence of activation to a more negative potential (Ulbricht, 1969; 
Albuquerque et al., 1971). These effects are achieved by allosteric modulation of the 
channel, shifting the channel conformational equilibrium to the activated state (Catterall, 
1977, 1980). It is proposed that the antiepileptic and anticonvulsant drug phenytoin also 
binds to this region (Ragsdale et al., 1994, 1996). 
α scorpion toxins and sea-anemone toxins (ATX) bind to an extracellular region 
between S3 and S4 in domain IV, and this site is known as neurotoxin binding site 3 
(Catterall & Beress, 1978; Rogers et al., 1996). Because the S4 segments are voltage 
sensors, it is proposed that α scorpion toxins and ATX inhibit conformational changes 
during the fast inactivation stage by restricting the movement of the S4 segment in 
domain IV (Rogers et al., 1996), and therefore keeping VGSCs in their activated state. 
β scorpion toxins act on the neurotoxin-binding site 4 in the S1–S2 and S3–S4 
loops in domain II (Cestele et al., 1998). By binding to the voltage sensor extracellular 
domain, β scorpion toxins restrict the movement of the S4 segment in domain II and 




activation and a negative shift in the voltage-dependence of activation (Cestele et al., 
1998; Cestele & Catterall, 2000). 
Similar to site 2, neurotoxin binding site 5 is also a transmembrane region at S6 in 
domain I plus S5 in domain IV, and its binding toxins include lipid-soluble brevetoxins 
and ciguatoxins (Benoit et al., 1986; Lombet et al., 1987; Trainer et al., 1994). As with 
site 2-binding compounds, these toxins block the inactivation of the channel and result in 
a negative shift in the voltage-dependence of activation (Huang et al., 1984; Benoit et 
al., 1986). 
The location of neurotoxin binding site 6 is as yet unknown. A site-6-binding toxin 
isolated from the venom of the cone snail Conus textile, TxVIA, increases action 
potential duration by inhibiting VGSC inactivation (Hasson et al., 1993). 
 
1.2.4 Localisation of VGSC α subunits in excitable cells 
Different α subunit isoforms show significant diversity in tissue-specific expression 
(Table 1.1). In humans, Nav1.1, Nav1.2, Nav1.3 and Nav1.6 are widely expressed in the 
central nervous system (CNS) (Lu et al., 1992; Malo et al., 1994a; Malo et al., 1994b; 
Plummer et al., 1997), whereas the most abundant α subunits in dorsal root ganglion 
(DRG) neurones in the peripheral nervous system (PNS) are Nav1.7, Nav1.8 and Nav1.9 
(Klugbauer et al., 1995; Rabert et al., 1998; Dib-Hajj et al., 1999a; Dib-Hajj et al., 1999b; 
Jeong et al., 2000). Nav1.4 is mainly localised in skeletal muscle (George et al., 1991; 
Wang et al., 1992a), whereas Nav1.5 is present mainly in the heart (Gellens et al., 1992; 
George et al., 1995). Finally, NaX has been found abundantly in uterus muscle, heart 
(George et al., 1992) and hippocampus (Gorter et al., 2010), where it may contribute to 
Na+ sensing (Shimizu et al., 2007). 
VGSC α subunits also have dynamic expression profiles during development 
(Waxman, 2000). For example, in rats, the level of Nav1.3 in the CNS peaks at birth and 




adulthood, Nav1.1, Nav1.2 and Nav1.6 become the major VGSCs in the CNS (Beckh et 
al., 1989; Brysch et al., 1991; Waxman et al., 1994; Felts et al., 1997; Schaller & 
Caldwell, 2000). During postnatal development, Nav1.2 is replaced by Nav1.6 following 
myelination and formation of nodes of Ranvier (Westenbroek et al., 1989; Boiko et al., 
2001; Kaplan et al., 2001). In addition, in rats, Nav1.5 is expressed in neonatal but not 
adult skeletal muscle (Kallen et al., 1990). Furthermore, genes encoding VGSC α 
subunits show alternative splicing during development (Copley, 2004; Diss et al., 2004). 
For example, alternative splicing of two exons encoding the domain I segment 3 (DI:S3) 
region is responsible for expression of either “adult” and “neonatal” isoforms of Nav1.2 
(Sarao et al., 1991), Nav1.3 (Gustafson et al., 1993; Lu & Brown, 1998), Nav1.5 (Diss et 
al., 2001), Nav1.6 (Plummer et al., 1997) and Nav1.7 (Belcher et al., 1995). 
Immunocytochemistry and electron microscopy have demonstrated specific 
subcellular localisations of α subunit isoforms. At rat nodes of Ranvier, VGSCs are 
clustered at > 103/μm2 (Quick & Waxman, 1977; Ritchie & Rogart, 1977a; Waxman, 
2000). This is in sharp contrast to the density of VGSCs in the internodal axon 
membrane, which is < 25/μm2 (Ritchie & Rogart, 1977b; Shrager, 1989). In rat 
hippocampal neurones, Nav1.1 is highly expressed in the cell bodies, whereas Nav1.2 is 
observed mainly in the axons (Gong et al., 1999). In mouse cortical pyramidal neurones, 
a computation model estimated a high VGSC density that gives a conductance of ~2500 
pS/μm2, which is ~50 times of that in the proximal dendrites (Kole et al., 2008). 
 
1.2.5 Localisation and function of VGSC α subunits in non-excitable cells 
The localisation of VGSCs is not restricted to the so-called “excitable cells” in the 
CNS/PNS, heart and skeletal muscle. Over the past four decades, VGSCs have also 
been found in “non-excitable” cells (Table 1.3) (Black & Waxman, 2013). The expression 
of VGSCs in these cells contributes to their cellular functionality: inhibiting VGSC α 




Table 1.3. The expression and function of voltage-gated Na+ channel (VGSC) α 
subunits in non-excitable, non-cancerous cell types 
Cell type 
Type of VGSC α 
subunit or Na+ 
current 
expressed 
Effects upon VGSC 
blockade with TTX References 
Astrocytes Nav1.2, 1.3, 1.5 and 1.6 
Reduced Na+/K+-ATPase 
activity and increased 
cell death 
(Sontheimer et al., 
1994) 
Chrondrocytes TTX-sensitive Unknown (Sugimoto et al., 1996) 
Dendritic cells 
(CD1a+) Nav1.7 
Inhibited cell migration; 
attenuated secretion; 
sensitised cells for 
activation 
(Kis-Toth et al., 2011) 




(Traub et al., 1999) 
Fibroblasts Nav1.2, 1.3, 1.5, 1.6 and 1.7 Unknown 
(Chatelier et al., 
2012) 
Keratinocytes Nav1.1, 1.6 and 1.8 Inhibited ATP release (Zhao et al., 2008) 
Islet β-cells Nav1.2 and 1.3 Reduced insulin release 
(Donatsch et al., 
1977; Pressel & 
Misler, 1991) 
Macrophages Nav1.5 and 1.6 
Attenuated phagocytosis 
and invasion; reduced 
podosome formation 
(Carrithers et al., 
2007; Black et al., 
2009; Carrithers et 
al., 2009) 
Microglia Nav1.1, 1.5 and 1.6 
Reduced cell migration, 
phagocytosis and 
cytokine release 
(Black et al., 2009) 
Odontoblasts Nav1.2 
Reduced transmission of 




TTX-sensitive Reduced ligand-induced migration (Tong et al., 2009) 
Osteoblasts Nav1.2 Unknown (Black et al., 1995) 
Red blood cells Nav1.4 and 1.7 Unknown (Hoffman et al., 2004) 
Retinal glial cells Nav1.6 
Reduced ligand-induced 
glutamate release (Linnertz et al., 2011) 
Schwann cells Nav1.2 and 1.3 Unknown (Oh et al., 1994) 
T lymphocytes Nav1.5 
Inhibited cell migration; 
prevention of the positive 
selection of CD4+ T cells 
(Fraser et al., 2004; 
Lo et al., 2012) 






(Craner et al., 2005; Black et al., 2009; Pappalardo et al., 2014a; Pappalardo et al., 
2014b) and NG2+ oligodendrocyte precursor cells (Tong et al., 2009). TTX also reduces 
the invasiveness of macrophages (Carrithers et al., 2007; Carrithers et al., 2009), T 
lymphocytes (Fraser et al., 2004) and cancer cells (Section 1.4). Nav1.5 contributes to 
CD4+ CD8+ double-positive selection of thymocytes by causing a sustained Ca2+ influx 
(Lo et al., 2012). In certain cell types, VGSCs also play a role in secretion: blocking 
Nav1.7 with TTX in CD1a+ dendritic cells reduces the release of tumour necrosis factor 
(TNF)-α and interleukin (IL)-10 from these cells (Kis-Toth et al., 2011). Additionally, TTX 
reduces IL-1α, IL-1β and TNF-α release in microglia (Black et al., 2009). In pancreatic 
islet β-cells, TTX attenuates insulin release (Donatsch et al., 1977; Pressel & Misler, 
1991). TTX-mediated blockage of Nav1.6 in retinal glial cells reduces ligand-induced 
release of glutamate (Linnertz et al., 2011). Moreover, TTX application inhibits 
subcutaneous ATP release in keratinocytes (Zhao et al., 2008). Reduced levels of 
phagocytosis have been reported in TTX-treated macrophages and microglia (Carrithers 
et al., 2007; Black et al., 2009; Carrithers et al., 2009). Furthermore, TTX reduces 
Na+/K+-ATPase activity and increases cell death in astrocytes (Sontheimer et al., 1994). 
Finally, an increased activation of the shear-stress-induced extracellular signal-regulated 
kinase (ERK) 1/2 has been reported in TTX-treated endothelial cells (Traub et al., 1999). 
 
1.2.6 Regulation of VGSC α subunits 
VGSC α subunits are subject to post-translational modifications. Soon after their 
purification, researchers found out that the VGSC α subunits can be phosphorylated by 
both cAMP-dependent protein kinase (PKA) (Costa et al., 1982; Costa & Catterall, 
1984a) and protein kinase C (PKC) (Costa & Catterall, 1984b). Protein sequencing of rat 
Nav1.2 has demonstrated that PKA phosphorylates on four serine residues (S573, S610, 
S623 and S687) in the intracellular loop between domain I and II (Murphy et al., 1993), 




same intracellular loop, and S1506 in the inactivation loop between domain III and IV 
(Figure 1.1) (Numann et al., 1991; Schreibmayer et al., 1991; West et al., 1991). The 
dephosphorylation of VGSC α subunits in rat brain neurones is mediated by calcineurin, 
a Ca2+-regulated phosphatase also known as phosphatase 2B, and phosphatase 1A or 
2A (Murphy et al., 1993; Chen et al., 1995). Additionally, VGSCs in rat brain neurones 
are tyrosine phosphorylated and are modulated by association with the catalytic domain 
of receptor protein kinase tyrosine phosphatase β (RPTPβ) (Ratcliffe et al., 2000). 
The activation of PKA reduces INa in Nav1.2-expressing Xenopus oocytes and 
human embryonic kidney (HEK) 293 cells (Smith & Goldin, 1996; Cantrell et al., 1997). 
Phosphorylation by PKC also reduces VGSC activity in Chinese hamster ovary (CHO) 
cells (Numann et al., 1991) and Xenopus oocytes expressing Nav1.2 (Dascal & Lotan, 
1991; Schreibmayer et al., 1991). Neither PKA nor PKC modulation changes the 
voltage-dependence of activation or kinetics in these cell models. The reduction of peak 
INa caused by PKA phosphorylation is because VGSCs are shifted to a “null gating 
mode” in which the channels have lower probability of transiting to the open state upon 
Vm depolarisation (Li et al., 1992; Cantrell & Catterall, 2001). On the other hand, COS-7 
cells that were transfected with mouse Nav1.8 bearing mutated PKA phosphorylation 
sites at the domain I–II intracellular loop show a depolarised shift in the voltage-
dependence of activation compared with those transfected with normal mouse Nav1.8 
(Fitzgerald et al., 1999). In rat sensory neurones, activating PKA or PKC increases peak 
INa, and rather than modulating the channel directly, PKC enables subsequent PKA-
mediated VGSC modulation (Gold et al., 1998). Both the PKA- and PKC-mediated 
VGSC modulations show functional effects in the nervous system. For example, D1 G-
protein-coupled dopamine receptors reduce peak INa and therefore increase the 
threshold for action potential firing via PKA-dependent phosphorylation of VGSCs 
(Surmeier & Kitai, 1997). In rat pyramidal neurones, muscarinic receptor activation slows 




duration of action potentials, reducing the action potential firing frequency (Azouz et al., 
1994; Alroy et al., 1999). 
VGSC α subunits expressed in various mammalian cell models are also modulated 
by Ca2+ (Young & Caldwell, 2005; Van Petegem et al., 2012; Gabelli et al., 2015). Ca2+ 
directly regulates VGSCs by interacting with the EF-hand-like motifs in the C-terminus of 
the α subunit (Figure 1.1). The EF-hand-like motifs in different VGSC α subunit isoforms 
consist of overlapping, but not identical, residues: NMR data have demonstrated that 
Nav1.5 residues 1788–1862 fold into the motifs (Chagot et al., 2009), whereas in Nav1.2 
the responsible residues span from 1777 to 1882 (Miloushev et al., 2009). In addition, 
Ca2+ can indirectly modulate VGSCs by binding to calmodulin (CaM) (Deschenes et al., 
2002; Sarhan et al., 2009; Sarhan et al., 2012; Gabelli et al., 2014; Gabelli et al., 2015). 
CaM is a 17 kDa protein that can bind up to four Ca2+ ions with its four EF-hand motifs 
(Chou et al., 2001). CaM binds to VGSC α subunits at the isoleucine-glutamine (IQ) 
domains of the C-terminus (Herzog et al., 2003; Biswas et al., 2008; Sarhan et al., 
2012). Experiments using Nav1.5 have shown that the increased intracellular Ca2+ 
results in a ~10 mV depolarising shift in the steady-state inactivation relationship (Tan et 
al., 2002; Wingo et al., 2004; Biswas et al., 2009). 
The α subunits possess glycosylation sites located in the extracellular loop 
between S5 and S6 in domain I (Figure 1.1) (Bennett, 2002). In neuroblastoma cells in 
which endogenous VGSCs are expressed, inhibition of glycosylation reduced the 
number of α subunits at the cell surface (Waechter et al., 1983). The removal of 
glycosylation in Nav1.4 caused a depolarising shift in the voltage-dependence of 
activation and steady-state inactivation (Bennett et al., 1997). However, for Nav1.5, a 
depolarising shift was observed in activation and a hyperpolarising shift in inactivation 
(Zhang et al., 2003), suggesting that glycosylation has different effects on individual 




In tsA-201 cells, co-expression of Nav1.2 with βγ subunits of G proteins (Gβγ) 
causes a hyperpolarising shift in the voltage-dependence of activation and steady-state 
inactivation (Ma et al., 1997). Gβγ also increases persistent INa, which therefore enhances 
neuronal excitability (Ma et al., 1997). Furthermore, for Nav1.8, annexin II light chain 
(p11) binds to the N-terminus of the channel and facilitates translocation to the plasma 
membrane (Okuse et al., 2002). In rat Nav1.2, a 9-amino acid motif at the intracellular 
loop between domain II and III (loop 2) is required for binding to ankyrin G (Lemaillet et 
al., 2003), which is necessary for the retention of the neurofascin/Nav1.2 loop 2 chimeric 
molecule at the axon initial segment (AIS) in cultured hippocampal neurones (Lemaillet 
et al., 2003). Multicopy suppressor of Gsp1 (MOG1) binds to the loop 2 of Nav1.5 (Wu et 
al., 2008). Overexpression of MOG1 increases the expression of Nav1.5 at the cell 
surface of neonatal cardiomyocytes, which leads to increased INa density (Wu et al., 
2008).  
The C-terminus of Nav1.5 also contains a binding site for Nedd4/Nedd4-like 
ubiquitin-protein ligases, where Nedd4-2-dependent Nav1.5 ubiquitination in heart 
extracts and transfected HEK cells was observed (van Bemmelen et al., 2004). Nedd4-2 
does not alter the kinetics of Nav1.5 in HEK cells but results in a reduced Nav1.5 
localisation at the cell membrane and therefore a decrease in INa density (van Bemmelen 
et al., 2004). The C-terminus of rat Nav1.4 and brain VGSCs also contains the binding 
sites for syntrophin and dystrophin, which links VGSCs to the cytoskeleton and the 
extracellular matrix via dystrophin-associated protein complex (DAPC) (Gee et al., 
1998). Cardiomyocytes from dystrophin-deficient mice have reduced INa, suggesting the 
requirement of DAPC in maintaining the proper function of Nav1.5 (Gavillet et al., 2006). 
The interaction between Nav1.5 and protein tyrosine phosphatase 1 (PTPH1) is also 
found at the C-terminus of the channel (Jespersen et al., 2006). Co-expression of Nav1.5 




(Jespersen et al., 2006). Finally, the auxiliary VGSC β subunits also play an important 
role in modulating the activity of α subunits (Section 1.3.5). 
 
1.2.7 VGSC α subunits and channelopathies 
Mutations in VGSC α subunits lead to a number of diseases (channelopathies), in 
part due to alterations of the structure and/or the biophysical properties of the channel 
(Table 1.1) (Mantegazza et al., 2010a; Mantegazza et al., 2010b; Mantegazza & 
Catterall, 2012). To begin with, SCN1A missense mutations result in channel loss of 
function due to folding defects in the protein (Mantegazza et al., 2010a). SCN1A 
mutations cause various types of epilepsy, including febrile epilepsy, Dravet syndrome 
and generalised epilepsy with febrile seizure plus (GEFS+) (Escayg et al., 2000; Claes 
et al., 2001; Spampanato et al., 2001; Lossin et al., 2002). In addition, a group of 
patients with benign familial neonatal-infantile seizures carry SCN2A mutations 
(Sugawara et al., 2001; Misra et al., 2008). An SCN3A mutation has also been described 
in a patient with cryptogenic paediatric partial epilepsy (Holland et al., 2008). Frame-shift 
mutations in SCN8A have been identified in patients with familial ataxia (Trudeau et al., 
2006). 
VGSC mutations are also linked to channelopathies in skeletal muscle. Four 
known missense mutations in exons 22 and 24 of SCN4A associate with paramyotonia 
congenita (Matthews et al., 2008). Moreover, three mutations in the S4 segment have 
been shown to cause hypokalemic periodic paralysis (Sokolov et al., 2007). 
A group of mutations that cause cardiac channelopathies have also been identified 
in SCN5A. One of the most well-known cardiac disorders caused by mutations in SCN5A 
is long QT syndrome (Wang et al., 1995), which is due to abnormal Nav1.5 inactivation 
delaying the repolarisation stage during cardiac action potential firing. Long QT 
syndrome increases the risk for ventricular arrhythmias. It has also been reported that  




Other typical cardiac diseases that relate to mutations in SCN5A include sudden cardiac 
death, sudden infant death syndromes, cardiac arrhythmia (Wilde & Brugada, 2011) and 
atrial fibrillation (Olson et al., 2005). 
Nav1.7 and Nav1.8, expressed in the PNS, are involved in neuropathic pain 
syndromes, including spinal cord injury pain, phantom limb pain and painful diabetic 
neuropathy (Lampert et al., 2010). Nav1.7 plays a crucial role in mediating pain signals in 
the PNS. Mutations in SCN9A associate with congenital insensitivity to pain (Cox et al., 
2006), paroxysmal extreme pain disorder and inherited erythromelalgia (Dib-Hajj et al., 
2009a; Dib-Hajj et al., 2009b). In addition, Nav1.8 contributes to inflammatory pain and 
peripheral pain syndromes (Liu & Wood, 2011; Schuelert & McDougall, 2012). Nav1.9 
plays an important role in pain signalling (Dib-Hajj et al., 2015). Gain-of-function 
mutations in SCN11A can cause familial episodic pain (Zhang et al., 2013), painful 
peripheral neuropathy (Huang et al., 2014) and loss of pain perception (Leipold et al., 
2013). Finally, mutations in SCN7A, which encodes NaX in human cerebellum, associate 
with temporal lobe epilepsy (Gorter et al., 2010).  
 
1.3 VGSC β subunits 
Four β subunit genes that encode five β subunit proteins have been identified in 
humans (Table 1.4) (Brackenbury & Isom, 2011). SCN1B encodes β1 and its splice 
variant β1B, whereas SCN2B, SCN3B and SCN4B encode β2, β3 and β4, respectively. 
 
1.3.1 Structure of VGSC β subunits 
β1–β4 are transmembrane proteins, containing an extracellular N-terminus, single 
transmembrane segment and an intracellular C-terminus (Isom & Catterall, 1996). The 
alternative splice variant β1B is a soluble, secreted molecule without a transmembrane 





   
Table 1.4. The expression of voltage-gated Na+ channel β subunits in humans 
Gene Protein Primary tissues Related neuronal disorders in humans Reference 
SCN1B β1 CNS, PNS, skeletal muscle and heart 
GEFS+; Dravet 
syndrome; Brugada 
syndrome; familiar atrial 
fibrillation; neuropathic 
pain 
(Wallace et al., 
1998; Coward et 
al., 2001; 
Wallace et al., 
2002; Scheffer et 
al., 2007; Patino 
et al., 2009; 
Ogiwara et al., 
2012) 
SCN1B β1B CNS, PNS, skeletal muscle 
Brugada syndrome; 
epilepsy 
(Watanabe et al., 
2008; Hu et al., 
2012) 
SCN2B β2 CNS, PNS skeletal muscle and heart Neuropathic pain 
(Coward et al., 
2001) 
SCN3B β3 CNS, PNS and heart Temporal lobe epilepsy (van Gassen et al., 2009) 
SCN4B β4 CNS, PNS and heart Huntington’s disease? (Oyama et al., 2006) 






loop structure is unique among ion channel auxiliary subunits (Brackenbury & Isom, 
2011). The intracellular domain of β1 and β2 interacts with ankyrin (Malhotra et al., 
2000), by which these β subunits anchor themselves to cytoskeleton (Malhotra et al., 
2002; Malhotra et al., 2004). 
Residues at both the N- and C-terminus of β1 and β3 non-covalently interact with 
the α subunit (Hartshorne et al., 1982; Messner & Catterall, 1985; McCormick et al., 
1998; Meadows et al., 2001; Spampanato et al., 2004). However, both β2 and β4 
covalently associate with α subunits via a single disulphide bond that is formed between 
the C26 residue at the extracellular region of either β subunit and one of multiple 
cysteine residues at the S5–S6 loop of the α subunit (Hartshorne et al., 1982; Messner & 
Catterall, 1985; Yu et al., 2003; Chen et al., 2012). 
 
1.3.2 Localisation of VGSC β subunits 
The expression of β subunits has been reported in neurones in the CNS and PNS, 
as well as skeletal and cardiac muscle cells (Table 1.4) (Isom et al., 1992; Isom et al., 
1995a; Morgan et al., 2000; Yu et al., 2003; Maier et al., 2004; Lopez-Santiago et al., 
2007; Brackenbury et al., 2010; Lopez-Santiago et al., 2011; Kaufmann et al., 2013). 
Similar to the α subunits, β subunits have also been identified in non-excitable cells, 
including rat astrocytes (Oh & Waxman, 1995), human glia (Aronica et al., 2003) and 
endothelial cells (Andrikopoulos et al., 2011b), as well as in cancer cells (Section 1.4.4). 
β subunit expression profiles depend on developmental stage. For example, in rat brain, 
the level of β1 and β2 increases during postnatal development and replaces β1B and 
β3, which peak at birth (Kazen-Gillespie et al., 2000; Shah et al., 2001). β1B is also the 
predominant splice variant during human foetal brain development (Patino et al., 2011).  
β subunits are localised to the AIS (Rasband, 2010; Buffington & Rasband, 2013) 




Buffington & Rasband, 2013), agreeing with their roles in regulating the expression and 
gating of α subunits during action potential firing at these regions. Moreover, β1 localises 
to the growth cone in mouse cerebellar granule neurones (CGNs), where it contributes 
to the neurite outgrowth and pathfinding (Davis et al., 2004; Brackenbury et al., 2008; 
Brackenbury et al., 2010).  
 
1.3.3 VGSC β subunits are cell adhesion molecules 
All VGSC β subunits are members of the Ig superfamily of cell adhesion molecules 
(CAMs) (Isom et al., 1995a; Brackenbury & Isom, 2011). To date, both the homophilic 
interactions, by which the Ig domains from two identical β subunits interact, and the 
heterophilic interactions, by which the Ig domain of a β subunit interacts with other 
CAMs, have been reported (Malhotra et al., 2000; McEwen & Isom, 2004).  
β1-β1 homophilic interactions increase cell aggregation and ankyrin recruitment in 
Drosophila S2 cells (Malhotra et al., 2000). Heterophilic adhesion partners of β1 include 
contactin (Kazarinova-Noyes et al., 2001), neurofascin-155, neurofascin-186 (Ratcliffe et 
al., 2001; McEwen et al., 2004), N-cadherin (Malhotra et al., 2000) and tenascin-R 
(Srinivasan et al., 1998). Heterophilic interactions with β1 lead to various outcomes: β1-
contactin (as well as β2-contactin) co-expression increases Nav1.2 expression at the 
plasma membrane of CHL cells (Kazarinova-Noyes et al., 2001). β1 (as well as β2)-
bearing CHL cells are repelled from tenascin-R expressing extracellular matrix, 
indicating a role of β subunits in directing cell migration (Xiao et al., 1999). β3 homophilic 
interactions have been reported in transfected HEK293 cells (Yereddi et al., 2013) but 
not in transfected Drosophila S2 cells (McEwen et al., 2009). It is proposed that, in 
contrast to β1, β3 has limited heterophilic interactions with other CAMs: for example, β3 
does not associate with contactin (McEwen et al., 2009). Finally, the homophilic 
interaction between β4-β4 has been identified in mouse striatum and striatonigral fibres 




β1-β1 homophilic interactions mediate neurite outgrowth in mouse CGNs (Davis et 
al., 2004). Overexpression of β4 also induces neurite outgrowth in Neuro2a cells 
(Oyama et al., 2006). Interestingly, co-culture of CGNs with β2-expressing fibroblast 
monolayers reduces the neurite length (Davis et al., 2004), suggesting different β 
subunits have distinct roles in modulating neurite outgrowth in the CNS. β1-mediated 
neurite outgrowth requires the presence fyn kinase and contactin (Brackenbury et al., 
2008). In addition, INa carried by Nav1.6 is required for β1-mediated neurite outgrowth, 
and in turn, β1 expression enhances the size of the INa (Brackenbury et al., 2010). 
Therefore, there is reciprocal interaction between Nav1.6 and β1 to regulate neurite 
outgrowth and excitability (Brackenbury et al., 2010). 
 
1.3.4 Regulation of VGSC β subunits 
β subunits are subject to post-translational regulation. There is a tyrosine 
phosphorylation site at the intracellular domain of β1 (β1Y181) (Figure 1.1) (Malhotra et 
al., 2002). The phosphorylation status of β1Y181 has been shown to affect the functional 
localisation of β1: in cardiomyocytes, tyrosine-phosphorylated β1 colocalises with Nav1.5 
at intercalated discs, whereas non-phosphorylated β1 is found at the T-tubules, 
colocalising with TTX-sensitive VGSCs (Malhotra et al., 2004). 
Three to four glycosylation sites are present at the Ig loop region of the β subunits 
(Messner & Catterall, 1985; Isom et al., 1992). Sialylation, a common type of 
glycosylation in VGSCs induced by sialic acids, is necessary for the β1-dependent 
modulation of channel gating in CHO cells (Johnson et al., 2004).  
β1–β4 are all subject to proteolytic cleavage by α-, β- and γ-secretase (Kim et al., 
2005; Wong et al., 2005). Both α- and β-secretase release the extracellular domain of 
β1–β4 from the full-length protein, whereas γ-secretase releases the intracellular 




domain of β2 traffics to the nucleus and increases Nav1.1 mRNA and protein levels in 
cells from mouse cerebellum (Kim et al., 2007).  
 
1.3.5 β subunits modulate the activity of α subunits 
The activity of VGSC α subunits is modulated by the auxiliary β subunits in the 
protein complex. In heterologous systems, co-expression of β1, β2 or β3 with rat Nav1.2 
in Xenopus oocytes accelerates channel inactivation and results in a shift of steady-state 
inactivation towards a more negative voltage (Isom et al., 1992; Patton et al., 1994; Isom 
et al., 1995a; Isom et al., 1995b; Morgan et al., 2000). Co-expression of β1 or β2 with rat 
Nav1.6 in Xenopus oocytes also accelerates channel inactivation and causes a 
hyperpolarising shift in the voltage-dependence of activation but shows no effect on the 
steady-state inactivation (Smith et al., 1998a). Moreover, both β1 and β2 increase peak 
INa density carried by Nav1.2 in oocytes (Isom et al., 1992; Isom et al., 1995a). Finally, β4 
has been shown to cause a negative shift in the voltage-dependence of Nav1.2 or Nav1.4 
activation (Yu et al., 2003) and in the steady-state inactivation of Nav1.5 (Medeiros-
Domingo et al., 2007). 
In Chinese hamster lung (CHL) cells, co-expressing β1 and Nav1.2 gives similar 
results to Xenopus oocytes, including an increase in peak INa density and a negative shift 
in the steady-state inactivation (Isom et al., 1995b). Interestingly, β2 requires co-
expression of β1 to exert its modulatory roles on Nav1.2 in CHL cells (Kazarinova-Noyes 
et al., 2001). In rat brain neurones, β2 increases membrane capacitance, likely due to its 
role in facilitating insertion of α subunits into the cell membrane (Schmidt et al., 1985; 
Schmidt & Catterall, 1986; Isom et al., 1995a). In HEK293 cells, co-expression of β1 or 
β3 increases the peak INa carried by Nav1.7, whereas β2 or β4 has no significant effect 
on the peak INa (Laedermann et al., 2013). β1 and β3 also cause a positive shift in 




Nav1.5, β3 negatively shifts the steady-state inactivation in CHO cells (Meadows et al., 
2002; Ko et al., 2005). 
The effect of β subunits on action potential firing and INa has also been 
investigated in vivo using transgenic mice. Electrophysiological recordings from 
postnatal (10–18 days) Scn1b null mice show hyperexcitability in the CA3 region of the 
hippocampus (Brackenbury et al., 2013). The hyperexcitability has also been reported in 
DRG neurones in the same animal model (Lopez-Santiago et al., 2011). On the other 
hand, reduced INa and impaired excitability have been observed in CGNs from Scn1b-
null mice (Brackenbury et al., 2010). Thus, β1 regulates neuronal excitability in a cell-
type dependent manner.  
In vivo evidence has also demonstrated that β1 regulates excitability in the heart. 
Increased transient and persistent INa were recorded from ventricular cardiomyocytes of 
Scn1b null mice, leading to prolonged action potential repolarisation and QT interval 
(Lopez-Santiago et al., 2007). Interestingly, 3H-saxitoxin binding experiments show that 
the number of TTX-sensitive and TTX-resistant VGSCs increased in Scn1b-null 
ventricular myocytes (Lopez-Santiago et al., 2007).  
It is noteworthy that β1 also regulates the distribution and expression of the α 
subunits: compared to wildtype, CA3 hippocampal neurones in Scn1b-null mice have 
reduced Nav1.1 but increased Nav1.3 protein levels (Chen et al., 2004), and a 
subpopulation of Scn1b-null CGNs show an increase in Nav1.1 at the AIS (Brackenbury 
et al., 2010). Localisation of Nav1.6 at the AIS in a subpopulation of CGNs is also 
dependent on β1 (Brackenbury et al., 2010). Additionally, Scn2b-null mice have reduced 
INa at the nodes of Ranvier of mouse optic nerves (Chen et al., 2002). 
 
1.3.6 β subunits and neuronal disorders 
Mutations in human β subunit genes associate with neuronal disorders (Table 1.4) 




SCN1B have been reported in GEFS+ patients (Wallace et al., 1998; Wallace et al., 
2002). Six of these (C121W, R85C, R85H, I70_E74del, R125L and D25N) occur in the 
β1 Ig loop, suggesting the significance of the Ig structure in regulating excitability. Two 
β1 mutations, R125C and I106F, have been found in Dravet syndrome patients (Patino 
et al., 2009; Ogiwara et al., 2012). Brugada syndrome is associated with mutations 
including R214Q and E87Q in β1/β1B (Watanabe et al., 2008; Hu et al., 2012). R85H, 
another mutation in the Ig domain, and D153N mutation in the intracellular domain of β1 
have been reported in patients with familial atrial fibrillation (Scheffer et al., 2007). β1, as 
well as β2, has functional roles in conducting neuropathic pain (Coward et al., 2001). 
Reduced β3 protein level can lead to temporal lobe epilepsy (van Gassen et al., 2009). 
Finally, down-regulation of β4 may cause neurite degeneration in the striatum of 
Huntington’s disease transgenic mice and patients with Huntington’s disease (Oyama et 
al., 2006).  
 
1.4 The involvement of VGSCs in cancer progression 
1.4.1 Breast cancer 
Cancer is one of the leading causes of deaths. Globally, approximately 14 million 
new cancer cases and eight million cancer-related deaths were reported in 2012 (Torre 
et al., 2015). 11 % of all cancer cases are breast cancer (BCa) (Maxmen, 2012). In 
women, BCa had the highest incidence (> 1.6 million) and was the leading cause of 
cancer-related deaths (> 0.5 million) worldwide in 2012, which accounted for 15 % of 
cancer-related deaths in females (Torre et al., 2015). BCa is categorised into three 
groups according to the expression profiles of oestrogen receptor (ER), progesterone 
receptor (PR) and human epidermal growth factor receptor 2 (HER2). In the US, the 
“triple-negative (ER—/PR—/HER2—)” subtype has been found in 13 % of BCa patients. 




increased likelihood of distant recurrence within five years of diagnosis compared with 
those diagnosed with other types of BCa (Dent et al., 2007). Until recently, adjuvant 
chemotherapy, which includes anthracyclines and/or taxanes (Joensuu & Gligorov, 
2012; von Minckwitz & Martin, 2012), is the primary therapy for triple-negative BCa 
(Anders & Carey, 2008; Irvin & Carey, 2008), since this BCa subtype is resistant to 
HER2-targeted treatments using trastuzumab and hormonal therapies using tamoxifen 
and aromatase inhibitors (Cleator et al., 2007). Triple-negative BCa shares many 
molecular features with cancers that carry breast cancer 1 (BRCA1) mutations (Cleator 
et al., 2007), including p53 mutations (Crook et al., 1997; Schlichtholz et al., 1998), ER 
negativity (Lakhani et al., 2005) and HER2 negativity (Lakhani et al., 2002). Because 
BRCA1 plays a central role in repairing double-stranded DNA breaks by homologous 
recombination (Turner et al., 2004), dysfunctional BRCA1 repairs damaged DNA with 
less accuracy that can lead to genome instability (Cleator et al., 2007), one of the 
hallmarks of cancer (Hanahan & Weinberg, 2011). When the BRCA1 pathway is 
compromised, poly (ADP-ribose) polymerase (PARP)-dependent non-homologous 
recombination becomes the primary pathway during DNA repair (Javle & Curtin, 2011). 
A novel targeted therapy using PARP inhibitors was proposed for BRCA1-associated 
cancers, and the efficacy of PARP inhibitors in triple-negative BCa therapy has gained 
attention in the past few years (Do & Chen, 2013). 
Cancer becomes difficult to cure when the cancer at the primary site (primary 
tumour) spreads to distant sites (metastasis). In BCa patients, the most common 
metastasis sites include lungs, bones, liver, pleura and adrenal glands, and metastases 
at multiple sites have been frequently found in patients (Weigelt et al., 2005). Recent 
reports also showed increased incidence of brain metastasis arising from triple-negative 
BCa (Lin et al., 2008; Niwinska et al., 2010).  Once BCa metastasises, the five-year 
survival rate is only 26 % (Lu et al., 2009). Although adjuvant therapy, in which 




ER+ and HER2+ BCa patients, respectively), after primary BCa removal, has been used 
in treating BCa metastases, its side effects, such as premature menopause (Ganz, 
2005), infertility (Ganz et al., 2003) and sexual dysfunction (Howard-Anderson et al., 
2012), often lead to deteriorated quality of life in patients. Metastasis is regarded one of 
the hallmarks of cancer (Hanahan & Weinberg, 2011), and one of the key goals in 
clinical and basic cancer research is to effectively detect and reduce BCa metastasis 
and therefore improve the prognosis of BCa patients. 
 
1.4.2 The metastatic cascade: involvement of migration and invasion 
Metastasis is a complex sequence of events that includes cell detachment from the 
primary site, migration and invasion through the local tissue, penetration through the 
basement membrane into lymphatic and blood vessels (intravasation), travelling through 
the circulation, exiting the circulation (extravasation), settling at distant sites, and 
proliferation into new tumours (Figure 1.2) (Gupta & Massague, 2006). 
An important event during malignant cancer cell migration and invasion in vivo is 
the way that the cells “sense” their surrounding environment and hence exert metastatic 
behaviours (Allinen et al., 2004). Integrins, a family of cell adhesion receptors that bind 
to ligands in extracellular matrix (ECM), have a crucial role in interacting with the ECM 
and thus activating receptor tyrosine kinases (RTKs) and intracellular signals leading to 
cell migration and invasion (Giancotti & Ruoslahti, 1999; Hynes, 2002). Upon binding to 
the ECM, integrins recruit and partially activate focal adhesion kinase (FAK) (Oktay et 
al., 1999), a molecule that is regarded as a central hub in cancer cell migration control 
(Sieg et al., 2000; Schlaepfer & Mitra, 2004). Full phosphorylation of FAK is mediated by 
src kinase (Xing et al., 1994), resulting in recruitment of a number of important effectors 
that promote cancer cell metastasis (Mitra & Schlaepfer, 2006), including the small 








Figure 1.2. The metastatic cascade.  
Metastasis involves several key steps, including (1) the detachment of cells from the 
primary site, (2) migration and invasion through the local tissue, (3) penetration through 
the basement membrane into lymphatic and blood vessels (intravasation), (4) travelling 
through the circulation, (5) exiting the circulation (extravasation), settling at distant sites, 






(GEFs) (Zhai et al., 2003), scaffold proteins GRB2 and ezrin (Schlaepfer et al., 1994; 
Poullet et al., 2001) and the proteolytic enzyme calpain (Carragher et al., 2003; Chan et 
al., 2010). A group of molecules from the small GTPase family are then activated by 
FAK, including Rho (Palazzo et al., 2004), Rac and Cdc42 (Keely et al., 1997). All of 
these proteins contribute to cell migration as well as invasion (Ridley et al., 2003; 
Raftopoulou & Hall, 2004; Ridley, 2011). Rac and Cdc42 promote actin polymerisation 
by activating the Arp2/3 complex at the leading edge of the cell, leading to the formation 
of lamellipodia and filopodia, respectively (Nobes & Hall, 1995). On the other hand, Rho 
activation links to the ERK-Jun-amino-terminal kinase (JNK) pathway (Krueger et al., 
2001), which promotes cell migration by controlling myosin contraction (Kimura et al., 
1996) .  
The invasion of cancer cells also involves the proteolytic cleavage of the ECM by 
matrix metalloproteinases (MMPs) (Egeblad & Werb, 2002; Bacac & Stamenkovic, 
2008). A number of MMPs, including MMP-14, -15 and -16, are involved in the 
degradation of the basement membrane upon the first steps of invasion. MMP-14 has 
also been reported to regulate cancer cell morphology during invasion (Hotary et al., 
2003). CD44, a cell surface proteoglycan that promotes metastasis (McFarlane et al., 
2015), is also an interaction partner of MMP-14 (Kajita et al., 2001; Mori et al., 2002). 
Next, before invading through the basement membrane completely, MMPs indirectly 
promote local invasion, angiogenesis, and evasion of apoptosis by facilitating the 
maturation of growth factors including the epidermal growth factor (EGF) (Yu et al., 
2002), or by activating the tumour growth factor β (TGF-β) in a CD44-dependent 
pathway (Yu & Stamenkovic, 2000). 
The cellular machineries and mechanisms involved in the metastatic cascade are 
highly complex and are often cell-type dependent. Although membrane proteins such as 
integrins and MMPs perform key roles in this process, interestingly, many types of ion 




contribute to the metastasis. Thus, modulating ion channels and transporters in cancer 
has recently emerged as a potentially novel therapeutic modality. In addition to the 
reports showing the roles of K+ channels (Huang & Jan, 2014; Pardo & Stuhmer, 2014), 
Ca2+ channels (Prevarskaya et al., 2007; Prevarskaya et al., 2014), Cl- channels (Turner 
& Sontheimer, 2014) and ion transporters (Lastraioli et al., 2015; Stock & Schwab, 2015) 
in promoting cancer cell metastatic behaviours, the therapeutic value of targeting 
VGSCs in cancer is becoming increasingly promising, given that VGSCs specifically 
promote cell metastatic behaviours, such as migration and invasion, in vitro, as well as 
tumour growth and metastasis in vivo (Besson et al., 2015; Roger et al., 2015). 
 
1.4.3 α subunits in cancer 
1.4.3.1 Expression of α subunits in cancer 
The first evidence of VGSC expression in cancer cells was reported in 1987 in 
theK562/ADM multidrug-resistant (MDR) human leukaemia cancer cell line (Yamashita 
et al., 1987). Immediately following this study, another group found TTX-sensitive INa in 
the human MDR T-cell leukaemia CCRF-CEM/VLB100 cell line but not in the drug-
sensitive CCRF-CEM cell line (Lee et al., 1988). Both studies imply a relationship 
between INa/VGSC expression and malignancy. Since then, the VGSC mRNA and/or 
proteins have been found in increasing number of human cancer cell lines and patient 
tissue samples originating from various organs (Table 1.5). 
In BCa cells, INa carried by VGSCs was first identified in 2003 in the triple-negative, 
highly metastatic human MDA-MB-231 BCa cell line (Roger et al., 2003). The INa was 
absent in non-tumourigenic MCF-10A mammary epithelial cells and weakly metastatic 
MCF-7 and MDA-MB-468 BCa cells (Roger et al., 2003; Fraser et al., 2005). The mRNA 
expression level is > 100-fold higher in MDA-MB-231 cells compared with MCF-7 cells 































































































































































































































































































































































































































































































































































































































































































































in MDA-MB-231 cells, Nav1.5 contributes to ~82 % of the total VGSC expression (Fraser 
et al., 2005), and following studies using small-interfering RNA (siRNA) (Brackenbury et 
al., 2007) and anti-peptide antibody (Chioni et al., 2005) confirmed the INa recorded in 
MDA-MB-231 cells is mainly carried by the neonatal splice variant of Nav1.5. Neonatal 
Nav1.5 protein is also found in human BCa tissues but not in normal breast, and 
increased neonatal Nav1.5 mRNA expression associates with lymph node metastasis 
(Fraser et al., 2005). 
In prostate cancer (PCa) cell lines, INa has been recorded from the highly 
metastatic rat Mat-LyLu but not weakly metastatic AT-2 cells (Grimes et al., 1995). The 
INa in Mat-LyLu cells is abolished by 100 nM TTX, suggesting presence of a TTX-
sensitive VGSC isoform, later found to be neonatal Nav1.7 (Diss et al., 2001). TTX-
sensitive INa, which is carried by Nav1.7 (Diss et al., 2001), was found in highly invasive 
human PC-3 cells, but was absent in the less invasive LNCaP cells (Laniado et al., 
1997). This is in agreement with VGSC mRNA expression levels in these cells: the 
Nav1.7 mRNA level is ~1 × 106-fold higher in Mat-LyLu cells than in AT-2 cells, and in 
PC-3 cells it is ~1100-fold higher compared to LNCaP cells (Diss et al., 2001). The 
expression of α subunits in specimens from patients with benign prostatic hyperplasia or 
low-grade prostatic intraepithelial neoplasia is low compared to high-grade PCa, and the 
Nav1.7 mRNA level is greater in high-grade PCa (Diss et al., 2005; Diss et al., 2008). 
INa carried by VGSCs has been reported in strongly metastatic H460, H23 and 
Calu-1 non-small-cell lung cancer (NSCLC) cell lines, but the current is absent in weakly 
invasive A549 and non-cancerous lung epithelial NL20 and BEAS-2B cells (Roger et al., 
2007; Campbell et al., 2013). However, Nav1.6 and Nav1.7 mRNA are expressed in all of 
these cells (Roger et al., 2007). In addition, TTX-sensitive current has also been 
recorded in human NCI-H128, NCI-H69 and NCI-H146 small-cell lung cancer cell lines 




and H510 small-cell lung cancer (SCLC) cells, and Nav1.9 mRNA was also identified in 
H510 cells (Onganer et al., 2005). 
Nav1.5 is functionally expressed in SW620, SW480 and HT29 human colon cancer 
cell lines (House et al., 2010; Baptista-Hon et al., 2014). Nav1.5 expression is 
significantly higher in human colon cancer specimens than in normal colon tissues 
(House et al., 2010). The Nav1.6 mRNA expression level is significantly higher in 
colorectal carcinoma tissues compared to normal counterparts (Igci et al., 2015). 
Moreover, TTX-sensitive INa has been recorded in the primary cultures of human cervical 
cancer, where mRNA for Nav1.2, Nav1.4 and Nav1.7 are found (Diaz et al., 2007). 
Interestingly, analyses of RNA levels from biopsies showed that normal cervical cells 
express mRNA for Nav1.4, whereas cervical cancer cells have up-regulated Nav1.2, 
Nav1.6 and Nav1.7 mRNA (Diaz et al., 2007). Agreeing with this, another study showed 
that Nav1.6 and Nav1.7 mRNA levels are higher in cervical cancer than in non-cancerous 
cervical biopsies (Hernandez-Plata et al., 2012). The localisation of Nav1.6 and Nav1.7 is 
limited to the plasma membrane of cells from the intermediate and superficial zone of 
the cervical squamous epithelium in non-cancerous cervical biopsies, but VGSC 
expression is widely distributed in the plasma membrane, cytoplasm and nucleus region 
in most of the cells from cervical cancer biopsies (Hernandez-Plata et al., 2012). Nav1.6 
contributes ~51 % of the total INa in cervical cancer primary culture cells (Hernandez-
Plata et al., 2012). Additionally, real-time PCR (qPCR) analyses have shown increases 
in Nav1.2, Nav1.4, Nav1.5 and Nav1.7 mRNA expression in strongly metastatic ovarian 
cancer cells (Caov-3 and SKOV-3) in comparison to weakly metastatic Anglne ovarian 
cancer cells (Gao et al., 2010). Nav1.5 expression was only found in ovarian cancer with 
lymph node metastasis specimens (Gao et al., 2010). 
Finally, other cancerous tissue/cell lines in which VGSCs have been identified 
include human neoplastic mesothelial cells, where the TTX-sensitive INa was reported 




channels was reported (Xing et al., 2014). Functional Nav1.5 is present in NB-1 
neuroblastoma cells (Ou et al., 2005). THP-1 and HTB-66 melanoma cells express 
functional Nav1.6 (Carrithers et al., 2009). Nav1.1, Nav1.2, Nav1.3, Nav1.4, Nav1.6 and 
NaX mRNA have also been identified in human glioma specimens, but further studies are 
needed in order to assess the VGSC protein level (Schrey et al., 2002). 
 
1.4.3.2 Functional roles of α subunits in cancer 
VGSC activity potentiates a number of cell behaviours that contribute to metastasis 
in vitro including invasion, transwell migration, lateral motility, galvanotaxis, process 
extension, adhesion, plasma membrane endocytic activity, vesicular patterning, and 
gene expression (Table 1.6) (Brackenbury, 2012). 
Blocking VGSCs using TTX (Fraser et al., 2005; Brackenbury et al., 2007), 
phenytoin (Yang et al., 2012), ranolazine (Driffort et al., 2014), or silencing Nav1.5 with 
siRNA also reduces MDA-MB-231 cell invasion through Matrigel (Brackenbury et al., 
2007; Gillet et al., 2009), whereas the cell in vitro proliferation is not affected. Similarly, 
TTX reduces Mat-LyLu and PC-3 PCa cell invasion but shows no effects on AT-2 and 
LNCaP cells where functional VGSCs are absent (Grimes et al., 1995; Laniado et al., 
1997). Interestingly, overexpression of Nav1.4 in LNCaP cells increases cell 
invasiveness, which can be reversed by TTX application, suggesting that VGSC 
expression is sufficient to promote invasion (Bennett et al., 2004). Na+ influx carried by 
VGSCs also increases H460, H23 and Calu-1 NSCLC cell invasion (Roger et al., 2007). 
Moreover, TTX and siRNA targeting Nav1.5 reduce the invasiveness of SW620, SW480 
and HT29 human colon cancer cells, and blocking Nav1.5 with ropivacaine in SW620 
cells showed a similar effect (House et al., 2010; Baptista-Hon et al., 2014). 
Furthermore, in primary cervical cancer culture, TTX inhibits cell invasion but does not 
affect cell proliferation (Diaz et al., 2007). Caov-3 and SKOV-3 ovarian cancer cells 




In addition, TTX also suppresses the invasion of Jurkat lymphocytes (Fraser et al., 
2004), human neoplastic mesothelial cells (Fulgenzi et al., 2006), and THP-1 and HTB-
66 melanoma cells (Carrithers et al., 2009). Finally, silencing neonatal Nav1.5 with 
siRNA reduces U251 human brain astrocytoma cell invasion (Xing et al., 2014). 
Whether VGSCs control cell motility in vitro is under debate: TTX reduces the 
number of migrated MDA-MB-231 cells in some transwell migration studies (Fraser et 
al., 2005; Isbilen et al., 2006; Brackenbury et al., 2007; Chioni et al., 2010) but not others 
(Roger et al., 2003). In addition, phenytoin reduces the lateral motility of MDA-MB-231 
cells in wound healing assays (Yang et al., 2012; Aktas et al., 2015). TTX-treated Mat-
LyLu cells show reduced transwell migration (Brackenbury et al., 2007) and lateral 
motility (Fraser et al., 2003). The transwell migration of PC-3M cells (Uysal-Onganer & 
Djamgoz, 2007) and the lateral motility of U251 cells (Xing et al., 2014) are also reduced 
after TTX treatment. However, the transwell migration of H460, H23 and Calu-1 cells 
(Roger et al., 2007), Caov-3 and SKOV-3 cells (Gao et al., 2010), and primary cervical 
cancer culture cells is not affected by TTX (Diaz et al., 2007). Therefore, whether or not 
VGSCs promote cancer cell migration is highly cell type-dependent. More experiments 
are needed in order to elucidate the role of VGSCs in controlling cancer cell migration. 
Both Mat-LyLu and MDA-MB-231 cells are galvanotactic, meaning that they move 
directionally in response to an electric field. Mat-LyLu cells move towards the cathode 
(Djamgoz et al., 2001), whereas MDA-MB-231 cells move towards the anode (Fraser et 
al., 2005), following the application of an electric field of 3 V/cm. TTX application 
significantly reduces the galvanotaxis in both types of cells (Djamgoz et al., 2001; Fraser 
et al., 2005). On the other hand, veratridine enhances the galvanotactic movement of 
Mat-LyLu cells (Djamgoz et al., 2001). 
VGSCs change the morphology of Mat-LyLu cells by decreasing cell process 






















































































































































































































































































































































































































































































































































































































































































































































































































MDA-MB-231 cells, inhibiting Nav1.5 using small-hairpin RNA (shRNA) (Brisson et al., 
2013; Nelson et al., 2015b) or ranolazine (Driffort et al., 2014) causes less elongated cell 
morphology. Moreover, PC-3M and Mat-LyLu cells pre-treated with TTX show reduced 
adhesion to glass coverslips (Palmer et al., 2008). Additionally, TTX reduces the 
endocytic/vesicular uptake of horseradish peroxidase in Mat-LyLu and MDA-MB-231 
cells (Mycielska et al., 2003; Krasowska et al., 2004; Fraser et al., 2005; Krasowska et 
al., 2009), whereas opening VGSCs in MDA-MB-231 cells with aconitine has the 
opposite effect (Fraser et al., 2005; Krasowska et al., 2009). Aggregated vesicles are 
observed in Mat-LyLu and MDA-MB-231 cells following the uptake of horseradish 
peroxidase, which is attenuated by TTX treatment (Mycielska et al., 2003; Krasowska et 
al., 2004, 2009). Furthermore, interestingly, in NCL-H146 SCLC cells, VGSCs are 
involved in the initiation of action potential firing (Blandino et al., 1995). 
VGSC α subunits also regulate expression of invasion-related genes. In colon 
cancer, using HT29 cells, bioinformatic analyses revealed that Nav1.5 mRNA may 
regulate the expression of genes that encode MMPs (e.g. ADAM9), members involved in 
Ca2+ signalling (e.g. CCR9) and membrane remodelling (e.g. CHMP4C) (House et al., 
2010). A following study demonstrated that activating Nav1.5 with veratridine increases 
invasion-related gene expression in SW620 cells, including CD44, CLIC, WNT9A, ITGB, 
SEMA6A and VEGFC (House et al., 2015). 
VGSCs potentiate cancer progression in vivo. Rats subcutaneously implanted with 
Mat-LyLu cells show significantly reduced tumour metastases and improved survival as 
a result of daily TTX injection into the tumour (Yildirim et al., 2012). Daily injection with 
phenytoin significantly reduced tumour growth and metastasis to lungs, liver and spleen 
in mice bearing orthotopic tumour of MDA-MB-231 cells (Nelson et al., 2015a). In 
addition, ranolazine treatment reduces metastasis to lungs after injection of MDA-MB-
231 cells into the mouse tail vein (Driffort et al., 2014). More recently, it has been shown 




MDA-MB-231 cells where Nav1.5 expression is suppressed by shRNA, compared to 
those implanted with MDA-MB-231 cells infected with control scrambled shRNA (Nelson 
et al., 2015b). Therefore, an increasing body of evidence shows the expression of 
VGSCs in cancer cells and cancer patient biopsies, and suggests a role in promoting 
metastatic behaviours, both in vitro and in vivo.  
 
1.4.3.3 Mechanisms underlying α subunit-dependent cancer cell metastatic 
behaviours 
Several models have been proposed in order to explain enhanced metastatic 
behaviours caused by VGSC α subunits, which include regulation of pH, gene 
expression and activity of protein kinases. 
In MDA-MB-231 cells, Nav1.5 has been shown to increase cell invasion by 
allosterically activating Na+-H+ exchanger type 1 (NHE1) at the plasma membrane. 
NHE1 regulates the intracellular pH and acidifies the immediate extracellular 
environment by extruding H+, favouring the proteolytic activity of cathepsin B and S 
(Gillet et al., 2009; Brisson et al., 2011). Nav1.5 co-immunoprecipitates with NHE1, and it 
is proposed that both the proteins form functional complexes located in caveolin-1-
containing lipid rafts at invadopodia (Brisson et al., 2011; Brisson et al., 2013). 
Moreover, Nav1.5 promotes src kinase activity and phosphorylation of cortactin and 
cofilin, which both lead to actin polymerisation (Brisson et al., 2013). In addition, 
silencing Nav1.5 expression by using shRNA reduces the protein level of the metastasis-
promoting molecule CD44 in MDA-MB-231 cells (Nelson et al., 2015b). 
In SW620 colon cancer cells, veratridine increases the size of INa, cell 
invasiveness, and activates mitogen activated protein kinase (MAPK) signalling (House 
et al., 2015). U0126, an inhibitor of MAPK/ERK kinase (MEK), abolishes the ERK 
phosphorylation caused by veratridine, suggesting VGSCs enhance SW620 cell invasion 




Rap1B, and ultimately leads to activation of various transcription factors (TFs) including 
ELK1, ETS-1 and c-Jun (House et al., 2015). Interestingly, veratridine also increases the 
protein level of CD44, as in MDA-MB-231 cells (House et al., 2015; Nelson et al., 
2015b), suggesting that the Nav1.5-CD44 signalling axis may be universal in promoting 
metastasis in various types of cancer. 
In H460 NSCLC cells, EGF increases cell invasion in a Nav1.7-dependent manner 
(Campbell et al., 2013). Application of the ERK inhibitor U0126 inhibits cell invasion and 
co-application of U0126 and TTX showed no additive effect, suggesting that Nav1.7-
dependent H460 cell invasion is via the ERK pathway (Campbell et al., 2013). In 
summary, the proposed models suggest α subunits increase cancer cell invasion by 
several mechanisms. However, there may be further undiscovered mechanism(s), and 
future experiments are needed to clarify whether these mechanisms are widely 
applicable among all cancers. 
 
1.4.3.4 Regulation of α subunit expression in cancer cells 
The expression of α subunits in cancer cells is also subject to a variety of 
regulations. Autoregulation of VGSCs has been reported in PCa cells, where 48 h TTX 
pre-treatment reduces Nav1.7 mRNA level in PC-3M cells (Mycielska et al., 2005). In 
Mat-LyLu PCa cells, INa activates PKA, which in turn potentiates Nav1.7 mRNA 
expression and protein trafficking to the plasma membrane (Brackenbury & Djamgoz, 
2006). Similarly, in MDA-MB-231 BCa cells, pre-treatment with the PKA activator 
forskolin for 24 h increases Nav1.5 mRNA level as well as the protein level at the plasma 
membrane (Chioni et al., 2010); on the other hand, pre-treatment with TTX reduces PKA 
phosphorylation and PKA-induced cell transwell migration (Chioni et al., 2010). 
Serum affects the size of INa and the kinetics of the α subunits in Mat-LyLu cells 
(Ding & Djamgoz, 2004). Growth factors in serum have a number of effects on VGSCs: 




potentiates cell migration, invasion and endocytosis (Uysal-Onganer & Djamgoz, 2007). 
In Mat-LyLu cells, EGF increases INa density as well as cell transwell migration (Ding et 
al., 2008). The mRNA level of Nav1.7 is also up-regulated in H460 NSCLC cells after 
EGF treatment, along with increased cell invasion (Campbell et al., 2013). Nerve growth 
factor (NGF) enhances INa in Mat-LyLu cells (Brackenbury & Djamgoz, 2007); however, 
the NGF-induced increase in cell transwell migration is independent of VGSC activity 
(Brackenbury & Djamgoz, 2007). Additionally, the estrogen β-estradiol increases INa in 
MDA-MB-231 cells, and the action is dependent on GPR30, a G-protein-coupled ER, 
and PKA (Fraser et al., 2010). In summary, both the expression and function of α 
subunits in cancer cells are regulated by growth factors and hormones, and the 
autoregulation of α subunits also occurs. 
 
1.4.4 β subunits in cancer 
In addition to α subunits, VGSC β subunits have been identified in a number of 
cancer cells (Table 1.7) where they contribute to metastatic behaviour (Table 1.6). β1 
has a relatively higher expression in MCF-7 cells than in MDA-MB-231 cells, and it  
facilitates MCF-7 cell adhesion to substrate but slows transwell migration (Chioni et al., 
2009). Overexpression of β1 in MDA-MB-231 cells increases MDA-MB-231 cell-cell 
adhesion and process outgrowth but reduces cell migration in vitro (Chioni et al., 2009). 
Interestingly, silencing β1 using siRNA increases the Nav1.5 mRNA and protein level in 
MCF-7 cells (Chioni et al., 2009), whereas overexpressing β1 in MDA-MB-231 cells 
enhances INa density (Chioni et al., 2009). β1 mRNA and protein are present in patient 
BCa samples, and the β1 protein expression, determined by immunohistochemistry, is 
significantly higher in tumour tissue than normal breast tissue (Nelson et al., 2014). 







Table 1.7. Voltage-gated Na+ channels β subunit expression in cancer 
Protein Gene Cancer type References 
β1 SCN1B Breast, prostate, cervical, NSCLC 
(Roger et al., 2007; 
Diss et al., 2008; 
Chioni et al., 2009; 
Hernandez-Plata et 
al., 2012; Nelson et 
al., 2014) 
β2 SCN2B Breast, prostate, cervical, NSCLC 
(Roger et al., 2007; 
Diss et al., 2008; 
Chioni et al., 2009; 
Hernandez-Plata et 
al., 2012; Jansson et 
al., 2012) 
β3 SCN3B Prostate, NSCLC 
(Roger et al., 2007; 
Hernandez-Plata et 
al., 2012) 
β4 SCN4B Breast, prostate, cervical, NSCLC 
(Roger et al., 2007; 
Diss et al., 2008; 
Chioni et al., 2009; 
Hernandez-Plata et 
al., 2012) 




adhesion, which is dependent on fyn kinase and Na+ influx through α subunits (Nelson et 
al., 2014), similar to its role in the CNS (Brackenbury et al., 2008; Brackenbury et al., 
2010). Compared to control MDA-MB-231 cells, mice bearing β1-overexpressing MDA-
MB-231 cells show increased tumour growth and vascularisation, together with 
increased metastasis to lungs and liver (Nelson et al., 2014). Taken together, β1 
expression enhances cell adhesion and process outgrowth but retards migration of BCa 
cells in vitro, where it also regulates the expression and activity of α subunits. In vivo, β1 
potentiates BCa tumour growth and metastasis.  
The total β subunit mRNA level in metastatic PC-3 and PC-3M cells is significantly 
higher than in weakly metastatic LNCaP cells, and β1 is again the predominant isoform 
(Diss et al., 2008). However, the mRNA levels of β1–β4 are similar comparing PCa and 
non-PCa biopsies (Diss et al., 2008), possibly because the processing of the tissue 
causes inaccuracy by including cells not only from PCa but also surrounding non-
cancerous tissues, such as skeletal muscle, where β subunits are also expressed (Diss 
et al., 2008). Additionally, β1–β4 mRNAs have been found in cervical cancer tissues. 
Compared to non-cancerous cervix tissues, β2, β3 and β4 mRNA levels are up-
regulated in cervical cancer, whereas in primary culture, β2 and β4 mRNAs are hardly 
detected (Hernandez-Plata et al., 2012). One possible explanation is that the roles of β 
subunits as cell adhesion molecules are different in biopsies and primary cultures 
(Hernandez-Plata et al., 2012). 
LNCaP cells overexpressing β2 display an elongated cell body with a reduced cell 
volume and increased migratory and invasive capacity, as well as a preferential binding 
to vitronectin compared to control LNCaP cells (Jansson et al., 2012). In contrast to the 
role of β1 in the MDA-MB-231 BCa mouse model, subcutaneously implanted LNCaP-β2 
cells show reduced tumour take and tumour volume in vivo (Jansson et al., 2012). Thus, 
β1 and β2 may interact with different extracellular proteins in these different models and 




SCN3B contains two response elements to p53 (Adachi et al., 2004). SCN3B is 
up-regulated after DNA damage in a p53-dependent manner in mouse embryonic 
fibroblasts, and overexpression of p53 up-regulates the β3 mRNA level in HCT116, 
Saos2 and H1299 human cancer cell lines (Adachi et al., 2004). Finally, although β1–β4 
mRNA has been found in SCLC cell lines, their roles in regulating cell activity have not 
been studied (Roger et al., 2007). In summary, VGSC β subunits are present in several 
cancer types, and they regulate key steps associated with metastasis.  
 
1.4.5 Therapeutic value of VGSCs in BCa 
Tumour microarray data have revealed that the Nav1.5 mRNA level is significantly 
higher in BCa biopsies from patients than in normal breast samples, and is higher in 
BCa samples from patients who developed metastasis, recurrence, or who died in five 
years (Yang et al., 2012), suggesting a relationship between Nav1.5 expression and 
malignancy in patients. Recent in vivo data show that suppressing VGSC activity 
reduces tumour growth and metastasis in rodents (Yildirim et al., 2012; Driffort et al., 
2014; Nelson et al., 2015a; Nelson et al., 2015b). Importantly, some of the studies 
adopted drugs inhibiting VGSCs that are approved by the US Food and Drug 
Administration (FDA) (Driffort et al., 2014; Nelson et al., 2015a), and repurposing these 
drugs may be a new strategy for cancer treatment. Riluzole, a compound that blocks 
VGSCs and the metabotropic glutamate receptor 1, reduces BCa growth in mice 
(Speyer et al., 2012) and supresses metabolic activity in patients with melanoma (Yip et 
al., 2009). A novel VGSC blocker, RS100642, reduces oxidative stress and improves 
animal survival in 7,12-dimethylbenz(a)anthracene (DMBA)-induced rat BCa model 
(Batcioglu et al., 2012). Taken together, an increasing amount of evidence suggests that 





1.5 Membrane potential as a functional signal in cancer progression 
An important outcome of collective ion channel and transporter activity is the 
change in cellular Vm. Vm, defined as the voltage across the plasma membrane, arises 
due to the unequal distribution of various types of ions, including Na+, K+, Cl- and Ca2+. 
As described by the Goldman-Hodgkin-Katz equation (Equation 1.1), the Vm depends on 
the permeability (P) and both the intracellular and extracellular concentrations of major 










)  (Equation 1.1) 
 
where R is the ideal gas constant, T temperature and F Faraday’s constant. As 
described in Section 1.1, in excitable cells including neurones, skeletal muscle fibres and 
cardiomyocytes, action potentials initiate from the depolarisation of Vm.  
Seminal work describing the functional roles of Vm in non-excitable cells began in 
the late 1960s, pioneered by Clarence D. Cone Jr. While studying mitotic activities in 
sarcoma cells, he reported that Vm undergoes hyperpolarisation before entering M phase 
(Cone, 1969), and that Vm hyperpolarisation reversibly blocks DNA synthesis and mitosis 
(Cone, 1970). Cone and colleagues then demonstrated that Vm depolarisation is able to 
initiate mitosis in CHO cells and mouse spleen lymphocytes (Cone & Tongier, 1971; 
Kiefer et al., 1980), whereas hyperpolarised Vm immediately precedes mitotic arrest 
(Cone & Tongier, 1973).  
 
1.5.1 Depolarised Vm correlates with tumourigenesis   
As early as the 1970s, Clarence D. Cone Jr. postulated that the Vm is correlated 
with the level of cell differentiation (Cone, 1971). A similar phenomenon was seen in 




transformation of normal cells (Tokuoka & Morioka, 1957; Johnstone, 1959). Indeed, 
recordings from rodent and human tissues revealed that proliferative cells, especially 
rapidly proliferating tumour cells, display relatively depolarised Vm, whereas non-
proliferating, terminally differentiated somatic cells, such as muscle cells and neurones, 
are characterised by their hyperpolarised Vm (Figure 1.3) (Binggeli & Weinstein, 1986; 
Blackiston et al., 2009; Yang & Brackenbury, 2013).  
Direct in vitro and in vivo comparisons of Vm levels between normal and cancerous 
breast cells (Marino et al., 1994), hepatocytes and hepatocellular carcinoma cells 
(Binggeli & Cameron, 1980; Stevenson et al., 1989), normal and neoplastic 
adrenocortical tissues (Lymangrover et al., 1975), normal embryonic fibroblasts and 
fibrosarcoma (Binggeli & Weinstein, 1985), benign and cancerous skin cells (Melczer & 
Kiss, 1957; Woodrough et al., 1975), and between normal and cancerous ovarian tissue 
(Redmann et al., 1972) show that cancer cells tend to be more depolarised than their 
normal counterparts. In a study where the Vm of MCF-10A, MCF-7, MDA-MB-468 and 
MDA-MB-231 BCa cells was compared, Vm was found to be more depolarised as the 
metastatic potential of the cell line increased: the Vm of the strongly metastatic MDA-MB-
231 cells is ~-19 mV, whereas the Vm is ~-40 and ~-50 mV in MCF-7 and MCF-10A 
cells, respectively (Fraser et al., 2005). In PCa, the Vm of strongly metastatic PC-3 cells 
is ~5 mV more depolarised than the weakly metastatic LNCaP cells (Laniado et al., 
1997). These findings suggest a correlation between depolarised Vm and cancer 
malignancy. Since Vm is determined by the combined activities of ion 
channels/transporters at the cell membrane, it would be natural to consider Vm merely as 
an epi-phenomenon resulting from changes in intracellular concentration of ions. 
However, over the past four decades, increasing evidence has shown that Vm is a 
functional signal regulating a number of cell behaviours, including cell proliferation, 








Figure 1.3. Membrane potential (Vm) scale.  
Rapidly proliferating cancer cells possess relatively  depolarised Vm (red box), while the 
Vm of quiescent cells is generally more hyperpolarised (cyan box). The Vm of proliferative 
somatic cells is also depolarised. Figure is adapted from (Binggeli & Weinstein, 1986; 




1.5.2 Vm and cell proliferation 
Depolarisation can function as a signal initiating mitosis and DNA synthesis in both 
highly proliferative tumour and non-tumour cells (Orr et al., 1972; Binggeli & Weinstein, 
1986). Artificially altering the Vm by modulating the extracellular ionic composition or 
applying the Na+/K+-ATPase inhibitor ouabain revealed interesting results: firstly, 
hyperpolarising the Vm of CHO cells to -45 mV induces mitotic arrest, and cell division is 
fully blocked at -75 mV. The cell cycle is resumed by depolarising the Vm to -10 mV 
(Cone, 1971). Secondly, quiescent (G0) mature chick spinal cord neurones show mitotic 
activity after depolarisation (Cone & Cone, 1976). By contrast, hyperpolarised Vm 
immediately precedes mitotic arrest (Cone & Tongier, 1973).  
An additional layer of complexity in this model is that the Vm fluctuates during cell 
cycle progression, and follows a multi-step and rhythmic pattern (Wonderlin & Strobl, 
1996; Blackiston et al., 2009) (Figure 1.4). Vm hyperpolarisation at the G1/S checkpoint is 
generally required for S phase initiation. For example, depolarising the cell membrane 
halts G1/S progression in glia (Canady et al., 1990), Schwann cells (Wilson & Chiu, 
1993), lymphocytes (Price et al., 1989; Freedman et al., 1992; Wang et al., 1992b), V79 
Chinese hamster lung cells (Sachs et al., 1974), C1300 mouse neuroblastoma cells 
(Boonstra et al., 1981) and MCF-7 human BCa cells (Wonderlin et al., 1995). The Vm 
then remains relatively hyperpolarised through S phase in some cell types (Sachs et al., 
1974; Boonstra et al., 1981; Strobl et al., 1995; Wonderlin et al., 1995), and more 
depolarised in others (Arcangeli et al., 1995; MacFarlane & Sontheimer, 2000). 
Moreover, the G2/M transition exhibits a depolarised Vm (Sachs et al., 1974; Boonstra et 
al., 1981; Blackiston et al., 2009), although it is not yet clear whether or not this 
depolarisation is a prerequisite for G2/M progression. In rat cardiomyocytes, ouabain-
induced depolarisation leads to an increased population in G2/M (and S) phase (Lan et 








Figure 1.4. Membrane potential (Vm) and the progression of cell cycle.  
Vm undergoes  hyperpolarisation at G1/S border, by virtue of K+ efflux through various 
types of K+ channels.  Before cells enter M phase, increased Cl- efflux accompanies Vm 
depolarisation.  Quiescent cells at G0 stage show mitotic activities after Vm depolarisation. 




 mediated by Cl- efflux through the outward rectifying ClC3 channels (Habela et al., 
2008). In addition, exogenous ClC2 channels are highly expressed in M phase in NRK-
49F rat kidney fibroblasts (Zheng et al., 2002).  
The fluctuation of Vm levels across the cell cycle does not necessarily contradict 
the observation that depolarised Vm could be a signature of cancer cells. The mean Vm 
values in cancer cells are consistently depolarised relative to most normal somatic cell 
types (Figure 1.3). For example, MCF-7 cells arrested at G1 phase have a Vm of -9 mV 
and hyperpolarize to ~-30 mV in the S phase (Wonderlin et al., 1995). Both these values 
are more depolarised than normal breast cells, e.g. the mean Vm of unsynchronised 
MCF-10A cells is between -40 and -58 mV (Wonderlin et al., 1995; Fraser et al., 2005). 
Evidence suggests that the fluctuation in K+ conductance contributes significantly 
to changes in Vm during the cell cycle. For example, in neuroblastoma and Ehrlich 
ascites cells, there is a transient decrease in K+ efflux before entering the G2 phase, and 
a relatively high level of K+ efflux during the M phase (Mills & Tupper, 1976; Boonstra et 
al., 1981). Given the diversity of K+ channel types (Hille, 1992; Miller, 2000; Wang, 
2004), their contributions to the Vm and Vm-dependent cell cycle progression are 
probably context-dependent and highly complex. For example, inhibition of cell 
proliferation with K+ channel inhibitors does not correlate with changes in the Vm in rat 
C6 glioma cells (Rouzaire-Dubois et al., 2000). In addition, the Vm is likely to be 
determined by the collective activities of a variety of ions channels/transporters, which 
may exhibit reciprocal interactions and form a large and complex network responsible for 
Vm regulation and its downstream effects.  
 
1.5.3 Ion channel-dependent regulation of proliferation and Vm 
Numerous studies have shown that pharmacological or genetic block of VGPCs 
reduces proliferation of cancer cells (Fraser et al., 2000; Ouadid-Ahidouch et al., 2000; 





































































































































































































































































































































































































































Increasing evidence suggests that Ether à go-go (EAG) K+ channels may serve as 
biomarkers for cancer (Ouadid-Ahidouch et al., 2001; Farias et al., 2004; Pardo et al., 
2005; Hemmerlein et al., 2006; Ousingsawat et al., 2007; Ortiz et al., 2011; Rodriguez-
Rasgado et al., 2012). Inhibition of EAG channel expression reduces proliferation in 
several cancer cell lines, whereas implantation of CHO cells overexpressing EAG 
channels in mice induces tumours (Pardo et al., 1999). In synchronised SH-SY5Y 
neuroblastoma cells, EAG current (IEAG) is reduced to less than 5 % in G1 phase, 
compared to unsynchronised controls, suggesting that the activity of EAG channels is 
cell-cycle dependent (Meyer & Heinemann, 1998). Indeed, in MCF-7 cells, inhibiting 
EAG channels with astemizole increases the proportion of cells in G1 phase and reduces 
the proportion in S phase (Borowiec et al., 2007). In contrast, activation of human EAG 
(hEAG) channels is responsible for hyperpolarisation at late G1 before the cells enter the 
S phase (Ouadid-Ahidouch et al., 2001). Interestingly, the hyperpolarisation is 
accompanied by increased Ca2+-activated K+ (KCa) channel currents (Ouadid-Ahidouch 
et al., 2001), which might result from the elevated intracellular Ca2+ due to the increased 
electrochemical gradient during the hyperpolarisation (Nilius & Wohlrab, 1992; Ouadid-
Ahidouch & Ahidouch, 2008). 
KCa channels were thought to be one of the main controllers of the Vm in Friend 
murine erythroleukemia cells (Arcangeli et al., 1987). KCa channels have been found in 
glioma (Liu et al., 2002), PCa (Gessner et al., 2005), BCa (Haren et al., 2010) and the 
CD133+ subpopulation of SH-SY5Y cells (Park et al., 2010). Inhibiting KCa channels with 
iberiotoxin (IbTx) arrests D54-MG glioma cells in S phase, and leads to apoptosis 
(Weaver et al., 2004). Thus, the functional contribution of KCa channels to cell cycle 
regulation appears to be distinct from VGPC channels. In addition, in MCF-7 cells, 
inhibition of ATP-sensitive K+ (KATP) channels reversibly arrests cells in the G0/G1 phase 
(Woodfork et al., 1995). The two-pore domain K+ channel, TREK1, increases 





overexpression of TREK1 increases the number of cells in S phase, and reduces the 
number of cells at G0/G1 phase (Voloshyna et al., 2008). 
Human EAG-related gene (HERG) K+ channels are strongly inwardly rectifying and 
conduct K+ influx when the voltage is more negative than the K+ equilibrium potential 
(Trudeau et al., 1995; Smith et al., 1996). HERG current (IHERG) is expressed at early 
developmental stages in the neural crest, central nervous system, dorsal root ganglion 
(DRG) and skeletal muscle, and is replaced by classic inward rectifier K+ current (IKir) 
later in development (Arcangeli et al., 1997; Crociani et al., 2000). HERG channels are 
up-regulated in a number of cancers (Arcangeli, 2005). Moreover, IHERG increases 
tumour cell proliferation (Bianchi et al., 1998; Wang et al., 2002). The activity of IHERG 
itself is cell cycle dependent (Arcangeli et al., 1995), suggesting a complex relationship 
between IHERG, Vm and proliferation. Additionally, inward rectifier K+ (Kir) channels have 
been reported in various cancer cell types, and are required for proliferation, including 
Kir2.2 (Lee et al., 2010), Kir3.1 and Kir3.4 (Plummer et al., 2004; Takanami et al., 2004; 
Plummer et al., 2005; Wagner et al., 2010). In contrast, overexpression of Kir4.1 in 
glioma cells hyperpolarises the Vm and increases the number of cells in quiescent G0/G1, 
reducing the proportion in G2/M phase (Higashimori & Sontheimer, 2007). Thus, different 
Kir channels may play opposing roles in regulation of Vm/proliferation, as a result of their 
heterogeneous voltage dependence.  
The mechanisms underlying ion channel-dependent proliferation of cancer cells 
include direct interaction between ion channels and other pro-proliferative signalling 
pathways (Wang, 2004; Ouadid-Ahidouch & Ahidouch, 2008; Prevarskaya et al., 2010). 
For example, co-expression of HERG and tumour necrosis factor receptor 1 (TNFR1) 
has been found at the cell membrane of SKBR3 BCa and SH-SY5Y neuroblastoma 
cells, and HERG appears to recruit TNFR1 to the membrane, therefore enhancing TNF-
α-induced cancer cell proliferation (Wang et al., 2002). Alternatively, ion channel-




therefore elevate the intracellular Ca2+ concentration through voltage-independent Ca2+ 
channels, such as transient receptor potential (TRP) channels (Nilius & Wohlrab, 1992; 
Wang, 2004; Ouadid-Ahidouch & Ahidouch, 2008). Ca2+ signalling is functional across 
the whole cell cycle (Santella et al., 2005). For example, Ca2+ is required for G1 
progression and G1/S transition (Hazelton et al., 1979; Choi et al., 2006). In turn, 
intracellular Ca2+ and CaM can regulate KCa and EAG channels (Khanna et al., 1999; 
Ziechner et al., 2006; Ouadid-Ahidouch & Ahidouch, 2008). Thus, there may be a 
reciprocal, autoregulatory relationship between ion channel activity, Vm, intracellular Ca2+ 
signalling, and proliferation. 
Changes in Vm are likely to trigger intracellular signalling messengers such as Ca2+ 
in order to drive sustained proliferation. Vm is a double-edged sword when fulfilling its 
role in regulating intracellular Ca2+: a depolarised Vm activates voltage-gated Ca2+ 
channels (VGCCs) that result in Ca2+ influx (Borodinsky & Fiszman, 1998; Zhang et al., 
2008), whereas a hyperpolarised Vm increases the transmembrane electrochemical 
gradient and therefore enhances the driving force for entry of Ca2+ and other types of 
cations (Prevarskaya et al., 2010; Schwab et al., 2012; Yang & Brackenbury, 2013). 
Inhibition of Ca2+ entry or CaM/CaM kinase (CaMK) shows cell cycle arrest at specific 
checkpoints. For example, depleting extracellular Ca2+ results in human WI-38 
fibroblasts accumulating at G1 (Hazelton et al., 1979); inhibition of CaMK arrests 3T3 
cells at G1 phase (Tombes et al., 1995; Morris et al., 1998). Moreover, TFs including the 
nuclear factor of activated T cells (NFAT), c-Myc, c-Jun and c-Fos are also Ca2+-
dependent (Prevarskaya et al., 2014). Activation of these TFs then promotes cancer cell 
growth by inducing the expression of cyclins and cyclin-dependent kinases (CDKs) 
(Roderick & Cook, 2008). In summary, a multiplicity of ion channels (predominantly K+-
conducting) participates in Vm regulation (both depolarisation and hyperpolarisation) in 





1.5.4 Role of Vm in cancer cell migration  
Vm is regarded as an indirect factor that can affect cell migration, whose main 
regulatory role might be setting up the electrical driving force for Ca2+ (Prevarskaya et al., 
2010; Schwab et al., 2012). Intracellular Ca2+ concentration ([Ca2+]i) displays a gradient 
in migrating cells, with the lowest concentration at the leading edge (Brundage et al., 
1991). “Ca2+ flicker” describes a phenomenon whereby local [Ca2+]i undergoes dynamic 
regulations during cell migration (Wei et al., 2009; Wei et al., 2012). In WI-38 fibroblasts, 
the membrane-stretch sensitive TRP melastatin channel TRPM7 collaborates with the 
store Ca2+releasing inositol 1,4,5-trisphosphate (IP3) receptor to induce stochastic Ca2+ 
flicker activity at the leading edge of migrating cells. The transient increase in local Ca2+ 
concentration steers directional turning. It is proposed that the Ca2+ flickers facilitate 
local cytoskeletal rearrangement, force generation and integrin turnover (Wei et al., 
2009; Wei et al., 2012). More, the retraction of the rear-end body is mediated by myosin 
contraction controlled by the phosphorylation of myosin regulatory light chain (MLC) 
through Ca2+-dependent MLC kinase (MLCK) (Olson & Sahai, 2009). The [Ca2+]i 
fluctuations play a role in regulating tractional forces (Lee et al., 1999; Ridley et al., 
2003), direction sensing, and cytoskeleton reorganisation (Figure 1.6) (Pettit & Fay, 
1998).  
Vm may also affect downstream intracellular signalling cascades that could 
contribute to cell migration in a Ca2+-independent way. In kidney epithelial cells, Vm 
depolarisation induces phosphorylation of MLC without inducing Ca2+ signalling, but 
instead by activating the Rho-associated kinase (ROCK) pathway (Szaszi et al., 2005). 
In addition, actin filaments undergo reorganisation following Vm depolarisation in bovine 
eye endothelial and epithelial cells (Chifflet et al., 2003; Chifflet et al., 2004), suggesting 
a functional role for Vm in cytoskeletal reorganisation, although it is not clear whether or 








Figure 1.6. Relationships between Na+, K+, Cl- channels and membrane potential (Vm) in 
cancer cell  migration.  
Vm provides the driving force for Ca2+, and downstream Ca2+ signalling  leads to cell 
migration. Vm also regulates cytoskeleton  reorganisation. Cl- and K+ channels 
both  contribute to Vm regulation and cell volume control. Inhibiting particular  Na+, K+ and 
Cl- channels can reduce cancer cell migration.  However, how Na+ contributes to Vm 
regulation and Ca2+ signalling in cancer is less understood (dashed lines). Figure is 




A number of Na+, K+ and Cl- channels, which may potentially contribute to the Vm, 
are directly implicated in cancer cell migration (Section 1.4.3.2). In several breast 
carcinoma/melanoma cell lines, KCa2.3, which is responsible for maintaining a 
hyperpolarised Vm, enhances migration, likely via promotion of intracellular Ca2+ 
signalling (Potier et al., 2006; Chantome et al., 2009). In addition, KCa3.1 activity causes 
a local shrinkage at the rear of migrating MDCK-F cells, therefore supporting retraction 
at this pole during movement (Schwab et al., 2006). In order to maintain 
electroneutrality, K+ efflux must be accompanied by an anion, which is Cl- under most 
circumstances (Schwab et al., 2007; Schwab et al., 2012). In agreement with this, Cl- 
channels, which contribute to the depolarised Vm in glioma cells, enhance migration and 
invasion by permitting the release of K+, Cl- and water at the leading edge, resulting in 
shrinkage and facilitating movement into tortuous extracellular spaces (Soroceanu et al., 
1999; Sontheimer, 2008; Habela et al., 2009; Schwab et al., 2012). In summary, a direct 
role for Vm in regulating cancer cell migration is much less clear than for proliferation. 
Additionally, it is noteworthy that the contribution of Na+ channels to Vm, and whether Na+ 
channel activity affects Ca2+ signalling in cancer cells, are less studied (Figure 1.6). 
 
1.5.5 Vm and the differentiation of cancer stem cells 
Stem cells and cancer cells share similar properties, such as the ability to 
differentiate and self-renew, increased membrane transporter activity and the ability to 
migrate and metastasise (Wicha et al., 2006). The cancer stem cell (CSC) hypothesis 
contains two key concepts: (1) cancers arise from dysregulated transformation of normal 
tissue stem cells or progenitor cells, and (2) cellular components that display stem cell 
properties can lead to cancer progression (Wicha et al., 2006). In contrast to normal, 
regulated asymmetric division of stem cells during tissue homeostasis, where a stem cell 
produces one copy of itself and one cell that later differentiates into a mature cell (Figure 






Figure 1.7. Membrane potential (Vm) in normal stem cell differentiation and hypothesised 
role for Vm in  cancer stem cells (CSCs).  
Depolarised Vm is needed during the maintenance of stem cells.  Stem cell undergoes 
asymmetric division where it produces one copy of itself and one  progeny that later 
differentiates into mature cells. The maturation requires Vm hyperpolarisation 
(Sundelacruz et al., 2008). However, CSCs  frequently undergo symmetric division, in 
which one CSC divides into two identical  CSC progenies (Wicha et al., 2006). Sustained 
Vm depolarisation may help to  maintain the increasing CSCs in an undifferentiated state. 





division” in which each malignant CSC generates two identical daughter cells (giving rise 
to either proliferation or differentiation), which significantly expands the malignant CSC 
reservoir (Figure 1.7) (Liu et al., 2005). 
The involvement of Vm in differentiation of normal stem cells has been previously 
reported. Studies in quail neural crest cells and a subpopulation of SH-SY5Y 
neuroblastoma cells have demonstrated that stem cells exhibit distinct bioelectrical 
profiles during development (Arcangeli et al., 1997; Biagiotti et al., 2006; Sundelacruz et 
al., 2009). In particular, a hyperpolarised Vm is required during stem cell maturation 
(Sundelacruz et al., 2009). For example, Kir-induced Vm hyperpolarisation is required for 
human myoblast fusion (Liu et al., 1998). In a genome-wide microarray analysis of 
depolarisation-regulated genes in postnatal mouse cerebellar granule neurones, among 
87 depolarisation-responsive genes, 22 are developmentally up-regulated and 26 are 
developmentally down-regulated (Sato et al., 2005). Remarkably, 18 of the 22 (82 %) 
developmentally up-regulated genes coincide with depolarisation down-regulated genes, 
and 20 of 26 (77 %) developmentally down-regulated genes coincide with depolarisation 
up-regulated genes (Sato et al., 2005). Vm hyperpolarisation is also a functional 
determinant of human mesenchymal stem cell (hMSC) differentiation. Pharmacologically 
induced Vm depolarisation suppresses adipogenic and osteogenic differentiation of 
hMSCs (Sundelacruz et al., 2008). In addition, depolarisation reduces the differentiation 
phenotype of hMSC-derived cells and enables plastic transdifferentiation (Sundelacruz 
et al., 2013). Taken together, these data suggest that a depolarised Vm may maintain 
cells in an undifferentiated stage at the gene expression level. Therefore, it is not 
unreasonable to postulate that depolarised Vm may also contribute to maintaining a 





1.5.6 Depolarised Vm regulates tumourigenesis and development in vivo 
Studies published by Michael Levin’s group have examined the functional roles of 
Vm in development and tumourigenesis using Xenopus laevis and planarian flatworms. 
The researchers depolarised the Vm of Xenopus laevis embryos by reducing the 
environmental Cl- concentration and concurrently activating the endogenous glycine 
receptor Cl- channels using ivermectin (Lobikin et al., 2012). Using this method, the 
researchers found that during Xenopus laevis development, the depolarised 
melanocytes in the tadpole neural crest exhibit neoplastic phenotypes including over-
proliferation, arborized cell morphology and increased local invasion.  
One study demonstrated that these metastatic phenotypes are ion type and ion 
channel non-specific, because firstly, the phenotypes caused by depolarisation could be 
rescued by expressing hyperpolarising inward-rectifier K+ channels, and secondly, the 
malignant phenotype could be induced or suppressed simply by adjusting extracellular 
Cl- concentration, as predicted by Goldman-Hodgkin-Katz equation (Lobikin et al., 2012). 
Interestingly, overexpression of a human oncogene Gli1 in Xenopus laevis embryos by 
microinjection induced tumour-like structures in developed tadpoles, and Na+ imaging 
revealed that such structures are enriched for Na+ (Lobikin et al., 2012). SLC5A8, a 
sodium butyrate co-transporter, is shown to play a vital role in the Vm signal transduction 
pathway: butyrate is suggested to act as a histone deacetylase inhibitor upon Vm 
hyperpolarisation, and since acetylation of histones leads to arrest of cell proliferation, 
the over-proliferation of cells is reduced due to butyrate influx (Tseng & Levin, 2012; 
Chernet & Levin, 2013).  
Studies also proposed that these effects are mediated by voltage control of 
serotonin release from melanocytes (Blackiston et al., 2011; Chernet & Levin, 2013; 
Lobikin et al., 2015): a depolarised Vm increases serotonin export through the serotonin 
transporter (SERT) at plasma membrane, resulting in an increase in serotonin 




receptors, including 5HT-R2 and 5HT-R5, on nearby melanocytes and on pituitary 
melanotrope cells, are activated. The activation of 5HT receptors consequently 
stimulates adenylyl cyclase (AC), causing release of melanocyte-stimulating hormone; 
this increases the expression of Sox10 and Slug, both TFs, across the animal body, 
which ultimately result in cell over-proliferation (Lobikin et al., 2015). 
During development of the Xenopus laevis embryo, a gradual Vm hyperpolarisation 
is reported in the cells lining the neural tube at the start of neural fold formation and 
before the neural tube closure (Pai et al., 2015). Hyperpolarising the embryo by 
expressing hyperpolarising ion channels reduces expression of brain TFs including otx2, 
emx and bf1. Unlike the model proposed in the melanocytes using the same animal 
model, here, both Ca2+ flux and gap junction-mediated Vm regulation, but not the 
serotonin signalling pathway, are involved in Vm-dependent brain development (Pai et 
al., 2015).  
In Dugesia japonica planaria, Vm depolarisation plays a role during development 
and regeneration. Dissected planarian flatworm pharynx fragments (blastema) can 
regenerate and grow into a new flatworm. After dissection, it has been shown that H+-K+-
ATPase activity depolarises the Vm of the anterior blastema, and inhibition of the H+-K+-
ATPase with SCH-28080 abolishes the depolarised Vm and blocks anterior polarity and 
head regeneration (Beane et al., 2011; Beane et al., 2013). Interestingly, hyperpolarised 
blastemas become either tail- or headless, whereas ivermectin-induced Vm 
depolarisation at the posterior of pharynx results in head formation (Beane et al., 2011). 
It is suggested that depolarised Vm increases Ca2+ influx carried by VGCCs and 
therefore mediates regeneration (Beane et al., 2011).  
In summary, Vm has been previously regarded simply as an outcome of the 
collective activity of ion channels/transporters at the cell membrane. However, more and 
more data suggest that Vm is a functional signal in cell proliferation, migration and stem 




Cancer cells tend to possess a depolarised Vm, but the roles of Vm in regulating cancer 
cell metastatic behaviours including migration and invasion are less studied. Similarly, it 
is unknown whether VGSCs are functionally involved in regulating the Vm of BCa cells. 
 
1.6 Hypothesis and aims 
The overall hypothesis of the present study was that VGSCs in MDA-MB-231 cells 
increase cancer cell metastatic behaviours, including migration and invasion, via 
depolarising the Vm. The aims of this study were three-fold: 
(1) To investigate the involvement of VGSCs in Vm regulation in human MDA-
MB-231 cells. 
(2) To investigate whether Vm contributes to VGSC-dependent cancer cell 
migration and invasion. 
(3) To study the Vm and INa in primary tumours from mice xenografted with MDA-
MB-231 cells. 
The data presented in this thesis have resulted in several peer-reviewed 
publications, and a further manuscript in preparation, detailed in Error! Reference 








2 Chapter 2: Materials and Methods 
2.1 Cell culture 
2.1.1 Cell lines 
MDA-MB-231 human BCa cells were a gift from Prof Lori Isom (University of 
Michigan). MDA-MB-231 cells stably expressing enhanced green fluorescent protein 
(eGFP) and luciferase (Nelson et al., 2014) were stably transduced with lentivirus for 
shRNAs targeting Nav1.5 (hereafter called “Nav1.5-shRNA” cells) or non-targeting 
control shRNA  (hereafter called “shRNA control” cells) using MISSION pLKO.1-puro 
shRNA transduction particles (Sigma) (Nelson et al., 2015b). Molecular identify of cells 
was confirmed by short tandem repeat analysis (Masters et al., 2001). MCF-7 cells 
where the oestrogen receptor α was knocked-down using shRNA (namely pII cells) 
(Luqmani et al., 2009) and control MCF-7 cells were a gift from Prof Yunus A. Luqmani 
(Kuwait University). Cells were confirmed to be mycoplasma-free (Section 2.1.5). 
 
2.1.2 Maintenance and passage of cells 
MDA-MB-231 cells were grown in Dulbecco’s modified eagle medium (DMEM, 
Life Technologies) supplemented with 5 % foetal bovine serum (FBS, Life 
Technologies) and 4 mM L-glutamine (Life Technologies) at 37 °C, 5 % CO2, 100 % 
relative humidity. For Nav1.5-shRNA and shRNA control cells, G418 (4 μl/ml, Sigma), 
blasticidin (2 μl/ml, AppliChem) and puromycin (0.1 μl/ml, Sigma) were applied to the 
cell culture medium. Unless otherwise stated, cells were grown in T25 flasks (Corning) 
or 10 cm culture dishes (Corning). The cell culture medium was changed every 72 h for 




Cells were passaged when the density reached approximately 90 %. After 
aspirating the old medium, 1 ml trypsin-EDTA (0.05 %, Life Technologies) was applied 
to the cells, and the cells were transferred into cell incubator for 30 s before viewing at 
10X under an inverted microscope. Cells were incubated for a further 15 s if they were 
not starting to lift from the culture surface. Before the cells started to lift off, trypsin-
EDTA was removed from the culture dish or flask, and was replaced with 2 ml culture 
medium. Cells adherent to the surface were triturated gently using a P1000 pipette. 
Four to six drops of the cell suspension were transferred to a new culture dish or flask, 
and 10 ml culture medium was added. Cells were passaged no more than 10 times 
after thawing. 
 
2.1.3 Cell counting 
To count the cells, 20 μl of well-mixed cell suspension was placed in one 
chamber of an improved Neubauer haemocytometer and covered with a rectangular 
glass coverslip. Cells at each of the four corner squares were counted using a hand-
held counter. The number of cells in the suspension was calculated using the following 
equation: 
 
𝐶𝑒𝑙𝑙	𝑛𝑢𝑚𝑏𝑒𝑟	 𝑝𝑒𝑟	𝑚𝑙 = 	 &GH1;	IJ"KLM	GN	OL;;P	OGJIHLQ
R
	×	10R (Equation 2.1) 
	
2.1.4 Freezing and thawing cells 
Cells were transferred to a 15 ml falcon tube after being removed from the 
surface of a ~90 % confluent culture dish or flask. Cells in the falcon tube were pelleted 
using a bench-top centrifuge at ~200 g at room temperature. The supernatant was 




freezing medium, containing 70 % (v/v) DMEM, 20 % (v/v) FBS and 10 % (v/v) dimethyl 
sulfoxide (DMSO). Cells were then aliquoted into cryovials (200 μl/vial). The vials were 
placed upright in a polystyrene box and stored at -80 °C for one week before being 
transferred into a liquid nitrogen dewar for long-term storage. 
To thaw the cells, culture medium (10 ml) was prepared in an empty flask. A 
cryovial containing frozen cells was taken from the liquid nitrogen dewar and thawed in 
a water bath at 37 °C for 30 s. The defrosted suspension was then gently transferred to 
the flask. After 24 h, the medium was changed. 
 
2.1.5 Mycoplasma testing in cell cultures 
Cells were confirmed to be free of mycoplasma contamination before use in 
experiments and were routinely tested at six-month intervals. Cells were plated on 13 
mm uncoated glass coverslips in a 35 mm culture dish and cultured in culture medium 
for 48 h. The medium was then removed and cells were fixed with 1 ml methanol at 
room temperature for 5 min. Methanol was removed after cell fixation, 4',6-diamidino-2-
phenylindole (DAPI) (1 ml) prepared at 0.5 μg/ml in methanol was added. Cells were 
incubated at room temperature for a further 10 min before washing once with methanol, 
followed by two additional washes using phosphate buffered saline (PBS, Life 
Technologies). Approximately 20 μl of Faramount mounting medium (Dako) was 
applied to a rectangular No. 1 glass microscope slide. The glass coverslip was then 
mounted onto the slide suing a pair of forceps, with the cell-growing surface facing the 
mounting medium. The slides were examined using an epi-fluorescence microscope 
(Section 2.9). Cells without mycoplasma contamination showed no DAPI staining in the 






Drugs used in the present study and the concentrations used are detailed in 
Table 2.1. 
 
2.3 Tumour xenografts in mouse mammary fat pad 
2.3.1 Ethics statement 
Investigation has been conducted in accordance with the ethical standards 
according to the Declaration of Helsinki and according to national and international 
guidelines and has been approved by the University of York Ethical Review Process. 
The work presented in the current study was under authority of a Home Office-
approved protocol (Project Licence number: 60/4277). 
 
2.3.2  Animals 
Female immunocompromised mice (rag2-/-, gc-/-) were obtained from the 
Yorkshire Cancer Research Unit at the University of York. Mice were maintained under 
specific pathogen free (SPF) conditions in individually ventilated cages. Each cage 
contained three to five mice with food and water provided ad libitum. Mice were 
weaned three weeks after birth, and were maintained for a further three weeks before 
surgery. In total, 50 mice from 13 cages were used in this study. 
 
2.3.3 Tumour xenograft orthotopic implantation 
The following work was done in a class II bio-safety cabinet, which was cleaned 
with 70 % ethanol before the procedure. Each mouse was weighed on a scale before 
being transferred to an anaesthesia chamber supplied with 2 % isoflurane for 2 min. 





Table 2.1. Pharmacologial agents used in the study 
Name Manufacturer Solvent and stock concentration 
Working 
concentration 
Gramicidin Sigma Ethanol; 5 mM 0.4 % v/v (20  μM) 
IbTx Alomone Labs Water; 20 μM  0.5 % v/v (100 nM) 
Ionomycin Cayman Chemical Ethanol; 14.1 mM 0.46 % v/v (10 μM) 
Nifedipine Alomone Labs DMSO; 5 mM  0.2 % v/v (10 μM) 
NS-1619 Alomone Labs DMSO; 10 mM 0.01 – 0.4 % v/v (1–40 μM) 
Nystatin Serva DMSO; 30 mg/ml 0.4 % v/v (120 μg/ml) 
Phenytoin Sigma 75 mM NaOH; 180 mM  0.06 % v/v (100 μM) 
TTX Alomone Labs Water; 1 mM 3 % v/v (30 μM) 
Veratridine Alomone Labs DMSO; 5 mM 2 % v/v (20 μM) 




constant isoflurane at 1.5 % supplied via a nose cone. Carprofen (100 μl) at 0.75 
mg/ml was subcutaneously injected before an ear notch tag was applied. The mouse 
abdomen area was then gently shaved and cleaned with a piece of gauze sprayed with 
chlorhexidine (0.2 % w/v). A 2 mm-long incision was made at the centre of abdomen 
between the fourth inguinal mammary glands (Figure 2.1). The skin was separated 
from muscle and fat pad using forceps. Cells (5 × 105) suspended in Matrigel/PBS were 
gently injected via a 1 ml insulin syringe. The wound was then closed using sutures. 
The mouse was transferred to a recovery cage, and the recovery from anaesthesia 
was monitored for 20 min. The animal was returned to its home cage after checking the 
wound. 
 
2.3.4 Tumour size measurement using callipers 
The health status and weights of the mice were checked the day after surgery. 
Animals were weighed every other day thereafter, until tumours developed 
(approximately seven days after surgery). When the tumour was observed in the 
mammary fat pad, the weight of the animal was measured daily, and the size of the 
tumour was monitored using callipers once a day. To determine the tumour volume, 
both the greatest longitudinal diameter (length) and the greatest transverse diameter 
(width) were measured using callipers, and the tumour volume was calculated as: 
 
𝑇𝑢𝑚𝑜𝑢𝑟	𝑣𝑜𝑙𝑢𝑚𝑒/𝑤𝑒𝑖𝑔ℎ𝑡	(𝑚𝑚_	or	mg) = 0.5	×	(𝑙𝑒𝑛𝑔𝑡ℎ	×	𝑤𝑖𝑑𝑡ℎg) (Equation 2.2) 
 
Mice were euthanised using a Schedule 1 method 20–37 days after surgery, or 
before the weight of the tumour reached 10 % of the animal’s body weight, or if the 







Figure 2.1. Location of mammary tissues in the female mouse.  
In total, there are five pairs of mammary glands in the female mouse. The present 
study orthotopically implanted breast cancer cells in the fourth inguinal mammary 






2.4.1 Cell preparation 
Three days before recording, cells (6 × 104) were plated on two uncoated glass 
coverslips in a 35 mm culture dish with 2 ml culture medium. Cells were incubated as in 
Section 2.1.2. The medium was changed 48 h after seeding the cells. 
 
2.4.2 Solutions 
Extracellular and intracellular recording solutions used in the present study and 
their components are in Table 2.2 and Table 2.3, respectively. In Na+-free extracellular 
solutions, NaCl was replaced with equimolar choline chloride (ChoCl) or N-methyl-D-
glucamine (NMDG). Extracellular solution with Ba2+ was used to block BKCa channels, 
and extracellular solution with Cd2+ was used to block VGCCs (Hille, 2001).  
For intracellular solutions, ethylene glycol tetraacetic acid (EGTA) was used to 
buffer Ca2+. Free Ca2+ concentration in the intracellular solution was calculated using 
the MaxChelator program (Stanford University). Cs+ was used to inhibit VGPCs and Kir 
channels (Hille, 2001) 
 
2.4.3 Equipment for voltage- and current-clamp recordings 
Equipment for electrophysiology was set up as in Figure 2.2. A MultiClamp 700B 
amplifier (Molecular Devices) was used to record voltage-activated membrane current 
and voltage, and a Digidata 1440A data acquisition system (Molecular Devices) was 
used for analogue-digital signal conversion. A VC34 (Scientific Instruments) computer-
controlled valve system and a Dymax 5 (Charles Austen Pumps) air pump were used 
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Figure 2.2. Electrophysiology equipment used in this study.  
Perfusion of external solution was controlled by a VC34 valve control system and a 
Dymax 5 pump. Cells were immersed in extracellular solution and observed using an 
Olympus BX51WI microscope. Pipette movement was controlled by the PatchStar 
micromanipulator. The electrical signal was transmitted to the MultiClamp 700B 
amplifier through the CV-7B headstage. Analogue and digital signals were converted 
using the Digidata 1440A. User commands were sent to the amplifier using Clampex 




7B) was connected to a PatchStar micromanipulator (Scientifica) in order to control 
pipette movement. A silver wire was used as the recording electrode inside the pipette. 
Before installation onto the headstage the silver wire was chlorided by connecting to 
the positive pole of a 9 V cell, while the other end was soaked in 3 M KCl. It was re-
chlorided at regular intervals. 
Cells were observed using an Olympus BX51WI light microscope. A chamber 
(Warner Instruments RC-26GLP) fixed by a stage adaptor (Warner Instruments SA-
OLY/2) was used to hold cells on coverslips under constant perfusion with extracellular 
physiological saline solution (PSS). The data acquired by the Digidata 1440A were 
saved to a PC running Clampex 10.4 and MultiClamp 700B Commander 2.1.0 software 
(Molecular Devices). User commands were sent to the MultiClamp 700B using this 
software.  
 
2.4.4 Preparation of borosilicate pipettes 
Both blunt ends of borosilicate glass capillaries (Harvard Apparatus GC150TF-
7.5) were fire-polished in a Bunsen flame and then pulled into pipettes using a P-97 
micropipette puller (Sutter Instrument). After pulling, pipette tips were fire-polished 
using a Narishige MF-830 microforge, in order to give resistances of 3.5–4.5 MΩ when 
filled with internal solution.  
 
2.4.5 Recording current using whole-cell patch clamp from cultured cells 
Current across the plasma membrane was recorded using the whole-cell patch 
clamp technique. A single target cell was located at 40X magnification. Approximately 
10 μl intracellular solution was backfilled into glass pipette through a 0.45 μm filter and 
the pipette was installed onto the headstage. Approximately 2 ml of air was injected 




pressure. The pipette was firstly moved close to the bottom of the chamber under 10X 
magnification, and it was then moved to the target cell from above with 40X 
magnification. The pipette offset was compensated. When the pipette was slightly 
pressing the cell, giving a “dimple” on the cell membrane, positive pressure was 
released, and if a high resistance seal (gigaseal) did not start to form, 0.1–0.2 ml 
negative pressure was gently applied. When the seal resistance started to increase, 
holding voltage was set in Clampex (Table 2.4). When the seal resistance was stably at 
≥ 1.1 GΩ, approximately  0.3 ml suction was applied as negative pressure to break the 
cell membrane patch. Whole-cell capacitance, and fast and slow pipette capacitance 
values were displayed in the Multiclamp 700B Commander software panel, and were 
compensated. Typical series resistance was between 5–15 MΩ, and was compensated 
by 40–60 %.  
Membrane currents were acquired and digitised at 50 kHz using a Digidata 
1440A interface (Molecular Devices), low-pass filtered at 10 kHz and analysed using 
pCLAMP 10.4 software (Molecular Devices). Linear components of leak were 
subtracted using a P/6 protocol (Armstrong & Bezanilla, 1977). 
 
2.4.6 Perforated patch clamp recordings 
The perforated patch clamp technique was used to record the large-conductance 
Ca2+-activated K+ (BKCa) current in MDA-MB-231 cells (Akaike & Harata, 1994). A 
gigaseal was achieved as described above. However, instead of achieving whole-cell 
configuration by applying negative pressure, the target cell was continuously held 
between -25 and -60 mV, at whichever the seal was best maintained. In the 
“Membrane Test” window (2.5 mV test pulse sampling at 100 Hz), when the membrane 
capacitance transient current occurred (typically after 15–20 minutes), whole-cell 






Table 2.4. Holding potential applied to cells when forming a gigaseal 
Seal resistance Holding potential 
20–30 MΩ -25 mV 
30–100 MΩ -50 mV 
100–300 MΩ -65 mV 
300–500 MΩ -70 mV 




and 40 MΩ, and was compensated by 50–70 %.  
 
2.4.7 Voltage-clamp protocols 
The following protocols were used in the voltage-clamp experiments in this study. 
A 250 ms pre-pulse at -120 mV was applied to all of the protocols, unless otherwise 
stated: 
(1) Standard INa stimulation protocol: cells were depolarised from -120 mV to -
10 mV for 50 ms, repeated 10 times. The inter-pulse interval was 100 ms. 
(2) Standard INa stimulation protocol with -80 mV pre-pulse: cells were 
depolarised from -80 mV to -10 mV for 50 ms, repeated 10 times. The inter-
pulse interval was 100 ms. 
(3) Standard current-voltage protocol: cells were depolarised to voltages 
ranging from -80 mV to +30 mV for 60 ms in 5 mV increments. The inter-
pulse interval was minimum. 
(4) INa steady-state inactivation protocol: cells were depolarised to -10 mV for 
60 ms following 250 ms conditioning pulses between -120 mV to -10 mV in 
10 mV increments. The inter-pulse interval was 20 ms. 
(5) BKCa current (IBKCa)-voltage protocol in perforated patch configuration: cells 
were depolarised to voltages ranging from -60 mV to +90 mV for 300 ms in 
10 mV increments. The inter-pulse interval was 50 ms. 
 
2.4.8 Vm measurement in I=0 mode 
In the Multiclamp 700B, I=0 is a special mode of current clamp, where all input 
commands are disconnected. This mode reports the resting Vm of the cells1. When the 
recording pipette was in contact with the extracellular PSS, the bridge balance and 
                                                




pipette capacitance neutralisation were firstly adjusted in the current clamp mode. 
Gigaseal and whole-cell configuration were achieved in voltage clamp mode. Within 5 s 
of reaching whole-cell configuration, the steady-state Vm of a cell was recorded in the 
I=0 mode.  
To monitor the continuous Vm change in individual cells in response to 
treatments, cells were held for 60 s in the standard PSS, 150 s in PSS plus treatment 
and a further 150 s for treatment washout. The mean Vm over the last 5, 15, 30 and 60 
s in each of the three stages was used to quantify the data. The flow rate was 
approximately 2 ml/min. The Vm signal was sampled at 200 Hz, and low-pass filtered at 
10 kHz. Liquid junction potentials were calculated using the integrated tool in Clampex 
10.4 software and were compensated while analysing the data offline, using the 
following equation (Barry & Lynch, 1991): 
 
𝐶𝑜𝑚𝑝𝑒𝑛𝑠𝑎𝑡𝑒𝑑	𝑉"	 𝑚𝑉 = 𝑅𝑎𝑤	𝑉" − 	𝐿𝑖𝑞𝑢𝑖𝑑	𝑗𝑢𝑛𝑐𝑡𝑖𝑜𝑛	𝑝𝑜𝑡𝑒𝑛𝑡𝑖𝑎𝑙	(Equation 2.3) 
 
2.4.9 Slice recording 
Tumours were allowed to grow until diameter ≥ 6 mm before mice were 
euthanised by a Schedule 1 method. The tumour was then quickly dissected from the 
body and stored in ice-cold standard PSS for approximately 10 min. Fur and 
surrounding muscle tissues were removed from the tumour with a razor blade on ice. 
Tissue was kept moist by continually immersing with ice-cold PSS. The tumour tissue 
block was then fixed on the pedestal of vibratome (Campden Instruments) using 
cyanoacrylate glue and was horizontally supported by an ~8 mm × 8 mm 5 % agar 
block. The tissue was then covered with ice-cold PSS before slicing. A homemade 
holding chamber was made by putting 3–5 cell strainers (100 μm mesh, Corning) in a 




(250 μm) were cut and incubated in the cell strainers inside the holding chamber at 
room temperature for at least 20 minutes before recording. 
A slice was transferred from the holding chamber to the recording chamber by 
using a homemade glass Pasteur pipette, and was held in place with an SHD-26GH/15 
slice anchor (Warner Instruments). Areas without floating cells were firstly determined 
at 10X magnification, followed by targeting a healthy cell at 40X. The following criteria 
were applied when targeting a cell: the cell should be attached to the slice and should 
have a smooth plasma membrane, and for shRNA control cells, they should be eGFP-
positive. The eGFP was excited by using a pE100 CoolLED at 470 nm and the 
fluorophore emission was gathered at 525 ± 50 nm. Once a cell was selected, its 
distance to the edge of the tumour slice was determined by using an eyepiece reticle. 
The slices were divided into three regions according to the distance from the edge: (1) 
periphery, which is ≤ 1 mm from the edge; (2) intermediate region, which is ≥ 1 mm but 
≤ 1.5 mm from the edge; and (3) centre, which is ≥ 1.5 mm from the edge. INa and Vm 
were recorded as described in Section 2.4.5 and Section 2.4.8, respectively. 
 
2.5 In vitro assays 
2.5.1 MTT proliferation assay 
MDA-MB-231 cell proliferation was measured using the thiazolyl blue tetrazolium 
bromide (MTT) assay (Grimes et al., 1995). Stock MTT was dissolved in sterile PBS at 
5 mg/ml. Cells (3 × 105) were plated in each well of a 12-well plate supplemented with 
1 ml culture medium. Three wells were prepared for each condition. After 24 h, the old 
medium was replaced with fresh culture medium containing appropriate treatments 
(Table 2.1). Cells were incubated overnight. The medium was aspirated the next day, 
replaced with MTT diluted at 1:5 in culture medium (final MTT concentration at 1 




1 ml DMSO to lyse the cells for 10 minutes, before 125 μl autoclaved glycine buffer 
(0.1 M glycine + 0.1 M NaCl, adjusted to pH at 10.5 with NaOH) was added. The 12-
well plate was gently swirled and was incubated in the dark for a further 10 minutes. 
Aliquots (800 μl) were transferred to plastic cuvettes and absorbance at 570 nm was 
determined using a spectrophotometer. DMSO (1 ml) plus glycine buffer (125 μl) was 
used as blank during spectrophotometer calibration. 
To convert the absorbance to cell number, another 12-well plate seeded with 
1,000, 3,000, 1 × 104 and 3 × 104 cells (prepared in triplicate) was prepared along with 
the plate for experimental conditions. These cells were incubated for two hours before 
the medium was replaced with MTT. Cells were then lysed and the absorbance at 570 
nm was taken as described above to generate a standard curve (Figure 4.12). The 
experiment was repeated three times on different days. For each technical repeat, 
three wells were prepared per condition. 
 
2.5.2 Matrigel invasion assay 
The invasion assay was carried out using 24-well BioCoat Matrigel Invasion 
Chambers (Corning). MDA-MB-231 cells (2.5 × 104) were seeded in the upper 
compartment supplemented with 1 % FBS and appropriate treatments according to the 
manufacturer’s instructions. The lower compartment contained 10 % FBS as a 
chemoattractant and appropriate treatments (Table 2.1). Cells were incubated at 37 °C 
for 24 h before the removal of non-invaded cells from the upper surface of chambers 
using cotton buds. Cells that invaded through the Matrigel and polyethylene 
terephthalate membrane were fixed using 4 % (w/v) paraformaldehyde in PBS for 10 
min, and were washed three times with PBS, 5 min/time, before being stained with 
DAPI at 0.5 µg/ml in distilled water. The membrane was then carefully removed using a 




(Dako) and then sealed with 13 mm glass coverslip. DAPI-positive invaded cells on the 
membrane were counted using an epi-fluorescence microscope at 20X (Section 2.9). 
The experiment was repeated at least three times on different days. For each technical 
repeat, two wells were prepared per condition. 
 
2.5.3 Wound healing assay 
Cell migration was determined using wound healing assays (Fraser et al., 2003). 
Ptychography was used to monitor cell movement (Marrison et al., 2013). Cells (2 × 
105) were seeded on a glass bottomed 6-well plate and were allowed to grow for 48 h 
before a confluent cell monolayer was formed. A stainless steel spatula was used to 
make a straight wound through the cell monolayer (Figure 4.13a). Cells were then 
washed once with 37 °C DMEM to remove debris before appropriate treatments were 
applied (Table 2.1). Empirically, the doubling time of MDA-MB-231 cells cultured in our 
lab was 12-18 hours. To reduce the impact of cell proliferation on wound closure, given 
the accessibility of the image acquisition system, cells were allowed to migrate into the 
wound for 16 h. 
Image acquisition by ptychography was done by Dr Richard Kasprowicz and Dr 
Rakesh Suman (PhaseFocus Ltd.). Images of the wounds were acquired using a 
Phasefocus VL-21 microscope over 16 h at 9 min intervals. Image sequences of the 
gap closure were analysed in a semi-automated fashion using TScratch software 
(Geback et al., 2009), which calculated the percentage of cell-free space in each 
image. For each image sequence, the percentage of cell-free space was normalised 
relative to the initial free space measured in the first image. Half time (t1/2) values for 
gap closure were obtained in order to quantify the differences in speed of gap closure 
between treatments. The t1/2 of gap closure was obtained by averaging all time values 




proliferation during the wound healing assay was analysed by measuring the total cell 
volume of the whole field of view, over time using the Phasefocus Cell Analysis 
Toolbox image analysis package. To calculate proliferation, the cell volume data were 
normalised by expressing the cell volume as a ratio of the cell volume at 1.5 h. The 
experiment was repeated for three times on different days. For each technical repeat, 
two wells were prepared per condition. 
 
2.6 Immunocytochemistry 
MDA-MB-231 cells (1.6 × 105) were cultured on glass coverslips in 4-well plates 
for 48 h in order to form a confluent cell monolayer. A wound was made on the 
monolayer (Section 2.5.3). Cells were then washed once with 37 °C DMEM to remove 
debris. Appropriate treatments was subsequently applied, and cells were to allowed to 
migrate into the wound for 3 h. Cells were fixed in 4 % (w/v) paraformaldehyde in PBS 
for 10 min, followed by three PBS washes (5 min/wash). The fixed cells were then 
treated with blocking buffer (1x PBS, 5 % v/v normal goat serum and 0.3% v/v Triton X-
100) for 1 h. Cells were incubated with mouse anti-active Rac1 primary antibody 
(Neweast Biosciences) diluted to 1:500 in antibody dilution buffer (1% w/v bovine 
serum albumin and 0.3 % v/v Triton X-100 in PBS) at room temperature overnight. The 
solution was removed next day, and cells were washed three times with PBS before 
being incubated with Alexa 488-conjugated goat anti mouse IgG secondary antibody 
(1:500; Life Technologies) for 2 h at room temperature in the dark. Finally, after three 
washes with PBS, cells were then incubated with Alexa 633-conjugated phalloidin 
(1:50; Life Technologies) for 20 min at room temperature in the dark. Coverslips were 
then mounted on glass microscope slides in Prolong Gold with DAPI (Life 
Technologies). The slides were examined using a confocal microscope at 40X 





2.7 Ca2+ imaging 
Cells (9 × 104) were cultured on coverslips for 48 h before incubating with 2.5 μM 
Fura-2-AM (PromoKine) plus 0.05 % (v/v) Pluronic F-127 (Invitrogen) in DMEM for 20 
minutes at 37 °C in the dark. Cells were then washed twice in 37 °C DMEM with 5 % 
FBS, and were settled in dark at 37 °C for 20 min, and then at room temperature for a 
further 15 min before transferring onto a RC-20H closed bath imaging chamber 
(Warner Instruments) according to the manufacturer’s instructions. Cells were perfused 
with appropriate solutions at room temperature. The imaging chamber with P-2H stage 
adapter was mounted on an epi-fluorescence microscope and observed at 20X. 
Extracellular solutions were applied using a two-channel gravity perfusion system with 
a peristaltic pump. The flow rate was approximately 500 μl/min. Cells were treated with 
a second solution for 6–12 min, 2 min after the experiment began, and were 
subsequently washed with standard PSS for 6 min, if applicable. At the end of the 
experiment, ionomycin (10 μM, Table 2.1) was added to the standard PSS as a 
positive control (Liu & Hermann, 1978). 
 
2.8 Na+ imaging 
Cells (6 × 104) were grown on glass coverslip for 24 h and were then labelled with 
5 μM SBFI-AM (Sigma) and 0.1 % (v/v) Pluronic F-127 (Life Technologies) in DMEM 
with 0 % FBS at 37 °C in the dark for 1 h. Excess SBFI-AM was washed once with 37 
°C DMEM supplemented with 5 % FBS. The coverslip was placed in a RC-20H closed 
bath imaging chamber (Warner Instruments) and was perfused with standard PSS with 
appropriate treatments at room temperature (Table 2.1). The chamber was mounted on 
an epi-fluorescece microscope with a P-2H stage adapter, and cells were observed at 




with a peristaltic pump. The flow rate was approximately 500 μl/min. Cells were treated 
with test solution for 12 min, 2 min after the experiment began. Cells were then treated 
with extracellular solution containing 10 mM Na+ (Table 2.2). To calibrate the 
intracellular Na+ concentration ([Na+]i), cells were subsequently perfused with 
extracellular solution with 10 and 20 mM Na+ (Table 2.2) plus Na+ ionophore gramicidin 
(20 μM, Table 2.1) at the end of experiment, 12 min each (Figure 5.1a). The 
experiment was repeated three or six times.  
 
2.9 Epi-fluorescence microscopy 
A Nikon Eclipse TE200 epi-fluorescence microscope was used for all epi-
fluorescent imaging. SimplePCI 6.0 software was used to control the imaging system. 
Images were captured using a RoleraXR Fast1394 charge-coupled device (CCD) 
camera (QImaging). For mycoplasma test (Section 2.1.5) and Matrigel invasion assay 
(Section 2.5.2), DAPI was excited at 340 nm and the fluorescence signal was gathered 
at 512 nm. SBFI and Fura-2 were excited alternately at 340 and 380 nm, and 
fluorescence signal was collected at 512 nm. For Ca2+ imaging, images were captured 
at 0.2 frames/s. The image plane was auto-focused every 40 frames. For Na+ imaging, 
the image acquisition rate was 0.1 frames/s. 
 
2.10 Confocal microscopy 
Immunocytochemistry slides were examined using a Zeiss LSM 880 laser 
scanning confocal microscope with a 40X oil objective lens. ZEN 2012 software was 
used to control the microscope. The size of acquired images was 212.3 μm × 212.3 μm 
(1024 × 1024 pixels). The pinhole size was 1–1.05 airy unit. DAPI was excited at 405 
nm, and the emission was collected at 410–500 nm. Alexa Fluor 488 was excited at 




excited at 633 nm, and the fluorescence signal was collected at 638–747 nm. In each 
technical repeat, three or four images were taken on each coverslip, and two coverslips 
were examined in each experimental condition. Three technical repeats were 
performed. 
 
2.11 Image analyses 
Three analyses were performed to analyse different parameters in the 
immunocytochemistry study. Only cells at the edges of the wound were selected, and 
the image analyses were performed in a blinded fashion. Three technical repeats were 
performed. 
Firstly, cell circularity was calculated using a free-hand tool in ImageJ software 
using the following equation (Brisson et al., 2013): 
 
𝐶𝑖𝑟𝑐𝑢𝑙𝑎𝑟𝑖𝑡𝑦 = 4𝜋	×	 sML1
+LMt"LHLMu
	  (Equation 2.4) 
 
For each technical repeat, 20–25 cells per condition were analysed blinded to 
treatment. 
Secondly, cells were categorised into two groups: with and without obvious 
lamellipodia. For each technical repeat, 40–50 cells per condition were analysed 
blinded to treatment.  
Thirdly, the signal intensity of F-actin and active Rac1 at lamellipodia was 
analysed as described in (Dang et al., 2013), with the following modifications: ImageJ 
with the Radial Profile Extended plugin (Philippe Carl, CNRS, France) was used in the 
analysis. In the plugin, the starting radius was set to 0.28 μm, radius increment = 0.28 
μm, ending radius = 5.6 μm and total integrated angle = 90 °, resulting 20 arcs in total 




obtained and were normalised relative to those at the innermost arc. For each technical 
repeat, 20–30 cells were analysed blinded to treatment in each condition.  
For Ca2+ and Na+ imaging, image files (in stacked TIFF format) generated from 
the time-lapse experiments were opened in ImageJ software. 20–70 (in Ca2+ imaging) 
or 7–20 (Na+ imaging) randomly selected adhesive single cells in the field of view were 
selected as regions of interest (ROI). The images were split according to the excitation 
wavelength. The fluorescence intensities of all the cell of interest over time at the two 
wavelengths were gathered by using the stack measurement function of the ROI 
manager plugin in the ImageJ software. The ratio of fluorescence intensity at 340 and 
380 nm (340/380 ratio) was calculated for each cell in Microsoft Excel.  
In Na+ imaging, the [Na+]i equalled to the extracellular Na+ concentration ([Na+]o) 
after gramicidin treatment (Roger et al., 2007). A linear relationship between [Na+]i and 
fluorescence intensity was obtained for a given individual cell by correlating its mean 
340/380 ratio over the last 1 min of 10 and 20 mM Na+ treatment with [Na+]i = 10 and 20 
mM, respectively (Figure 5.1c). Using the linear relationship, the 340/380 ratio of the 
same cell in other experimental conditions was therefore converted to [Na+]i. Unless 
otherwise stated, [Na+]i of 7–20 cells in each technical repeat was calculated 
individually and then averaged. 
 
2.12 Curve fitting 
All curve fitting analyses were done using the Graphpad Prism 6.0 software. The 
conductance-voltage relationships were calculated using the following equation (Ding & 
Djamgoz, 2004): 
 
𝐺 = 	 w
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where G is the conductance, I the current amplitude, V the command voltage, and Vrev 







  (Equation 2.6) 
 
where R is the universal gas constant, T the absolute temperature, z valence of ion, F 
the Faraday constant. In the present study, the Vrev for Na+ was +86.3 mV when using 
the standard PSS and the standard intracellular solution. 
The steady-state inactivation (availability) and conductance-voltage relationship 
were fitted by the Boltzmann equation: 
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where X is the fitted parameter (availability or conductance), V1/2 the voltage at which 
half-maximal conductance or availability occurs, k the slope factor and V the command 
voltage.  
The current-voltage relationship of IBKCa was fitted to a single exponential 
equation (Sanguinetti & Jurkiewicz, 1990): 
 
𝑌 = 	𝑌	×	𝑒    (Equation 2.8) 
 
where Y0 is the Y value when x is at 0, and k the rate constant. 
Finally, the drug dose-response curve was fitted to a sigmoidal logistic equation 








	  (Equation 2.9) 
 
where IC50 is the concentration of drug at which half of its maximal effect occurs; and n 
the slope giving the Hill coefficient.  
 
2.13 Statistics 
Data are presented as mean ± SEM. Graphpad Prism 6.0 software was used to 
perform all statistical analyses. Paired or unpaired Student’s two-tailed t-test was used 
to compare two samples. Multiple comparisons were made using ANOVA followed by 
Tukey post-hoc tests. Fisher’s exact test was used to examine the distribution of 
samples within a population. To analyse tables with more than two rows or columns, 
Bonferroni correction was applied for multiple comparisons (MacDonald & Gardner, 









3 Chapter 3: Na+- and VGSC-dependent Vm regulation in MDA-MB-
231 cells 
3.1 Introduction 
VGSCs are protein complexes that comprise one pore-forming α subunit and one 
or more auxiliary β subunits (Catterall, 2012). In excitable cells, such as neurones, 
cardiomyocytes and skeletal muscle cells, VGSCs depolarise the Vm to initiate action 
potential firing (Hille, 2001). Functional α subunits have been identified in an increasing 
number of cancer cells and patient tissue samples from various tissue origins, including 
breast, prostate, colon, cervix, lungs and brain. VGSCs potentiate metastatic cell 
behaviours such as invasion and migration in vitro (Brackenbury, 2012; Roger et al., 
2015), and their activity/expression increases tumour growth (Nelson et al., 2015a) and 
metastasis (Yildirim et al., 2012; Driffort et al., 2014; Nelson et al., 2015a; Nelson et al., 
2015b) in rodent models. In BCa patient tissue samples, the mRNA level of Nav1.5 
correlates with lymph node metastasis (Fraser et al., 2005) and poor prognosis (Yang 
et al., 2012), suggesting that targeting VGSCs may have therapeutic value in cancer 
treatment.  
β subunits are also present in cancer cells originating from breast, prostate, 
cervix and lung (Roger et al., 2007; Diss et al., 2008; Chioni et al., 2009; Hernandez-
Plata et al., 2012; Jansson et al., 2012). β subunits regulate metastasis-related cell 
activity in vitro. For example, β1 overexpression increases invasion and process 
outgrowth in MDA-MB-231 cells (Nelson et al., 2014) and reduces migration in wound 
healing asays (Chioni et al., 2009). MDA-MB-231 cells overexpressing β1 show 
increased primary tumour growth, vascularisation and metastasis to lungs and liver in 




Several models have been proposed to explain the mechanisms underlying 
VGSC α subunit-dependent cancer cell invasion and migration. Firstly, in MDA-MB-231 
cells, Na+ influx carried by Nav1.5 allosterically regulates NHE1, which increases the 
efflux of H+ through plasma membrane and causes an acidic extracellular environment 
that favours the proteolytic activity of cysteine cathepsin B and S (Gillet et al., 2009; 
Brisson et al., 2011), and ultimately enhances cell invasion. Nav1.5 activity also 
increases src kinase activity and phosphorylation of the actin-nucleation-promoting 
factor cortactin, which can lead to invadopodia formation (Brisson et al., 2013). 
Additionally, reduced Nav1.5 expression decreases the protein level of the metastasis-
promoting molecule CD44 (Nelson et al., 2015b). Moreover, in SW620 colon cancer 
cells, increased Na+ influx carried by Nav1.5 causes sustained activation of MAPK and 
increases the expression of invasion-related genes including CD44, CLIC, WNT9A, 
ITGB, SEMA6A and VEGFC (House et al., 2015). In H460 NSCLC cells, Nav1.7-
dependent cell invasion is mediated via the ERK pathway (Campbell et al., 2013).  
Activity of ion channels can regulate the Vm of cells. Cancer cells usually possess 
a more depolarised Vm than their normal counterparts (Binggeli & Weinstein, 1986; 
Yang & Brackenbury, 2013). In PCa cells, the Vm of strongly metastatic PC-3 cells is ~5 
mV more depolarised than the weakly metastatic LNCaP cells (Laniado et al., 1997), 
and in BCa cells, depolarised Vm associates with increased cancer cell metastatic 
potential: compared to non-metastatic, VGSC-negative MCF-7 cells (~-40 mV), strongly 
metastatic VGSC-expressing MDA-MB-231 cells have a more depolarised Vm (~-20 
mV) (Fraser et al., 2005). However, whether the depolarised Vm is caused by Na+ influx 
via VGSCs is not known. 
Importantly, Vm is now regarded more than an epi-phenomenon in non-excitable 
cells: a large amount of data has shown that Vm regulates cell cycle progression in 
normal (Blackiston et al., 2009) and cancer cells (Yang & Brackenbury, 2013). A 




endothelial and epithelial cells (Chifflet et al., 2003; Chifflet et al., 2004; Chifflet et al., 
2005). In kidney epithelial cells, Vm depolarisation induces phosphorylation of MLC by 
activating the ROCK pathway (Szaszi et al., 2005). Furthermore, in vivo evidence 
shows that depolarised Vm leads to tumourigenesis in Xenopus laevis (Blackiston et al., 
2011; Lobikin et al., 2012; Lobikin et al., 2015). Taken together, Vm has been 
suggested as an instructive signal in cancer progression, but whether or not VGSCs 
increase cancer cells metastatic behaviours by depolarising the Vm is not known. 
The relationship between tumour ER status and prognosis in BCa patients has 
been long established. In general, compared to ER+ tumours, BCa patients bearing 
ER— tumours have higher risk of mortality (Parl et al., 1984; Aaltomaa et al., 1991b, a; 
Crowe et al., 1991; Dunnwald et al., 2007). ER status associates with distinct gene 
expression pattern in BCa patients (Perou et al., 2000; Gruvberger et al., 2001; Sorlie 
et al., 2001; van 't Veer et al., 2002), and is known as the most important discriminator 
of gene expression profiles (Sotiriou et al., 2003). Compared to ER— MDA-MB-231 
cells, ER+ MCF-7 cells show weaker metastatic potential (Thompson et al., 1992; 
Roger et al., 2003; Fraser et al., 2005). Indeed, C4 and C4-12, two MCF-7 cell sublines 
where ER expression is lost, show abolished oestrogen-mediated, insulin-like growth 
factor-I receptor-dependent cell growth (Oesterreich et al., 2001). Despite all the 
evidence showing the high malignancy of ER— cells and the roles of VGSCs in 
promoting cell metastatic behaviours, it was not until 2010 that researchers 
investigated the interplay between oestrogen signalling and VGSCs in cancer: GPR30 
(a G-protein-coupled oestrogen receptor) is identified in MDA-MB-231 cells, and 
external application of β-oestradiol (E2) or G-1, a GPR30 agonist, increases INa in a 
PKA-dependent manner (Fraser et al., 2010). Additionally, acute application of E2 
increased MDA-MB-231 cell adhesion, which is abrogated by co-application with TTX, 




2010). However, whether ERα regulates functional VGSC expression has not been 
studied.  
 
3.1.1 Hypotheses and aims 
The main hypothesis underlying this Chapter was that VGSCs depolarise the 
resting Vm of MDA-MB-231 cells. A second hypothesis was that ER knockdown in 
MCF-7 cells may lead to functional VGSC expression.  
 The specific aims were: 
(1) To investigate whether or not extracellular Na+ regulates the Vm in MDA-
MB-231 cells. 
(2) To study the involvement of VGSCs in regulating the Vm in MDA-MB-231 
cells. 
(3) To record membrane current in MCF-7 and pII (a derivative MCF-7 cell line 
where ERα expression was stably down-regulated) cells. 
 
3.2 Results 
3.2.1 Na+ conductance depolarises the Vm of MDA-MB-231 cells 
The effect of extracellular Na+ on the Vm of MDA-MB-231 cells was investigated 
using whole-cell patch clamp recording in I=0 mode (Section 2.4.8). Standard 
intracellular solution was used in all experiments recording the cell Vm (Table 2.3).  
Firstly, whether or not Na+ conductance through plasma membrane regulates the 
Vm was studied. In these experiments, NaCl in the standard extracellular PSS was 
replaced with equimolar ChoCl or NMDG (Table 2.2). The Vm of MDA-MB-231 cells 
was continuously measured over a 6 min experiment that comprised three steps: (1) 




PSS treatment for 150 s, and (3) a final washout with the standard PSS for a further 
150 s (Figure 3.1a).  
Replacement of extracellular NaCl with ChoCl reversibly hyperpolarised the Vm of 
MDA-MB-231 cells (Figure 3.1a). In order to quantify the data, the mean Vm over the 
ast 5 s, 15 s, 30 s and 60 s of each of the three experimental steps was analysed, with 
the liquid junction potentials compensated (3 mV in standard PSS and 5.3 mV in 
ChoCl, Section 2.4.8) (Figure 3.1b, Table 3.1). Comparisons of the mean Vm over the 
last 5 s of the three steps showed that the Vm of MDA-MB-231 cells significantly 
hyperpolarised from -10.4 ± 1.0 mV to -20.4 ± 2.0 mV after ChoCl treatment (P < 0.001; 
ANOVA with Tukey post-hoc test; n = 10). By washing out ChoCl with standard PSS, 
the Vm recovered to -12.9 ± 2.3 mV (P < 0.001 compared with ChoCl; P = 0.22 
compared with standard PSS; ANOVA with Tukey post-hoc test; n = 10). Statistical 
analyses comparing the Vm across other measurement intervals (15 s, 30 s and 60 s) 
are in Figure 3.1b and Table 3.1. 
Next, NMDG was used as an alternative extracellular NaCl substitute to confirm 
the results. Similar to ChoCl, NMDG reversibly hyperpolarised the Vm of MDA-MB-231 
cells (Figure 3.2a). Taking the mean Vm over the last 5 s of the three experimental 
steps as an example, with the liquid junction potentials compensated (3 mV in standard 
PSS and 7.7 mV in NMDG), NMDG significantly hyperpolarised the Vm from -10.3 ± 2.0 
mV to -24.8 ± 2.4 mV (P < 0.001; ANOVA with Tukey post-hoc test; n = 7), and the Vm 
subsequently recovered to -13.2 ± 2.7 mV after NMDG washout (P < 0.001 compared 
with NMDG; P = 0.15 compared with standard PSS; ANOVA with Tukey post-hoc test; 
n = 7). Statistical analyses of the Vm using other measurement intervals are shown in 
Figure 3.2b and Table 3.2. In summary, these two experiments demonstrated that 
extracellular Na+ depolarises the Vm of MDA-MB-231 cells by 10–15 mV, suggesting 








Figure 3.1. Replacement of extracellular NaCl with choline chloride (ChoCl) 
hyperpolarises the membrane potential (Vm) of MDA-MB-231 cells.  
(a) MDA-MB-231 cells were perfused with standard physiological saline solution (PSS) 
for 60 s followed by Na+-free ChoCl solution for 150 s, which was subsequently washed 
out using standard PSS for a further 150 s. Black and grey traces show mean ± SEM 
(n = 10). Dotted vertical lines take the ChoCl treatment period as an example to 
indicate various measurement intervals (last 5 s, 15 s, 30 s and 60 s) in each of the 
three steps. Liquid junction potentials (3 mV in standard PSS and 5.3 mV in ChoCl) are 
not compensated. (b) The mean Vm was compared over the indicated measurement 
intervals. Liquid junction potentials (3 mV in standard PSS and 5.3 mV in ChoCl) are 
compensated. (***) P < 0.001 compared with standard PSS; (##) P < 0.01 compared 







Table 3.1. Mean membrane potential (Vm) of MDA-MB-231 cells after choline chloride 
(ChoCl) treatment and washout. 
Measurement interval Vm in standard PSS (mV) 
Vm in ChoCl 
(mV) 
Vm in washout 
(mV) 
Last 5 s -10.4 ± 1.0 -20.4 ± 2.0 *** -12.9 ± 2.3 ## 
Last 15 s -10.4 ± 1.0 -19.9 ± 2.0 *** -13.0 ± 2.3 ## 
Last 30 s -10.3 ± 1.0 -19.6 ± 1.9 *** -13.0 ± 2.2 ## 
Last 60 s -10.3 ± 1.0 -18.5 ± 1.9 *** -13.0 ± 2.2 ## 
Liquid junction potentials (3 mV in standard PSS and 5.3 mV in ChoCl) were 
compensated offline. PSS: physiological saline solution. (***) P < 0.001 compared with 
Vm in standard PSS; (##) P < 0.01 compared with Vm in ChoCl; ANOVA with Tukey 






Figure 3.2. Replacement of extracellular NaCl with N-methyl-D-glucamine (NMDG) 
hyperpolarises the membrane potential (Vm) of MDA-MB-231 cells.  
(a) MDA-MB-231 cells were perfused with standard physiological saline solution (PSS) 
for 60 s followed by Na+-free NMDG solution for 150 s, which was subsequently 
washed out using standard PSS for a further 150 s. Black and grey traces show mean 
± SEM (n = 7). Dotted vertical lines take the NMDG treatment period as an example to 
indicate various measurement intervals (last 5 s, 15 s, 30 s and 60 s) in each of the 
three steps. Liquid junction potentials (3 mV in standard PSS and 7.7 mV in NMDG) 
are not compensated. (b) The mean Vm was compared over the indicated 
measurement intervals. Liquid junction potentials (3 mV in standard PSS and 7.7 mV in 
NMDG) are compensated. (***) P < 0.001 compared with standard PSS; (##) P < 0.01 
compared with NMDG solution; ANOVA with Tukey post-hoc test (n = 7). Data are 








   
Table 3.2. Mean membrane potential (Vm) of MDA-MB-231 cells after N-methyl-D-
glucamine (NMDG) treatment and washout. 
Measurement interval Vm in standard PSS (mV) Vm in NMDG (mV) Vm in washout (mV) 
Last 5 s -10.3 ± 2.0 -24.8 ± 2.4 *** -13.2 ± 2.7 ### 
Last 15 s -10.3 ± 2.0 -24.1 ± 2.5 *** -13.4 ± 2.5 ## 
Last 30 s -10.5 ± 2.0 -24.1 ± 2.5 *** -13.7 ± 2.6 ## 
Last 60 s -10.8 ± 1.8 -23.3 ± 2.4 *** -13.7 ± 2.5 ## 
Liquid junction potentials (3 mV in standard PSS and 7.7 mV in NMDG) were 
compensated offline. PSS: physiological saline solution. (***) P < 0.001 compared with 
Vm in standard PSS; (##) P < 0.01 compared with Vm in NMDG; ANOVA with Tukey 




3.2.2 VGSC window current in MDA-MB-231 cells 
In neurones, in spite of its small amplitude compared to the transient INa, 
persistent INa has an important role in shaping the action potential firing pattern, 
especially in the subthreshold voltage range (Stafstrom, 2011). Therefore, this study 
hypothesised that VGSCs may carry persistent INa, which would depolarise the steady-
state Vm in MDA-MB-231 cells. Indeed, eliciting INa in MDA-MB-231 cells using the 
standard INa stimulation protocol (Section 2.4.7) showed both transient and persistent 
INa (measured as mean current between 45 ms and 50 ms following depolarisation) 
(Figure 3.3a and b). Voltage-dependent activation (Figure 3.3c) and the steady-state 
inactivation (Figure 3.3d) of VGSCs were investigated. Normalised conductance 
(G/GMax) was calculated from the current data and plotted as a function of voltage 
(Section 2.12) (Figure 3.3e; n = 14). Normalised current (I/IMax) was plotted as a 
function of the pre-pulse voltage (Figure 3.3e; n = 9). Both G/GMax and I/IMax curves 
were fitted with Boltzmann functions (Section 2.12). Overlapping the G/GMax and I/IMax 
curves revealed a window INa between -50 mV and -10 mV (Figure 3.3e, dotted box; 
Figure 3.3f, shadowed area). At the typical resting Vm of ~-10 mV (Table 3.1 and Table 
3.2), 1.0 ± 0.4 % of the VGSCs in MDA-MB-231 cells are available to carry persistent 







Figure 3.3. The window Na+ current (INa) in MDA-MB-231 cells. 
(a) Typical whole-cell recording of INa in MDA-MB-231 cell. Dotted box shows the 
persistent INa. (b) The persistent INa in (a). Cells were depolarised to -10 mV for 50 ms 
following a 250 ms pre-pulse at -120 mV. Persistent INa was measured as mean current 
between 45 ms and 50 ms following depolarisation. (c) Typical whole-cell recording 
from MDA-MB-231 cell by depolarising the cells to voltages in the range -80 to +30 mV 
(60 ms) in 5 mV increments following a 250 ms pre-pulse at -120 mV. Every other INa 
trace is shown for clarity. (d) Steady-state inactivation of whole-cell INa. INa was elicited 
by -10 mV pulse (60 ms) following 250 ms conditioning voltage pre-pulses between -
120 mV and -10 mV in 10 mV increments. (e and f) Activation and steady-state 
inactivation of INa recorded from MDA-MB-231 cells. Normalised conductance (G/GMax) 
was calculated from the current data and plotted as a function of voltage (n = 14). 
Normalised current (I/IMax) was plotted as a function of the pre-pulse voltage (n = 9). 
Data are fitted with Boltzmann functions. The area inside the dotted box of (e) is 




3.2.3 TTX reduces INa and hyperpolarises the Vm of MDA-MB-231 cells 
The predominant VGSC isoform expressed in MDA-MB-231 cells is Nav1.5 
(Fraser et al., 2005), which is a TTX-resistant VGSC subtype that can only be blocked 
by TTX in the micromolar range (Goldin, 2001). To confirm the channel blocking effect 
of TTX, INa was firstly recorded in the standard PSS using the Cs+-containing 
intracellular solution. Perfusion with 30 μM TTX for 2 min significantly reduced transient 
(Figure 3.4a) as well as persistent INa (Figure 3.4b). Transient INa was reduced to 12.2 ± 
0.8 % after TTX treatment (Figure 3.4c; P < 0.001; ANOVA with Tukey post-hoc test; n 
= 7), and when TTX was subsequently washed out using standard PSS for 2 min, 
transient INa recovered to 106.4 ± 6.7 % (Figure 3.4c; P < 0.001 compared with TTX; P 
= 0.49 compared with standard PSS; ANOVA with Tukey post-hoc test; n = 7). As for 
persistent INa, TTX reduced the current to 26.7 ± 5.9 % of control (Figure 3.4d; P < 
0.05; ANOVA with Tukey post hoc test; n = 4), and following washout persistent INa 
recovered to 103.5 ± 31.2 % (Figure 3.4d; P < 0.05 compared with TTX; P = 0.99 
compared with control; ANOVA with Tukey post hoc test; n = 4). The data suggest that 
TTX at 30 μM potently blocks transient and persistent INa in MDA-MB-231 cells.  
Next, the study examined whether VGSCs regulate the Vm of MDA-MB-231 cells 
using TTX. Since TTX inhibited Na+ influx through VGSCs, the reduction in [Na+]i should 
cause a hyperpolarised Vm. To test this, cells were consecutively perfused with 
standard PSS for 60 s, followed by 30 μM TTX for 150 s, and finally washout with 
standard PSS for a further 150 s). TTX, but not the vehicle (148 μM citrate at pH = 4.8), 
significantly hyperpolarised the Vm of MDA-MB-231 cells (Figure 3.5a and b). The 
mean Vm over the last 5 s, 15 s, 30 s and 60 s of each of the three experimental steps 
after TTX and vehicle treatment was analysed with the liquid junction potentials (3 mV) 








Figure 3.4. Tetrodotoxin (TTX) reduces transient and persistent Na+ current (INa) in 
MDA-MB-231 cells. 
(a) Representative INa recorded from MDA-MB-231 cells in standard physiological 
saline solution (PSS) (blue), 30 μM TTX (red) and after washout (green). Transient INa 
is labelled, and the dotted box shows the persistent INa. (b) Enlargement of the dotted 
box in (a), showing the persistent INa. INa was elicited by depolarising the cell to -10 mV 
following a 250 ms pre-pulse at -120 mV. Persistent INa between 45–50 ms after 
depolarisation was adopted in data analyses. (c) Normalised transient INa after 30 μM 
TTX treatment and subsequent washout. (***) P < 0.001; ANOVA with Tukey post-hoc 
test (n = 7). (d) Normalised persistent INa after 30 μM TTX treatment and the 
subsequent washout (*) P < 0.05; ANOVA with Tukey post-hoc test (n = 4). Data are 








Figure 3.5. Tetrodotoxin (TTX) hyperpolarises the membrane potential (Vm) of MDA-
MB-231 cells. 
MDA-MB-231 cells were treated with standard physiological saline solution (PSS) for 
60 s before being perfused with (a) 30 μM TTX or (b) vehicle, 148 μM citrate at pH = 
4.8, for 150 s. TTX and citrate buffer were subsequently washed out with standard PSS 
for a further 150 s. Black trace shows the mean Vm of n = 17 (a) or n = 13 (b), and the 
grey traces show the SEM. Dotted vertical lines indicate the various measurement 
intervals (last 5 s, 15 s, 30 s and 60 s). Liquid junction potentials (3 mV) are not 
compensated. The mean Vm over indicated measurement intervals after (c) TTX or (d) 
citrate buffer treatment. Liquid junction potentials (3 mV) are compensated. (**) P < 
0.01 and (***) P < 0.001 compared to PSS; ANOVA with Tukey post-hoc test [n = 17 in 





   
Table 3.3. Mean membrane potential (Vm) of MDA-MB-231 cells after tetrodotoxin 
(TTX, 30 μM) treatment and washout. 
Measurement interval Vm in standard PSS (mV) 
Vm in 30 μM TTX 
(mV) 
Vm in washout 
(mV) 
Last 5 s -13.2 ± 1.3 -17.5 ± 1.6 *** -14.8 ± 1.4 
Last 15 s -12.9 ± 1.2 -17.5 ± 1.6 *** -14.9 ± 1.5 
Last 30 s -12.5 ± 1.2 -17.6 ± 1.7 *** -15.2 ± 1.6 
Last 60 s -12.2 ± 1.2 -16.8 ± 1.5 ** -15.3 ± 1.6 
Liquid junction potentials (3 mV) were compensated offline. PSS: physiological saline 
solution. (**) P < 0.01; (***) P < 0.001 compared with Vm in standard PSS; ANOVA with 






Table 3.4. Mean membrane potential (Vm) of MDA-MB-231 cells after citrate (148 μM; 
pH = 4.8) treatment and washout. 
Measurement interval Vm in standard PSS (mV) 
Vm in 148 μM citrate 
(mV) 
Vm in washout 
(mV) 
Last 5 s -12.0 ± 1.5 -11.2 ±1.7 (n.s.) -11.0 ± 1.0 
Last 15 s -12.0 ± 1.5 -11.5 ± 1.6 (n.s.) -10.9 ± 1.0 
Last 30 s -12.3 ± 1.4 -11.6 ± 1.5 (n.s.) -10.8 ± 1.0 
Last 60 s -12.7 ± 1.3 -11.6 ± 1.4 (n.s.) -10.7 ± 1.0 
Liquid junction potentials (3 mV) were compensated offline. PSS: physiological saline 
solution. n.s. not significant compared with Vm in standard PSS; ANOVA with Tukey 




At the last 5 s of each of the three steps, 30 μM TTX significantly hyperpolarised 
the Vm of MDA-MB-231 cells from -13.2 ± 1.3 mV to -17.5 ± 1.6 mV (P < 0.001; ANOVA 
with Tukey post-hoc test; n = 17). The Vm partially recovered to -14.8 ± 1.4 mV after 
drug washout, such that it was not significantly different compared to the Vm recorded in 
standard PSS (P = 0.37; ANOVA with Tukey post-hoc test; n = 17) or in TTX (P = 0.07; 
ANOVA with Tukey post-hoc test; n = 17). Statistical analyses of the Vm using other 
measurement intervals are in Figure 3.5c and Table 3.3.  
Importantly, applying the same experimental procedure, citrate (148 μM, pH = 
4.8), vehicle for 30 μM TTX, did not change the Vm significantly (Figure 3.5d; Table 
3.4). Taking the last 5 s of each of the three experimental steps as example, the mean 
Vm in standard PSS and citrate was -12.0 ± 1.5 mV and -11.2 ± 1.7 mV, respectively (P 
= 0.93; ANOVA with Tukey post hoc test; n = 13). After washout, the Vm was -11.0 ± 
1.0 mV (P = 0.99; ANOVA with Tukey post hoc test; n = 13). Statistical analyses of the 
Vm using other measurement intervals are in Figure 3.5d and Table 3.4, showing that 
citrate did not alter the Vm. In summary, the data showed that blocking VGSCs using 
TTX hyperpolarised the Vm by approximately 4.3 mV. 
 
3.2.4 Phenytoin reduces INa and hyperpolarises the Vm of MDA-MB-231 
cells 
Phenytoin is a class 1b VGSC-blocking antiarrhythmic agent. During action 
potential firing, phenytoin decreases the phase 0 (depolarisation) slope, reduces the 
action potential duration, and increases effective refractory period (Vaughan Williams, 
1975). Phenytoin causes tonic and use-dependent inhibition on INa in MDA-MB-231 
cells (Yang et al., 2012). The tonic block is more potent at more depolarised holding 
voltages (Ragsdale et al., 1991). Previously, phenytoin at 50 μM was shown to inhibit 




depolarised to -10 mV from -120 mV. The tonic block following depolarisation to -10 
mV from -80 mV was stronger, as the transient and persistent INa was inhibited by 80 % 
and 49 % (Yang et al., 2012). In the present study, 100 μM phenytoin was used in 
order to obtain greater inhibition of transient and persistent INa. The INa was recorded in 
standard PSS using Cs+-containing intracellular solution. When the holding potential 
was -120 mV, perfusion with phenytoin (100 μM) for 2 min inhibited both transient INa 
(Figure 3.6a) and persistent INa (Figure 3.6b): after incubation with phenytoin for 2 min, 
transient INa was reduced to 51.9 ± 3.2 %, compared to standard PSS (Figure 3.6c; P < 
0.001; ANOVA with Tukey post hoc test; n = 9). Washout (2 min) partially recovered 
the transient INa to 72.6 ± 4.0 % of control (Figure 3.6a and c; P < 0.001; ANOVA with 
Tukey post hoc test; n = 9). Similarly, phenytoin (100 μM) significantly reduced the 
persistent INa to 63.2 ± 10.8 %, compared to standard PSS (Figure 3.6b and d; P < 
0.01; ANOVA with Tukey post hoc test; n = 4). Washout recovered the persistent INa to 
102.6 ± 1.3 % compared to standard PSS (Figure 3.6b and d; P < 0.01 compared with 
phenytoin; P = 0.96 compared with standard PSS; ANOVA with Tukey post hoc test; n 
= 9). 
Phenytoin showed stronger inhibition when the holding potential was at -80 mV 
(Figure 3.7a and b). The transient INa was reduced to 11.9 ± 3.8 % of standard PSS 
(Figure 3.7c; P < 0.001; ANOVA with Tukey post hoc test; n = 4). The transient INa was 
partially recovered to 54.8 ± 7.5 % (Figure 3.7c; P < 0.001 compared with standard 
PSS and phenytoin; ANOVA with Tukey post hoc test; n = 4). Similarly, phenytoin 
reduced the persistent INa to 5.3 ± 8.2 %, compared to standard PSS (Figure 3.7d; P < 
0.001; ANOVA with Tukey post hoc test; n = 3), and the persistent INa only recovered to 
54.0 ± 12.2 % (Figure 3.7d; P < 0.05 compared with standard PSS and phenytoin; 
ANOVA with Tukey post hoc test; n = 3). In summary, phenytoin at 100 μM showed 











Figure 3.6. Phenytoin inhibits Na+ current (INa) in MDA-MB-231 cells at holding potential 
= -120 mV. 
(a) Representative INa recorded from MDA-MB-231 cells in standard physiological 
saline solution (PSS) (blue), 100 μM phenytoin (red) and after washout (green). 
Transient INa is labelled, and the dotted box shows the persistent INa. (b) Enlargement 
of the dotted box in (a), showing the persistent INa. INa was elicited by depolarising the 
cell to -10 mV following a 250 ms pre-pulse at -120 mV. Persistent INa between 45–50 
ms after depolarisation was adopted in data analyses. (c) Normalised transient INa after 
100 μM phentoin treatment and subsequent washout. (**) P < 0.01; ANOVA with Tukey 
post-hoc test (n = 9). (d) Normalised persistent INa after 100 μM phenytoin treatment 
and the subsequent washout (**) P < 0.001; ANOVA with Tukey post-hoc test (n = 4). 







Figure 3.7. Phenytoin inhibits Na+ current (INa) in MDA-MB-231 cells at holding potential 
= -80 mV. 
(a) Representative INa recorded from MDA-MB-231 cells in standard physiological 
saline solution (PSS) (blue), 100 μM phenytoin (red) and after washout (green). 
Transient INa is labelled, and the dotted box shows the persistent INa. (b) Enlargement 
of the dotted box in (a), showing the persistent INa. INa was elicited by depolarising the 
cell to -10 mV following a 250 ms pre-pulse at -80 mV. Persistent INa between 45–50 
ms after depolarisation was adopted in data analyses. (c) Normalised transient INa after 
100 μM phentoin treatment and subsequent washout. (***) P < 0.001; ANOVA with 
Tukey post-hoc test (n = 4). (d) Normalised persistent INa after 100 μM phenytoin 
treatment and the subsequent washout (***) P < 0.001; (*) P < 0.05; ANOVA with 




Next, the effect of 100 μM phenytoin on steady-state Vm of MDA-MB-231 cells 
was investigated. Cells were initially perfused with standard PSS for 60 s, followed by 
phenytoin/vehicle for 150 s, and then a washout step with standard PSS for a further 
150 s. Phenytoin, but not the vehicle (75 μM NaOH), significantly hyperpolarised the 
Vm (Figure 3.8a and b). At the last 5 s of each of the three experimental steps, the Vm 
of MDA-MB-231 cells hyperpolarised from -12.6 ± 1.5 mV to -15.7 ± 1.7 mV after 
phenytoin treatment (Figure 3.8c; Table 3.5; P < 0.001; ANOVA with Tukey post hoc 
test; n = 12), however, the Vm only partially recovered to -14.6 ± 1.9 mV following 
washout (Figure 3.8c; Table 3.5; P = 0.59; n = 12). Similarly, the Vm was significantly 
hyperpolarised in the last 15 s, 30 s and 60 s following phenytoin treatment (Figure 
3.8c; Table 3.5; n = 12). In contrast, NaOH (75 μM), the vehicle for 100 μM phenytoin, 
did not significantly change the Vm (Figure 3.8d), as the mean Vm was -10.8 ± 1.5 mV, -
11.0 ± 1.3 mV, and -10.1 ± 2 mV in standard PSS, NaOH and washout, respectively, in 
the last 5 s of each step (Figure 3.8d; Table 3.6; P = 0.98 comparing NaOH and 
standard PSS; n = 9). Similarly, the Vm was not significantly changed using other 
measurement intervals (Figure 3.8d; Table 3.6; n = 9). In summary, like TTX, phenytoin 








Figure 3.8. Phenytoin hyperpolarises the membrane potential (Vm) of MDA-MB-231 
cells. 
MDA-MB-231 cells were treated with standard physiological saline solution (PSS) for 
60 s before being perfused with (a) 100 μM phenytoin or (b) vehicle, 75 μM NaOH, for 
150 s. Phenytoin and NaOH were subsequently washed out with standard PSS for a 
further 150 s. Black trace shows the mean Vm of n = 12 (a) or n = 9 (b), and the grey 
traces show the SEM. Dotted vertical lines indicate the various measurement intervals 
(last 5 s, 15 s, 30 s and 60 s). Liquid junction potentials (3 mV) are not compensated. 
The mean Vm over indicated measurement intervals after (c) phenytoin or (d) NaOH 
treatment. Liquid junction potentials (3 mV) are compensated. (*) P < 0.05; (**) P < 
0.01 and (***) P < 0.001 compared to standard PSS; ANOVA with Tukey post-hoc test 






Table 3.5. Mean membrane potential (Vm) of MDA-MB-231 cells after phenytoin (100 
μM) treatment and washout. 
Measurement 
interval 
Vm in standard PSS 
(mV) 
Vm in 100 μM 
phenytoin (mV) Vm in washout (mV) 
Last 5 s -12.6 ± 1.5 -15.7 ± 1.7 *** -14.6 ± 1.9 
Last 15 s -12.7 ± 1.5 -15.9 ± 1.9 ** -14.8 ± 1.9 
Last 30 s -12.9 ± 1.5 -15.6 ± 1.9 ** -14.9 ± 1.9 
Last 60 s -13.0 ± 1.5 -15.4 ± 1.9 * -15.2 ± 2.0 
Liquid junction potentials (3 mV) were compensated offline. PSS: physiological saline 
solution. (*) P < 0.05; (**) P < 0.01; (***) P < 0.001 compared with Vm in standard PSS; 







Table 3.6. Mean membrane potential (Vm) of MDA-MB-231 cells after NaOH (75 μM) 
treatment and washout. 
Measurement 
interval 
Vm in standard PSS 
(mV) 
Vm in 75 μM NaOH 
(mV) Vm in washout (mV) 
Last 5 s -10.8 ± 1.5 -11.0 ± 1.3 (n.s.) -10.1 ± 2.0 
Last 15 s -10.9 ± 1.3 -11.1 ± 1.3 (n.s.) -10.2 ± 2.1 
Last 30 s -10.9 ± 1.3 -11.1 ± 1.2 (n.s.) -10.3 ± 2.1 
Last 60 s -10.9 ± 1.3 -11.1 ± 1.2 (n.s.) -10.3 ± 2.1 
Liquid junction potentials (3 mV) were compensated offline. PSS: physiological saline 
solution. n.s. not significant compared with Vm in standard PSS; ANOVA with Tukey 




3.2.5 Veratridine increases the persistent INa and depolarises the Vm in 
MDA-MB-231 cells 
Blocking VGSCs using TTX and phenytoin hyperpolarised the Vm. To further 
investigate the role of VGSC in the Vm regulation in MDA-MB-231 cells, the present 
study hypothesised that activating VGSCs would cause a Vm depolarisation. 
Veratridine is an alkaloid that binds to the toxin binding site 2, and it increases 
persistent INa by increasing the channel opening probability but decreases transient INa 
by decreasing single channel conductance (Ulbricht, 1998; Wang & Wang, 2003). In 
the following experiment, veratridine at 100 μM was adopted as a VGSC opener 
(House et al., 2015).  
Firstly, the effects of veratridine on INa were tested using the whole-cell patch 
clamp technique in voltage-clamp mode using the standard current-voltage protocol 
(Section 2.4.7). INa was firstly recorded in standard PSS before cells were perfused with 
100 μM veratridine for 2 min, followed by a 2 min washout. Veratridine increased 
persistent INa of MDA-MB-231 cells, and the persistent INa increased further even after 
washout (Figure 3.9a and b). The current-voltage relationships of both transient and 
persistent INa are shown in (Figure 3.9c and d), where the INa was normalised to whole-
cell capacitance: veratridine and the following washout did not significantly alter the 
transient current-voltage relationship (Figure 3.9c; ANOVA with Tukey post hoc test; n 
= 6). The peak transient INa was slightly reduced, albeit not significantly, from -12.1 ± 
2.2 pA/pF to -9.3 ± 1.2 pA/pF after veratridine treatment (Figure 3.9d; P = 0.10 
compared to standard PSS; ANOVA with Tukey post hoc test; n = 6), and was -9.8 ± 
1.5 pA/pF after washout. 
The persistent INa density, measured 45–50 ms after depolarisation, increased 
upon depolarisation to voltages in the range of -25 mV to -10 mV (Figure 3.9e; P < 






Figure 3.9. Veratridine increases the persistent Na+ current (INa) in MDA-MB-231 cells. 
Representative transient (a) and persistent (b) INa in an MDA-MB-231 cell in standard 
PSS, followed by 2 min veratridine (100 μM) treatment and 2 min washout. Cell was 
depolarised to 0 mV for 60 ms from a 250 ms pre-pulse at -120 mV. Dotted box in (a) 
represents the persistent INa that is shown in (b). Persistent INa between 45–50 ms after 
depolarisation was adopted in data analyses. (c) The current-voltage relationship of 
transient INa and (d) the peak transient INa density after veratridine treatment and 
washout (n = 6). (e) The current-voltage relationship of persistent INa. (*) P < 0.05 
comparing standard PSS and veratridine; (#) P < 0.05 comparing standard PSS and 
washout. (f) The mean persistent INa density after veratridine treatment and washout. 
(*) P < 0.05; n.s. not significant; ANOVA with Tukey post hoc test (n = 6). (g) The 
normalised conductance of INa in all experimental conditions (n = 6), fitted with 
Boltzmann equations. Cells were depolarised to voltages between -80 mV to +30 mV in 




further after washout (Figure 3.9e; P < 0.05; ANOVA with Tukey post hoc test; n = 6). 
The maximal persistent INa was increased from -0.5 ± 0.2 pA/pF in standard PSS to -
1.3 ± 0.2 pA/pF in veratridine (Figure 3.9f; P = 0.06; ANOVA with Tukey post hoc test; 
n = 6). Following washout the maximal persistent INa increased further to -2.1 ± 0.4 
pA/pF, which was significantly different compared with standard PSS (Figure 3.9f; P < 
0.05; ANOVA with Tukey post hoc test; n = 6) as well as the veratridine treatment 
(Figure 3.9f; P < 0.05; ANOVA with Tukey post hoc test; n = 6). 
Veratridine at 100 μM did not change the voltage-dependence of activation 
(Figure 3.9g). INa characteristics including V1/2, k, activation voltage (Va), voltage at 
current peak (Vp) and time to peak (Tp) were constant after veratridine treatment and 
following washout (Table 3.7). Because (1) veratridine increased the persistent INa in a 
non-reversible manner, and (2) 4 min after veratridine treatment (including washout) 
the persistent INa was significantly increased at voltages between -25 mV and -10 mV, 
the effect of veratridine on MDA-MB-231 cell Vm was assessed by measuring the 
steady-state Vm after incubating cells with 100 μM veratridine for 6 min, instead of 
performing a time-course Vm measurement as done in previous sections. Veratridine 
depolarised the Vm from -16.4 ± 1.4 mV to -12.6 ± 1.4 mV (Figure 3.10; P < 0.05; t-test; 
n = 14 in each condition). Together with the data presented in Section 3.2.3 and 
Section 3.2.4, modulation of VGSCs by using pharmacological agents has revealed a 









Table 3.7. Characteristics of Na+ current after veratridine (100 μM) treatment and 
washout. 
Parameters and 
conditions Standard PSS 
Veratridine (100 
μM) Washout P 
V1/2 (mV) -23.0 ± 1.8 -26.6 ± 1.8 -27.89 ± 1.5 0.07 
k (mV) 10.1 ± 0.8 10.1 ± 0.5 10.2 ± 0.5 0.98 
Va (mV) -39.2 ± 0.8 -42.5 ± 2.1 -42.5 ± 1.1 0.23 
Vp (mV) -1.7 ± 1.1 -1.7 ± 1.1 -5.0 ± 2.2 0.23 
Tp (ms) 2.7 ± 0.5 2.1 ± 0.6 2.1 ± 0.4 0.40 
V1/2: the voltage at which half-maximal conductance or availability occurs; k: slope 
factor; Va: activation voltage; Vp: voltage at current peak; Tp: time to peak. ANOVA with 







Figure 3.10. Veratridine depolarises the Vm of MDA-MB-231 cells. 
Cells were pre-treated with DMSO (2 % v/v) or 100 μM veratridine in the standard PSS 
for 6 min before their steady-state Vm was recorded. (*) P < 0.05; t-test (n = 14 in each 





3.2.6 Suppressing Nav1.5 expression using shRNA hyperpolarises the Vm 
of MDA-MB-231 cells 
In addition to inhibiting VGSC activity using pharmacological agents, Nav1.5, the 
main VGSC isoform in MDA-MB-231 cells (Fraser et al., 2005), was stably down-
regulated by lentiviral shRNA in order to specifically examine how Nav1.5 regulates cell 
metastatic behaviours compared to cells transduced with non-targeting control shRNA. 
Genetically suppressing Nav1.5 expression also has advantages such as the 
avoidance of non-target effects associated with certain pharmacological agents, e.g. 
phenytoin also inhibits HERG channels at high concentration (IC50 ≥ 300 μM) 
(Danielsson et al., 2003). Stable knockdown with shRNA also enables the study of 
long-term effects of Nav1.5 on cell behaviour. 
INa from cells that were stably transduced with two different sets of shRNA 
(“Nav1.5-shRNA 1” and “Nav1.5-shRNA 2” cells) or with non-targeting control shRNA 
(“shRNA control” cells) were tested in the study Figure 3.11. Both Nav1.5 mRNA and 
protein levels were reduced in Nav1.5-shRNA 1 and 2 cells (Nelson et al., 2015b). 
Using the standard current-voltage protocol (Section 2.4.7) whole-cell INa recording 
showed that both Nav1.5-shRNA 1 (Figure 3.11a) and Nav1.5-shRNA 2 (Figure 3.11b) 
cells had smaller INa compared to shRNA control cells (Figure 3.11c), which is also 
displayed in the current-voltage relationship (Figure 3.11d). The peak INa density of 
shRNA control, Nav1.5-shRNA 1 and Nav1.5-shRNA 2 cells was -14.9 ± 2.1 pA/pF, -0.1 
± 0.1 pA/pF and -7.9 ± 2.2 pA/pF, respectively (Figure 3.11e). Since Nav1.5-shRNA 1 
cells showed the greatest INa reduction than cells bearing Nav1.5-shRNA 2 (Figure 
3.11d and e; P < 0.05; ANOVA with Tukey post hoc test; n = 8), the steady-state Vm of 
Nav1.5-shRNA 1 cells (hereafter referred to as Nav1.5-shRNA cells) was recorded and 







Figure 3.11. Down-regulating Nav1.5 using small-hairpin RNA (shRNA) reduced the 
Na+ current (INa) in MDA-MB-231 cells. 
Representative INa traces in (a) non-targeting shRNA-expressing (shRNA control) cells, 
(b) Nav1.5-shRNA 1 cells and (c) Nav1.5-shRNA 2 cells. INa was elicited after 
depolarisation to voltages ranging from -80 mV to +30 mV in 5 mV increments following 
a 250 ms pre-pulse at -120 mV. Every other INa trace is shown for clarity. (d) Current-
voltage relationship of the transient INa recorded from shRNA control and Nav1.5-
shRNA 1 and 2 cells. (e) Peak transient INa density of shRNA control and Nav1.5-
shRNA 1 and 2 cells. (*) P < 0.05; (***) P < 0.001; ANOVA with Tukey post hoc test (n 







Figure 3.12. Nav1.5 causes a steady-state membrane potential (Vm) depolarisation in 
MDA-MB-231 cells. 
Comparison of the Vm recorded in cells bearing control non-targeting shRNA (shRNA 
control cells) and in cells where Nav1.5 expression was down-regulated with lentiviral 
shRNA (Nav1.5-shRNA cells). (**): P < 0.01; t-test (n = 16 in each condition). Data are 





significantly hyperpolarised the Vm from -12.6 ± 0.9 mV to -16.0 ± 0.8 mV (Figure 3.12; 
P < 0.01; t-test; n = 16 in each condition). Taken together, data presented in this 
Chapter so far suggest that VGSCs depolarise the steady-state Vm of MDA-MB-231 
cells by 3.2–4.3 mV. 
 
3.2.7 Voltage-dependent INa recorded in ERα- MCF-7 cells 
pII is an MCF-7 derivative cell line where ERα was stably knocked down by using 
shRNA (Luqmani et al., 2009). To test the hypothesis that down-regulation of ER in 
BCa cells may increase malignancy by inducing VGSC expression, the membrane 
currents of pII and parental control MCF-7 cells was also investigated in the present 
study.  
The standard intracellular solution (Cs+-free) was used while recording the whole-
cell current. In the control MCF-7 cells, both inward and outward current were absent in 
eight cells recorded after depolarisation from -120 mV (250 ms) to voltages ranging 
between -60 mV and +80 mV for 60 ms (Figure 3.13a). Interestingly, however, two out 
of five pII cells recorded showed fast voltage-dependent inward current together with 
voltage-dependent persistent outward current (Figure 3.13b). Additionally, two cells 
exhibited only persistent outward current. The current-voltage relationships of the 
inward and outward current are shown in Figure 3.13c (n = 2) and Figure 3.13d (n = 4), 
respectively. Alongside with these findings, our collaborators confirmed the expression 
of Nav1.5 mRNA and protein in pII cells (Mohammed et al., 2015). Therefore, it is likely 
that the fast inward current is INa carried by Nav1.5. In summary, a voltage-dependent 
inward INa, was seen in a proportion of ERα-knockdown pII cells but not in parental 
MCF-7 cells. Further experiments should examine the TTX sensitivity of the inward 








Figure 3.13. Membrane current recorded from pII and parental MCF-7 cells. 
Representative whole-cell current recorded from (a) control MCF-7 cells (n = 8) and (b) 
pII cells where ERα expression was down-regulated using shRNA. The current-voltage 
relationship of (c) inward (n = 2) and (d) outward (n = 4) current recorded from pII cells. 
Cells were depolarised to voltages between -60 mV and +80 mV in 10 mV increments 
following a 250 ms pre-pulse at -120 mV. Every other INa trace is shown for clarity. In 
(d), the mean current between 45 ms and 50 ms after the test-pulse was analysed. 





In the standard PSS, the Vm of MDA-MB-231 cells is approximately -10 mV. The 
value significantly deviates from the equilibrium potential of K+ and Cl- (-82 mV and 
0.06 mV, respectively, under the experimental condition in this study), while the Na+ 
equilibrium potential is +86.3 mV. Na+ conductance therefore may act as an important 
determinant of the depolarised Vm of MDA-MB-231 cells. Indeed, data in this Chapter 
show that depletion of extracellular Na+ hyperpolarises the Vm of MDA-MB-231 cells by 
10–14 mV. Using pharmacological agents or shRNA, data in this Chapter also show 
that VGSCs cause a steady-state Vm depolarisation of 3.2–4.3 mV in MDA-MB-231 
cells.  
Specifically suppressing Nav1.5 expression using shRNA abolishes the INa in 
MDA-MB-231 cells, supporting the previous study showing that Nav1.5 is the 
predominant VGSC isoform in MDA-MB-231 cells (Brackenbury et al., 2007). 
Considering that TTX (30 μM), phenytoin (100 μM) and Nav1.5-shRNA hyperpolarised 
the Vm to a similar extent, TTX- and phenytoin-induced Vm hyperpolarisation is likely 
caused by blockade of Nav1.5 in MDA-MB-231 cells. In addition, Nav1.5-dependent Vm 
depolarisation may be independent of other Vm regulation pathway, since the 
hyperpolarised Vm in Nav1.5-shRNA cells has not been compensated for over time in 
culture.  
In H460 NSCLC cells, blocking Nav1.7 with TTX (0.5 μM) hyperpolarises the Vm 
by 10 mV (Campbell et al., 2013), which is a greater effect than blocking Nav1.5 in 
MDA-MB-231 cells. One possible explanation is that H460 cells have a more 
hyperpolarised Vm (-27 mV), and at this voltage, the window INa is stronger in H460 
cells compared with that in MDA-MB-231 cells (Campbell et al., 2013). In addition, the 
present study has recorded the continuous Vm from individual cells that were perfused 
with phenytoin or TTX, which can reveal the immediate effect of the drugs on Vm and 




two conditions, as in (Campbell et al., 2013). Another study reported that the Vm of 
other VGSC-expressing NSCLC cells does not significantly differ from those where 
VGSCs are absent (Roger et al., 2007). Comparisons between a number of cell lines 
with distinct INa  and IK current profiles, as in (Roger et al., 2007), cannot determine 
whether or not VGSCs regulate cell Vm. On the other hand, continuous 
pharmacological experiments on single cells as in the present study, clearly shows that 
VGSCs regulate the Vm in MDA-MB-231 cells. 
The mean Vm did not fully recover after eliminating TTX or phenytoin from the 
recording chamber (Sections 3.2.3 and 3.2.4). Since phenytoin binds to the toxin 
binding site 2, which is at the intracellular side (Lipkind & Fozzard, 2010), it may require 
much longer time in the washout step before the drug dissociates from the VGSC 
complex. Additionally, when MDA-MB-231 cells are at their typical Vm (~-10 mV), 
VGSCs are mostly in the inactivated state that has higher affinity for phenytoin 
(Ragsdale et al., 1991; Kuo & Bean, 1994), making drug dissociation by washout more 
difficult. However, TTX can be washed out relatively easily since it binds to toxin 
binding site 1 at the extracellular loop (Noda et al., 1989; Terlau et al., 1991), confirmed 
by the voltage-clamp study (Figure 3.4). Considering that TTX does not show state-
dependent binding (Narahashi et al., 1964), one possible explanation is that other ion 
channels and transporters are activated when the Vm is hyperpolarised by blocking 
VGSCs, and therefore it may take longer for cells to recover their original Vm after 
washout. Indeed, the Vm slowly but constantly depolarises during washout. Further 
work is required to test these possibilities.  
Veratridine is a VGSC agonist that has been shown to increase persistent INa  
whilst decreasing transient INa (Ulbricht, 1969). In the present study, voltage-clamp 
experiments using veratridine (100 μM) showed a similar result (Figure 3.9). Moreover, 
the persistent INa increased further after veratridine washout. Possible reasons are: (1) 




site 2 (Ulbricht, 1998; Cestele & Catterall, 2000), and (2) veratridine binds preferentially 
to open channels (Barnes & Hille, 1988; Ulbricht, 1998). Consequently, the effect of 
veratridine became stronger because of repeated channel openings during the 
recording protocols. The persistent INa after depolarisation to voltages from -25 mV to -
10 mV significantly increased following veratridine application (Figure 3.9), and this 
agrees well with the findings that veratridine depolarised the Vm by 3.8 mV (Figure 
3.10), because the Vm of MDA-MB-231 cells lies within this voltage range. A similar 
result has been reported in H460 cells, where the Vm depolarised by 4 mV after 
treatment with 50 μM veratridine (Campbell et al., 2013).  
Several questions are raised by these results. The VGSC-dependent Vm 
regulation only contributes to 30–40 % of the extracellular Na+-dependent Vm 
depolarisation in MDA-MB-231 cells, suggesting that there are other Na+-permeable 
pathways at the cells plasma membrane that can depolarise the Vm, such as epithelial 
Na+ channels (ENaC), NHE1, Na+-Ca2+ exchanger (NCX) and Na+ transporters 
including the Na+-K+-2Cl- co-transporter. Further experiments should address their 
roles in Vm regulation in MDA-MB-231 cells. Additionally, compared to MCF-7 cells, 
which have a Vm of -40 mV (Fraser et al., 2005), results in this Chapter show that the 
depolarised Vm of MDA-MB-231 cells is only partly due to Na+ influx. Therefore, the 
absence of Vm-hyperpolarising ion channels/transporters and/or the presence of other 
Vm-depolarising ion channels/transporters may also contribute to the depolarised Vm of 
MDA-MB-231 cells. 
In pII cells, a MCF-7 cell derivative where ERα is stably knocked down, a voltage-
dependent fast inward current was recorded, which was absent in control MCF-7 cells. 
Further study suggested that the current is probably INa carried by Nav1.5. TTX, 
phenytoin and siRNA targeting Nav1.5 significantly reduced EGF-induced invasion in 
pII cells (Mohammed et al., 2015). Although microarray data show that Nav1.5 mRNA 




down-regulation may still increase functional channel expression and/or channel 
trafficking to the plasma membrane of BCa cells. Further study should focus on 
determining the electrophysiological characteristics of the INa-like current recorded in pII 
cells and investigate how ER down-regulation induced the functional current. 
 
3.4 Conclusion 
This Chapter demonstrated that replacement of the extracellular NaCl with ChoCl 
and NMDG hyperpolarised the Vm of MDA-MB-231 cells by approximately 10 and 14 
mV, respectively. In addition, inhibiting VGSC activity using TTX, phenytoin and 
Nav1.5-targeting shRNA showed that VGSCs depolarise the steady-state Vm of MDA-
MB-231 cells by 3.2–4.3 mV. On the other hand, increasing the persistent INa using 
veratridine depolarised the Vm by 3.8 mV. Thus, Na+ conductance across the plasma 
membrane regulates the Vm, partly contributed by VGSCs (Figure 3.14). Whether the 
depolarised Vm has functional roles in promoting MDA-MB-231 cells metastatic 







Figure 3.14. Na+ conductance contributes to membrane potential (Vm) regulation in 
cancer cells. 
An update to Figure 1.6 with the findings in this Chapter showing the involvement of 
Na+ in Vm regulation (red line). The relationship between Na+ and Ca2+ signalling has 





4 Chapter 4: Functional role of the depolarised Vm caused by 
VGSCs in MDA-MB-231 cells in vitro 
4.1 Introduction 
Over the past few decades, functional VGSCs have been identified in an 
increasing number of cancer cell lines where they promote metastatic cell behaviours 
including cell migration and invasion (Brackenbury, 2012; Roger et al., 2015). For BCa, 
recent in vivo experiments showed that inhibiting VGSC α subunits with phenytoin 
decreases BCa cell growth and metastasis (Nelson et al., 2015a), and that ranolazine-
treated mice had reduced BCa cell colonisation to the lungs (Driffort et al., 2014). 
However, the detailed mechanism(s) by which VGSCs increase cancer cell metastatic 
behaviours is not fully understood. It is proposed that in MDA-MB-231 cells, Nav1.5 
increases H+ efflux through NHE1, resulting in a lower extracellular pH that promotes 
proteolytic activity of cysteine cathepsin B and S, thus increasing cell invasion (Gillet et 
al., 2009; Brisson et al., 2011). A following study demonstrated that inhibiting Nav1.5 
with TTX decreased src kinase activity and phosphorylation of the actin nucleation 
promoting factor cortactin (Brisson et al., 2013). In MDA-MB-231 cells where Nav1.5 is 
down-regulated by using shRNA, the protein level of the metastasis-promoting 
molecule CD44 is also reduced (Nelson et al., 2015b). Furthermore, in SW620 human 
colon cancer cells, VGSC activity leads to persistent MAPK activation in a Rap1-
dependent manner, with the downstream effect of activating expression of invasion-
related genes including CD44 (House et al., 2015). Finally, β1–β1 homophilic adhesion 
increases MDA-MB-231 cell process outgrowth in a fyn kinase-dependent pathway, 
where Na+ influx is also required (Nelson et al., 2014). However, other undiscovered 




example, in a wound healing assay, rat cortical astrocytes show elevated [Ca2+]i upon 
wound scratching, which is attenuated by blocking NCX or VGSCs using KB-R7943 or 
TTX, respectively (Pappalardo et al., 2014b). The inhibitory effects on [Ca2+]i caused by 
these two compounds are similar, and therefore it is proposed that Na+ influx through 
VGSCs regulates [Ca2+]i through NCX (Pappalardo et al., 2014b). Na+ influx through 
VGSCs increases [Ca2+]i in THP-1 macrophages via NCX on the mitochondrial 
membrane (Carrithers et al., 2009). In human umbilical vein endothelial cells, Na+ 
carried by VGSCs increases Ca2+ influx through NCX, which is necessary in vascular 
endothelial growth factor (VEGF)-induced ERK1/2 activation (Andrikopoulos et al., 
2011a; Andrikopoulos et al., 2011b).  
Cancer cells possess a depolarised Vm compared to their counterparts from 
normal tissues (Binggeli & Weinstein, 1986; Yang & Brackenbury, 2013). A depolarised 
Vm is not merely an epi-phenomenon that is the outcome of the collective activity of 
many ion channels and transporters at the plasma membrane: apart from its 
involvement in promoting cell cycle progression and maintaining stem cells in an 
undifferentiated state (Sundelacruz et al., 2009; Yang & Brackenbury, 2013), 
depolarised Vm is also able to promote cytoskeleton reorganisation (Chifflet et al., 
2003; Chifflet et al., 2004). In a wound healing assay using bovine corneal endothelial 
cells, Vm depolarisation occurs in cells at the edge of the wound and extends inwards, 
and the depolarised Vm causes actin network reorganisation during wound healing 
(Chifflet et al., 2005). The Vm depolarisation is caused by increased Na+ permeability 
via ENaC, but the resulting cytoskeleton reorganisation is Na+-independent (Chifflet et 
al., 2005).  
Cell migration comprises several key steps, including extension of the 
lamellipodium, formation of new adhesion sites at the front, cell body contraction and 
detachment of adhesions at the rear (Raftopoulou & Hall, 2004). Members of the Rho 




migration. These GTPases switch between a GTP-bound active form and a GDP-
bound inactive form. GEFs activate small GTPases by increasing the release of GDP 
and binding of GTP. Upon activation, the most well established function of these small 
GTPases is their contribution to cell migration and morphogenesis by regulating the 
actin and microtubule cytoskeleton (Hall, 1998). However, Rho, Rac and Cdc42 have 
distinct effects on the actin cytoskeleton: in 3T3 fibroblasts, activation of Rho results in 
the formation of stress fibres at the rear of the cell, Cdc42 causes the formation of 
filopodia, and Rac leads to the formation of lamellipodia (Nobes & Hall, 1995). During 
lamellipodia formation, Rac initiates actin polymerisation through the Arp2/3 complex 
mediated by the nucleation-promoting Wiskott-Aldrich syndrome protein-family 
verprolin-homologous proteins (WAVE) (Jaffe & Hall, 2005). The instructive role of 
Rac1, a member of the Rac family, during lamellipodium formation has been confirmed 
by an optogenetic study: activation of a photoactivatable Rac1 is sufficient to induce 
lamellipodium extension, cell motility and control the directionality of cell movement 
(Wu et al., 2009). In addition to their roles in controlling the cytoskeleton, Rac GTPases 
are capable of activating JNKs, leading to alterations in gene expression (Coso et al., 
1995). Rac also participates in regulation of the mitogen-activated protein (MAP) 
signalling pathway: mixed lineage kinase 3 (MLK3), a MAP kinase kinase kinase, is a 
direct binding target of Rac (Brancho et al., 2005). In COS-7 cells, a MLK3 dominant 
negative mutant abolished JNK activation by Rac (Teramoto et al., 1996).  
Vm can be a functional signal in regulating small GTPases. The activation of Ras 
and Rap1, a small GTPase that is required in NGF-induced ERK activation (York et al., 
1998), caused by Vm depolarisation has been reported in mouse cortical neurones 
(Baldassa et al., 2003). In PC12 cells, the depolarised Vm increases the active Ras 
level in a PKA-dependent manner (Obara et al., 2007). More recently, a study has 
demonstrated that in baby hamster kidney cells, Vm depolarisation enhances 




frequently activated oncogenes (Kranenburg, 2005), and K-Ras-dependent MAPK 
signalling (Zhou et al., 2015). Therefore, Vm may regulate metastatic cell behaviours 
through small GTPases.  
In humans, BKCa channels are encoded by KCNMA1 and may associate with 
auxiliary β subunits (β1–β4) (Salkoff et al., 2006). The BKCa channel protein has seven 
transmembrane domains, an extracellular N-terminus, and an intracellular C-terminus 
(Meera et al., 1997; Yuan et al., 2010), where three Ca2+ binding sites are located 
(Schreiber & Salkoff, 1997; Xia et al., 2002). The channel monomer comprises one 
voltage-sensing module and one Ca2+-sensing module that are both important in 
channel opening (Barrett et al., 1982; Latorre & Brauchi, 2006). However, evidence 
suggests that the activation of BKCa channels is primarily caused by Vm depolarisation 
whereas Ca2+ functions as an amplifier (Meera et al., 1996; Stefani et al., 1997). In 
Xenopus oocytes, when [Ca2+]i is ≤ 100 nM, BKCa channels become purely voltage-
gated and independent of Ca2+, with an activation V1/2 ≥ 220 mV (Meera et al., 1996). In 
a physiological range of Vm, BKCa channels function in Ca2+-dependent mode, where 
V1/2 values linearly increase with cytosolic free [Ca2+] (Cui et al., 1997).  
VGSCs depolarise the Vm of MDA-MB-231 cells by approximately 4 mV (Section 
3.2.6). Considering that MDA-MB-231 cells have a Vm at ~-10 mV (Section 3.2.1), 
inhibition of VGSCs accounts for a ~40 % increase in the transmembrane voltage. 
Given that VGSCs regulate Vm in MDA-MB-231 cells and that Vm is functionally 
instructive in regulating metastatic cell behaviours in other cell models, it is possible 
that VGSCs may regulate metastatic cell behaviours via modulation of the Vm. To 
specifically study the role of Vm without altering the Na+ conductance through VGSCs, it 
is possible to modulate the Vm of MDA-MB-231 cells through activating endogenously 





4.1.1 Hypothesis and aims 
The hypothesis of the Chapter was that depolarised Vm is an instructive signal in 
promoting MDA-MB-231 cell metastatic behaviours including proliferation, migration 
and invasion. The specific aims were: 
(1) To investigate whether or not Vm can alter [Ca2+]i in MDA-MB-231 cells. 
(2) To hyperpolarise the Vm to a similar extent to 30 μM TTX by activating BKCa 
channels. 
(3) To study the effect of Vm hyperpolarisation on MDA-MB-231 cell migration 
and invasion. 
(4) To investigate the active Rac1 distribution in MDA-MB-231 cell lamellipodia 
after Vm hyperpolarisation. 
 
4.2 Results 
4.2.1 Monitoring [Ca2+]i in MDA-MB-231 cells using Fura-2 
Using MDA-MB-231 cells, Fura-2 was chosen as the intracellular Ca2+ fluorescent 
indicator for the following reasons: firstly, Fura-2 has the lowest dissociation constant 
(Kd) among all the Fura-2/Indo-1 derivatives at 0.14 μM, which is close to the [Ca2+]i of 
MDA-MB-231 cells reported previously [97 ± 2 nM in (Winnicka et al., 2008), and 142 ± 
39 nM in (Sareen et al., 2007)]. Since the sensitivity of a Ca2+ fluorescent indicator is 
most reliable in a [Ca2+]i range below or close to the Kd (Takahashi et al., 1999), Fura-2 
should be the most suitable intracellular Ca2+ indicator to use in MDA-MB-231 cells. 
Secondly, Fura-2 is a ratiometric fluorescent indicator that allows for better quantitative 
measurement of [Ca2+]i measurement compared to single wavelength indicators 
(Bootman et al., 2013).  
To begin with, a control experiment using standard PSS was carried out in order 




Fura-2 labelled MDA-MB-231 cells were observed under a Nikon Eclipse TE200 epi-
fluorescence microscope (Section 2.9) and perfused with standard PSS at room 
temperature for 14 min. Cells were excited alternately at 340 nm and 380 nm, and 
fluorescence emission at 512 nm was collected using a RoleraXR Fast 1394 CCD 
camera (Section 2.9). Over the standard PSS treatment period, the majority of the cells 
did not show obvious [Ca2+]i oscillations (Figure 4.1a and b; n = 55 from one of three 
repeats), whereas some cells (n = 5 out of 55) showed a slow increase and 
subsequent decrease in [Ca2+]i (“Ca2+ spike”; Figure 4.1c, arrow head).  At the end of 
the experiment, ionomycin (10 μM), a positive control (Liu & Hermann, 1978), 
increased the [Ca2+]i in all the cells. The 340/380 ratios of the individual cells were 
averaged in Figure 4.1e and f (n = 55).  
 
4.2.2 Extracellular Na+ depletion does not significantly alter [Ca2+]i in 
MDA-MB-231 cells 
Replacing extracellular Na+ with ChoCl caused a Vm hyperpolarisation of 10 mV 
(Section 3.2.1). This hyperpolarisation might increase the driving force of Ca2+ entry via 
Ca2+-permeable channels (Prevarskaya et al., 2014), and hence increase the [Ca2+]i in 
MDA-MB-231 cells. To test this, Fura-2 labelled cells were perfused with ChoCl 
solution for 6 min following 2 min in standard PSS. ChoCl did not change the [Ca2+]i in 
MDA-MB-231 cells (data from one of three technical repeats are shown in Figure 4.2a–
d; n = 70), nor did the following washout (Figure 4.2a–d). The mean 340/380 ratios of 
cells were 1.0 ± 0.1, 1.0 ± 0.1, and 1.0 ± 0.1 over the last 30 s of standard PSS, ChoCl 
and washout, respectively, showing no statistical difference (Figure 4.2e; P = 0.23; 
ANOVA with Tukey post hoc test; n = 3). Therefore, Vm hyperpolarisation by removal of 







Figure 4.1. Intracellular Ca2+ concentration ([Ca2+]i) of MDA-MB-231 cells in standard 
physiological saline solution (PSS). 
(a) The [Ca2+]i of individual cells, presented as the ratio of fluorescence signals 
subsequently collected at excitation wavelengths 340 nm and 380 nm (340/380 ratio), 
during standard PSS treatment for 14 min, before ionomycin (10 μM) as the positive 
control was applied. The 340/380 ratios of cells during standard PSS treatment are 
also shown in (b). (c) A representative cell exhibiting a Ca2+ spike. (d) and (e) show the 
averaged trace of (a) and (b), respectively (n = 55 from one of three repeats). Data are 





Figure 4.2. Intracellular Ca2+ concentration ([Ca2+]i) of MDA-MB-231 cells after choline 
chloride (ChoCl) treatment. 
(a) The [Ca2+]i of individual cells, presented as the ratio of fluorescence signals 
subsequently collected at excitation wavelength = 340 nm and 380 nm (340/380 ratio), 
in standard physiological saline solution (PSS) for 2 min, followed by 6 min ChoCl 
treatment and a further 6 min washout, before ionomycin (10 μM) as the positive 
control was applied. The 340/380 ratios of cells before ionomycin treatment are also 
shown in (b). (c) and (d) show the averaged trace of (a) and (b), respectively (n = 70 
from one of three repeats). (e) The mean 340/380 ratio over the last 30 s of standard 
PSS, ChoCl treatment and washout. (f) The number of cells that exhibit Ca2+ spikes in 
standard PSS and ChoCl. ANOVA with Tukey post hoc test in (e) (n = 3). Fisher’s 





cells. Additionally, the number of cells that exhibited Ca2+ spikes during ChoCl 
treatment did not significantly differ compared to that in the standard PSS (Figure 4.2f; 
P = 0.15; Fisher’s exact test; 178 cells from three repeats).  
 
4.2.3 TTX application does not change the [Ca2+]i in MDA-MB-231 cells 
Since depletion of extracellular Na+ does not change [Ca2+]i, blocking VGSCs 
with TTX should not bring significant change to the [Ca2+]i. Indeed, application of 30 μM 
TTX showed no significant change in the [Ca2+]i on individual MDA-MB-231 cells, nor 
did the following washout (data from one of three technical repeats are shown in Figure 
4.3a–d; n = 55). The mean 340/380 ratios over the last 30 s of standard PSS, TTX 
treatment and washout were 1.0 ± 0.0, 1.0 ± 0.1 and 1.1 ± 0.1, respectively (Figure 
4.3e; P = 0.24; ANOVA with Tukey post hoc test; n = 3). Compared to standard PSS, 
TTX at 30 μM did not significantly change the number of cells that showed Ca2+ spikes 
(Figure 4.3f; P = 0.15; Fisher’s exact test; 185 cells from three repeats).  
In a following experiment, MDA-MB-231 cells were pre-treated with 30 μM TTX 
for 48 h before the drug was washed out 2 min after starting image acquisition. This 
was to investigate whether or not [Ca2+]i changes when the VGSC-mediated Na+ influx 
is resumed after inhibition for 48 h. Representative 340/380 ratios of cells from one of 
three technical repeats are shown in Figure 4.4a–d. [Ca2+]i of MDA-MB-231 cells did 
not significantly change after TTX washout: the mean 340/380 ratio over the last 30 s 
of TTX treatment and washout was 1.1 ± 0.1 and 1.1 ± 0.1, respectively (Figure 4.4e; P 
= 0.40; t-test; n = 3). Washing out TTX using standard PSS did not significantly alter 
the number of cells that exhibited Ca2+ spikes (Figure 4.4f; P = 0.55; Fisher’s exact 
test; 100 cells from three repeats). In summary, these data demonstrate that in MDA-
MB-231 cells, replacing extracellular Na+ with choline does not significantly change the 







Figure 4.3. Intracellular Ca2+ concentration ([Ca2+]i) of MDA-MB-231 cells after acute 
tetrodotoxin (TTX) treatment. 
(a) The [Ca2+]i of individual cells, presented as the ratio of fluorescence signals 
subsequently collected at excitation wavelength = 340 nm and 380 nm (340/380 ratio), 
in standard physiological saline solution (PSS) for 2 min, followed by 6 min TTX (30 
μM) treatment and a further 6 min washout, before ionomycin (10 μM) as the positive 
control was applied. The 340/380 ratios of cells before ionomycin treatment are also 
shown in (b). (c) and (d) show the averaged trace of (a) and (b), respectively (n = 55 
from one of three repeats). (e) The mean 340/380 ratio over the last 30 s of standard 
PSS, TTX treatment and washout. (f) The number of cells that exhibit Ca2+ spikes in 
standard PSS and TTX. ANOVA with Tukey post hoc test in (e) (n = 3). Fisher’s exact 






Figure 4.4. Intracellular Ca2+ concentration ([Ca2+]i) of MDA-MB-231 cells released from 
48 h tetrodotoxin (TTX) treatment. 
(a) The [Ca2+]i of individual cells, presented as the ratio of fluorescence signals 
subsequently collected at excitation wavelength = 340 nm and 380 nm (340/380 ratio). 
Cells were pre-incubated with TTX (30 μM) for 48 h. TTX was washed out 2 min after 
image acquisition started for 12 min, before ionomycin (10 μM) as the positive control 
was applied. The 340/380 ratios of cells before ionomycin treatment are also shown in 
(b). (c) and (d) show the averaged trace of (a) and (b), respectively (n = 55 from one of 
three repeats). (e) The mean 340/380 ratio over the last 30 s of TTX treatment and 
washout. (f) The number of cells that exhibit Ca2+ spikes in TTX and following washout. 
n.s.: not significant. t-test in (e) (n = 3).  Fisher’s exact test in (f) (100 cells from three 




treatment did not change the [Ca2+]i. Therefore, Vm hyperpolarisation and/or VGSCs 
may not regulate [Ca2+]i in MDA-MB-231 cells. 
 
4.2.4 Recording endogenous IBKCa in MDA-MB-231 cells 
4.2.4.1 Whole-cell patch clamp recording 
In kidney tubular cells, Vm depolarisation induces MLC phosphorylation via the 
ROCK pathway in a Ca2+-independent manner (Szaszi et al., 2005). In the next part of 
the study, in order to hyperpolarise the Vm of MDA-MB-231 cells without blocking  
VGSCs, endogenously expressed BKCa channels were modulated (Roger et al., 2004; 
Khaitan et al., 2009). The typical Vm of MDA-MB-231 cells (~-10 mV) is more positive 
than the Vrev of K+ (-82 mV). Consequently, upon activation, BKCa channels should carry 
outward IBKCa and therefore hyperpolarise the Vm.  
Firstly, membrane current was recorded from MDA-MB-231 cells using the 
whole-cell patch clamp technique by depolarising the Vm from -120 mV to +80 mV 
using Cs+-free intracellular solution where the free [Ca2+] was buffered at 5.7 nM 
(Section 2.4.2). However, the outward IBKCa was not observed (Figure 4.5a). Since the 
activation of BKCa channels requires both Ca2+ and Vm depolarisation (Barrett et al., 
1982), the free [Ca2+] in the intracellular solution was increased to 100 nM, which is 
close to the concentration measured in MDA-MB-231 cells previously (Sareen et al., 
2007; Winnicka et al., 2008). At this concentration, persistent outward current was seen 
in one out of five MDA-MB-231 cells (Figure 4.5b).  
Next, the free [Ca2+] in the intracellular solution was increased further to 7.8 μM. 
Interestingly, in whole-cell patch clamp mode, in addition to the transient INa and the 
persistent outward current observed in Figure 4.5b, non-inactivating inward current was 
also recorded when depolarising the Vm to ≥ +30 mV (Figure 4.6a). The mean current 






Figure 4.5. Recording the current of large-conductance Ca2+ activated K+ (BKCa) 
channels in MDA-MB-231 cells using whole-cell patch clamp technique. 
Representative current traces from MDA-MB-231 cells with free [Ca2+] buffered at (a) 
5.7 nM and (b) 100 nM in the intracellular (pipette) solution. At free [Ca2+] = 100 nM, 
one out of five cells showed persistent outward current. Cells were held at -120 mV 
for 250 ms before depolarising to voltages ranging from -60 mV to +80 mV for 100 






Figure 4.6. A persistent inward current recorded in MDA-MB-231 cells. 
(a) The representative current trace and (b) the current-voltage relationship recorded 
from MDA-MB-231 cells in whole-cell patch clamp mode where the free [Ca2+] in the 
intracellular (pipette) solution was buffered at 7.8 μM. Cells were depolarised to 
voltages from -60 mV to +90 mV for 300 ms in 10 mV increments following a 250 ms 
pre-pulse at -120 mV. Every other current trace is shown for clarity. Panel (b) shows 
the mean current over 50 ms, 100 ms after the depolarisation takes place (n = 3). Data 




because (1) the transient INa was inactivated within 10 ms after depolarisation, and (2) 
50 ms after depolarisation, the size of the persistent INa is small (Section 3.2.3), and 
therefore INa at 100 ms after depolarisation would not contaminate measurement of 
other currents. As shown in the current-voltage relationship (Figure 4.6b; n = 3), the 
outward current density gradually increases from -60 mV. The membrane current 
peaks at +30 mV with the value of 4.0 ± 1.0 pA/pF (n = 3), and the inward current 
becomes the dominant type of current after this voltage, indicated by the decrease of 
membrane current density. The size of the slow inward current increases linearly as the  
depolarisation becomes more positive. At +90 mV, where the recording protocol 
terminates, the mean current density is -4.7 ± 1.0 pA/pF (n = 3). 
This persistent inward current has not been previously reported in MDA-MB-231 
cells. The characteristic slow inactivation and voltage-dependent activation are similar 
to those of L-type VGCCs (Hille, 2001). In order to investigate whether or not the 
current is Ca2+ carried by VGCCs, extracellular Ca2+ was replaced with Ba2+. Ba2+ 
blocks BKCa channels but can be a charge carrier through VGCCs (Armstrong & 
Matteson, 1985; Neyton & Miller, 1988; Hainsworth et al., 2006). None of the three 
tested cells treated with Ba2+-containing PSS showed persistent inward current at 
depolarised voltages (Figure 4.7a; n = 3). The current density at +90 mV was 1.5 ± 0.9 
pA/pF (n = 3), significantly different to that recorded using Ba2+-free extracellular saline 
solution, which was -4.7 ± 0.9 pA/pF (Figure 4.6; P < 0.01; t-test; n = 3). There was 
also a reduction, although not statistically significant, of the peak outward current 
density compared with the cells in the standard extracellular PSS [1.8 ± 1.0 pA/pF at 
+80 mV in the Ba2+-containing extracellular saline solution (Figure 4.7b) vs. 4.0 ± 1.0 
pA/pF at +30 mV in the standard PSS (Figure 4.6b). P = 0.17; t-test; n = 3 in both 
conditions]. In addition, extracellular co-application of 20 μM nifedipine and 200 μM 









Figure 4.7. The effects of Ba2+, and co-application of nifedipine and Cd2+ on the 
membrane current. 
(a) The representative current trace, and (b) the current-voltage relationship of the 
membrane current recorded from MDA-MB-231 cells treated with extracellular Ba2+ in 
whole-cell patch clamp mode where the free [Ca2+] in the intracellular (pipette) solution 
was buffered at 12.2 μM (n = 3). (c, d) Without Ba2+, 200 μM Cd2+ was added to the 
PSS. Nifedipine (20 μM) was also applied extracellularly. The recorded membrane 
current from a single cell is shown in (c) and the current-voltage-relationship in (d) (n = 
1). Cells were depolarised to voltages from -60 mV to +90 mV for 300 ms in 10 mV 
increments following a 250 ms pre-pulse at -120 mV. Every other current trace is 
shown for clarity. Panel (b) and (d) show the mean current over 50 ms, starting from 




did not inhibit the persistent inward current (Figure 4.7c and d; n = 1). Taken together, 
these data suggest that VGCCs do not carry the persistent inward current.  
Because [Ca2+]i at micromolar range is much higher than in physiological 
conditions and the principle goal of the current experiment was to record IBKCa , the 
nature of this persistent inward current was not investigated further. 
 
4.2.4.2 Perforated patch clamp recording 
As an ionophore, nystatin selectively induces a conductance for monovalent ions 
but no permeability for divalent ions such as Ca2+ (Cass & Dalmark, 1973). Therefore, 
in order to leave the [Ca2+]i of MDA-MB-231 cells at its physiological level, perforated 
patch clamp using nystatin (120 μM) was adopted to isolate the outward IBKCa in MDA-
MB-231 cells. Both INa and persistent outward current were observed in all three cells 
tested (Figure 4.8).  
In order to further characterise the persistent outward current, in the next 
experiment, NS-1619, a BKCa channel activator (Macmillan et al., 1995), and IbTx, a 
BKCa channel blocker (Calderone, 2002), were applied to MDA-MB-231 cells and 
membrane current was recorded in perforated patch clamp mode. Compared to control 
(Figure 4.9a), application of 1 μM NS-1619 increased the amplitude of the persistent 
outward current (Figure 4.9b). Co-application of 1 μM NS-1619 and 100 nM IbTx 
inhibited the outward current (Figure 4.9c). The current-voltage relationships of the 
membrane current under three conditions are fitted into exponential equations (Section 
2.12), as shown in Figure 4.9d. In summary, the outward persistent current recorded in 







   
 
Figure 4.8. Recording the current of large-conductance Ca2+ activated K+ (BKCa) 
channels in MDA-MB-231 cells using perforated patch clamp technique. 
Nystatin (120 μM) was used in perforated patch clamp recordings. Three out of three 
cells tested showed both inward Na+ current and persistent outward current. Cells were 
held at -120 mV for 250 ms before depolarising to voltages ranging from -60 mV to +80 











Figure 4.9. The NS-1619- and iberiotoxin (IbTx)-sensitive large-conductance Ca2+-
activated K+ (BKCa) current in MDA-MB-231 cells. 
Perforated patch clamp recordings showing membrane current, elicited by +80 mV 
depolarisation following a 250 ms pre-pulse at -120 mV, in (a) control, (b) following 1 
μM NS-1619 treatment, and (c) after further co-application of 1 μM NS-1619 and 100 
nM IbTx. (d) Current-voltage relationship of the BKCa current. Data are fitted to single 
exponential equations. BKCa current was activated from a -120 mV (250 ms) pre-pulse 
to voltages between -60 mV and +90 mV for 300 ms in 10 mV increments (n = 5). 
Panel (d) analysed the mean current over 50 ms, starting from 100 ms after the 




4.2.5 Hyperpolarising the Vm of MDA-MB-231 cells using NS-1619 
When the resting Vm is more positive than the Vrev for K+, NS-1619 increases K+ 
efflux through BKCa channels, thus hyperpolarising the Vm (Prior et al., 1998). Next, 
using whole-cell patch clamp, the effect of NS-1619 on Vm of MDA-MB-231 cells was 
investigated. Using intracellular solution containing 100 nM [Ca2+] (Table 2.3), cells 
were incubated with NS-1619 for 6 min before the recording. NS-1619 at 1 μM, 5 μM, 
10 μM and 40 μM hyperpolarised the steady-state Vm of MDA-MB-231 cells to -15.0 ±  
0.6 mV (n = 12), -25.2 ± 1.13 mV (n = 6), -31.7 ± 3.2 mV (n = 10) and -51.8 ± 3.3 mV (n 
= 9), respectively, in a dose-dependent manner (Figure 4.10a). Compared with the Vm 
in the standard PSS, which is -10.6 ± 1.3 mV (n = 12), 1 μM NS-1619 significantly 
hyperpolarised the Vm by 4.4 mV to -15.0 ± 0.6 mV (Figure 4.10b; P < 0.01; t-test; n = 
12), similar to the hyperpolarisation caused by 30 μM TTX (Section 3.2.3). 
Finally, the Vm recorded using the standard intracellular solution (free [Ca2+] = 5.7 
nM, Table 2.3) is -10.3 ± 1.0 mV (n = 10), which does not significantly differ from that 
recorded using the intracellular solution with 100 nM free [Ca2+], which is -10.6 ± 1.2 
mV (Figure 4.11; P = 0.82; t-test; n = 12), suggesting that at the physiological [Ca2+]i of 
100 nM (Sareen et al., 2007; Winnicka et al., 2008), BKCa channels have negligible 
contribution to regulating the Vm in MDA-MB-231 cells in the absence of NS-1619. 
 
4.2.6 NS-1619 does not affect MDA-MB-231 cell proliferation 
The dynamic change of Vm has instructive roles in promoting cell cycle 
progression: Vm undergoes hyperpolarisation at G1/S border and depolarisation at G2/M 
(Blackiston et al., 2009; Yang & Brackenbury, 2013). Blocking VGSCs using TTX or 
phenytoin hyperpolarises the Vm in MDA-MB-231 cells (Section 3.2.3 and Section 








Figure 4.10. NS-1619 hyperpolarises the membrane potential (Vm) of MDA-MB-231 
cells. 
(a) The dose-response curve of 1, 5, 10 and 40 μM NS-1619 on the steady-state Vm of 
MDA-MB-231 cells (n ≥ 6). The data are fitted to a sigmoidal logistic equation. (b) 
Effect of 1 μM NS-1619 on the steady-state Vm of MDA-MB-231 cells. Cells were 
incubated with the drug for 2 min before their Vm was recorded using whole-cell patch 
clamp. (**) P < 0.01; t-test (n = 12 in each condition). Data are mean ± SEM. Liquid 







Figure 4.11. Membrane potential (Vm) recorded in whole-cell patch mode with different 
free [Ca2+] in the recording pipette.  
The Vm recorded using intracellular (pipette) solution with free [Ca2+] buffered at 5.7 nM 
and 100 nM using EGTA in whole-cell patch clamp mode. Liquid junction potential is 
compensated. n.s. not significant; t-test (n = 10 and 12 in 5.7 nM and 100 nM [Ca2+], 




the proliferation of MDA-MB-231 cells in vitro (Roger et al., 2003; Fraser et al., 2005; 
Yang et al., 2012). Here, NS-1619 was applied at two concentrations and its 
hyperpolarising effects on MDA-MB-231 cell proliferation was measured using the MTT 
assay (Section 2.5.1). Figure 4.12a shows a typical linear standard curve generated for 
one of the three technical repeats, relating the absorbance of MTT at 570 nm to cell 
number, with R2 = 0.98. The cell numbers after 24 h incubation with 1 μM or 40 μM NS-
1619 were (7.2 ± 0.6) × 104 and (7.1 ± 0.6) × 104, respectively, which is not significantly 
different from that of control at (7.2 ± 0.6) × 104 (Figure 4.12b; P = 1.00 and 0.94 
comparing control with 1 μM and 40 μM NS-1619, respectively; ANOVA with Tukey 
post hoc test; n = 9). In summary, these data suggest that hyperpolarising the Vm using 
NS-1619 does not affect MDA-MB-231 cell proliferation. 
 
4.2.7 NS-1619 reduces MDA-MB-231 cell migration 
Since blockade of VGSCs reduces MDA-MB-231 cell motility (Fraser et al., 2003; 
Yang et al., 2012), the effect of hyperpolarising the Vm with NS-1619 or TTX on 
migration was examined using ptychrography technique. MDA-MB-231 cells were 
grown into confluent monolayers before a wound was made. Cells were then washed 
once with 37 °C DMEM with 0 % FBS to remove cell debris before TTX (30 μM) or NS-
1619 (1 μM) was applied. The cells were then allowed to migrate into wounds for 16 h, 
at 37 °C, 5 % CO2 under a Phasefocus VL-21 microscope. Figure 4.13a shows 
representative wounds under all conditions at the beginning and end of the experiment. 
Because cells undergo volume increase during mitosis, the cell volume measured 
using ptychography is a direct indicator of cell proliferation (Marrison et al., 2013). 
Neither 30 μM TTX nor 1 μM NS-1619 significantly altered the rate of cell volume 
increase (Figure 4.13b; n = 3). The cell volume gradient was (2.8 ± 0.1) × 104 μm3/h in 






Figure 4.12. NS-1619 does not affect MDA-MB-231 cell proliferation. 
MDA-MB-231 cell proliferation was determined by using 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay. (a) Representative linear standard curve 
relating the absorbance of MTT at 570 nm (A570) with cell number. (b) The number of 
cells after 24 h treatment with 1 μM or 40 μM NS-1619. ANOVA with Tukey post hoc 





Figure 4.13. NS-1619 and tetrodotoxin reduce MDA-MB-231 cell lateral migration. 
(a) Representative wounds at the beginning (0 h) and the end (16 h) of wound healing 
assay with TTX (30 μM) or NS-1619 (1 μM) treatment. (b) Cell proliferation, indicated 
by the normalised cell volume during wound healing assays. Dashed lines show mean 
± SEM. (c) Cell volume gradient, an index of cell growth rate, during the wound healing 
assays. (d) Normalised wound area (“gap”) in the wound healing assays. Dashed lines 
show mean ± SEM. (e) t1/2 of wound closure in (d). Scale bar = 100 μm. (*) P < 0.05; 





NS-1619 treatment, respectively (Figure 4.13b; P = 0.10 and 0.16 comparing TTX and 
NS-1619 with control, respectively; P = 0.54 comparing with TTX and NS-1619; 
ANOVA with Tukey post hoc test; n = 3).  
While the cells migrated into the wound, the remaining wound area (gap 
remaining) was measured over 16 h (Figure 4.13d). The t1/2 of wound closure 
increased from 5.7 ± 1.1 h in control to 9.8 ± 0.7 h in 30 μM TTX and 9.9 ± 0.1 h in 1 
μM NS-1619 (Figure 4.13e; P < 0.05 comparing TTX or NS-1619 with control; P = 1.00 
comparing 30 μM TTX with 1 μM NS-1619; ANOVA with Tukey post hoc test; n = 3). 
Thus, by hyperpolarising the Vm to a comparable voltage, TTX and NS-1619 increased 
the t1/2 of wound closure to a similar extent, suggesting that VGSCs may increase 
MDA-MB-231 cell motility by depolarising the Vm. 
 
4.2.8 NS-1619 does not affect MDA-MB-231 cell invasion 
Blocking VGSCs with TTX reduces MDA-MB-231 cell Matrigel invasion (Fraser et 
al., 2005; Brackenbury et al., 2007). Next, the functional role of Vm in mediating 
invasion was investigated. MDA-MB-231 cells were grown on Matrigel-coated invasion 
chambers with TTX or NS-1619 for 24 h before the invaded cells were fixed using 
paraformaldehyde and stained with DAPI. The number of DAPI-positive cells was 
counted under an epi-fluorescence microscope. TTX at 30 μM significantly reduced the 
number of invaded cells to 58.3 ± 6.5 % of control (Figure 4.14a; P < 0.01 compared 
with control, ANOVA with Tukey post hoc test; n = 7), whereas NS-1619 at 1 μM did 
not significantly alter the number of invaded cells (Figure 4.14a; P = 0.98 compared 
with control and P < 0.05 compared with TTX; ANOVA with Tukey post hoc test; n = 7). 
Moreover, using 40 μM NS-1619 to hyperpolarise the Vm of MDA-MB-231 cells further 
to -51.8 ± 3.3 mV (Figure 4.10a) did not significantly change the number of invaded 






Figure 4.14. NS-1619 does not alter MDA-MB-231 invasion in vitro. 
(a) Invaded cells (normalised to control) after 24 h treatment with 30 μM TTX or 1 μM 
NS-1619 were measured using the Matrigel invasion assay. (*) P < 0.05; (**) P < 0.01, 
respectively; ANOVA with Tukey post hoc test (n = 7). (b) Invaded cells after 40 μM 




with Tukey post hoc test; n = 6), suggesting that Vm may not be a factor regulating 
MDA-MB-231 cell invasion in vitro. 
 
4.2.9 TTX and NS-1619 alter MDA-MB-231 cell morphology 
In MDA-MB-231 cells, Nav1.5 modulates cytoskeletal components and promotes 
an elongated cell morphology (Brisson et al., 2013; Nelson et al., 2015b). Additionally, 
blocking VGSCs with ranolazine increases the circularity of MDA-MB-231 cells (Driffort 
et al., 2014), whereas TTX application reduces process length on Mat-LyLu cells 
(Fraser et al., 1999). To test whether Nav1.5-mediated morphology regulation is 
dependent on Vm, a wound was made on confluent MDA-MB-231 cell monolayer 
followed by a wash with 37 °C DMEM with 0 % FBS to remove cell debris before TTX 
(30 μM) or NS-1619 (1 μM) was applied. Cells were then allowed to migrate into the 
wound for 3 h before being fixed with paraformaldehyde. F-actin and nucleus were 
labelled with Alexa 633-conjugated phalloidin and DAPI, respectively. Cells were then 
examined using a Zeiss LSM 880 laser scanning confocal microscope. The boundaries 
of single cells (20–25 cells per condition in each of three technical repeats) at both 
ends of the wound were determined using the free-hand line tool in ImageJ software 
(Figure 4.15a), and circularity was calculated using the same software according to 
Equation 2.4. TTX (30 μM) significantly increased the circularity from 0.54 ± 0.17 in 
control to 0.64 ± 0.15 (Figure 4.15a and b; P < 0.001; ANOVA with Tukey post hoc test; 
n = 61 in control and n = 62 in TTX). Similarly, NS-1619 (1 μM) increased the circularity 
to 0.61 ± 0.15 (P < 0.05 compared with control; ANOVA with Tukey post hoc test; n = 
61 in control and n = 67 in NS-1619). Interestingly, there was no statistically significant 
difference in circularity between TTX and NS-1619 treatment (P = 0.56; ANOVA with 
Tukey post hoc test; n = 62 in TTX and n = 67 in NS-1619), suggesting both the drugs 






Figure 4.15. Tetrodotoxin (TTX) and NS-1619 increase MDA-MB-231 cell circularity.  
(a) Representative cell morphology after TTX (30 μM) and NS-1619 (1 μM) treatment 
for 3 h. Cells were stained with Alexa 633-conjugated phalloidin (red) and DAPI (blue). 
Lower row shows the boundaries of cells of interest in the upper row, by which the 
circularity of cells was calculated. (b) Circularity of MDA-MB-231 cells after TTX and 
NS-1619 treatment. (*)P < 0.05; (***) P < 0.001; n.s. not significant; ANOVA with Tukey 
post hoc test (n = 61, 62 and 67 in control, TTX and NS-1619, respectively). Data are 




4.2.10 TTX and NS-1619 reduce the proportion of MDA-MB-231 cells 
bearing lamellipodia 
The protrusion of lamellipodia initiates cell migration (Small et al., 2002). Given 
that both TTX and NS-1619 reduce MDA-MB-231 cell migration and induce a round 
morphology, these compounds may reduce the formation of lamellipodia in MDA-MB-
231 cells. The proportion of cells with a lamellipodium after TTX (30 μM) and NS-1619 
(1 μM) treatment was analysed using the images acquired in Section 4.2.9. The 
proportion of cells with lamellipodium was compared pairwise using Fisher’s exact tests 
among control, TTX and NS-1619 treatments, resulting in three comparisons. 
Bonferroni correction was applied for multiple comparisons: with three pairwise 
comparisons, the P value must be less than 0.05 ÷ 3 = 0.016 to be significant at the P 
< 0.05 level (MacDonald & Gardner, 2000). The pairwise P value between control and 
TTX was 0.0002, suggesting the distribution of samples was significantly different 
between the two conditions, i.e. TTX reduced the proportion of MDA-MB-231 cells 
bearing a lamellipodium (Table 4.1). The P value comparing NS-1619 and control was 
< 0.0001, suggesting that NS-1619 also reduced the proportion of cells with 
lamellipodium (Table 4.1). However, the proportion of cells bearing a lamellipodium did 
not differ between TTX and NS-1619 (P = 0.84). In summary, both TTX (30 μM) and 
NS-1619 (1 μM) significantly reduced the proportion of cells bearing a lamellipodium to 
a similar degree, consistent with these compounds inhibiting migration. 
 
4.2.11 TTX and NS-1619 reduce the active Rac1 level at the leading edge of 
MDA-MB-231 cells 
The small GTPase Rac1 is one of the key molecules required for the formation of 
lamellipodia, by promoting the assembly of actin filaments (Ridley, 2015). Activating 





Table 4.1. The proportion of MDA-MB-231 cells bearing a lamellipodium after 
tetrodotoxin (TTX) and NS-1619 treatment. 
 Control 30 μM TTX 1 μM NS-1619 
Representative 
cells 
   
Cells with 
lamellipodium 109 72 * 66 * 
Cells without 
lamellipodium 41 69 * 73 * 
Total # of cells 150 141 139 
(*) adjusted P < 0.05 compared with control. Fisher’s exact test with Bonferroni 
corrections for multiple comparisons. Three technical repeats were preformed. Red: F-




hyperpolarising Vm using TTX (30 μM) and NS-1619 (1 μM) retarded MDA-MB-231 cell 
migration (Section 4.2.7) and reduced the proportion of cells with a lamellipodium 
(Section 4.2.10), it is possible that Vm may regulate Rac1 activity, actin filament 
assembly and thus cell migration. To test this, MDA-MB-231 cells were fixed during a 
wound healing assay using paraformaldehyde as described in Section 4.2.9, and were 
labelled with an anti-active Rac1 antibody. Cells were then labelled with Alexa 488-
conjugated secondary antibody and Alexa 633-conjugated phalloidin, and nuclei were 
labelled with DAPI. Samples were examined using a Zeiss LSM 880 confocal 
microscope. The active Rac1 fluorescence intensity was strong at the leading edge of 
cells in control, but was weaker in TTX (30 μM)- or NS-1619 (1 μM)-treated MDA-MB-
231 cells (Figure 4.16, arrows).   
In order to quantify the data, a 90 ° quadrant mask with a radius of 5.6 μm 
encompassing the lamellipodium/cell leading edge was applied to cells that were 
migrating into the wound (Figure 4.17a). Inside the mask, the signal density of F-actin 
and active Rac1 across a series of arcs with various radii was gathered and normalised 
to that of the innermost arc (Figure 4.17b). Treatment with TTX (30 μM) or NS-1619 (1 
μM) reduced the F-actin signal density in outer arcs within the lamellipodia (Figure 
4.15a, Figure 4.17c, Table 4.1). The active Rac1 signal density at the leading edge of 
lamellipodia was also significantly reduced (Figure 4.15a, Figure 4.17d, Table 4.1). For 
example, the active Rac1 signal in the arc with radius of 4.76 μm was 129.4 ± 4.6 % in 
control, 113.9 ± 4.2 % in TTX (P < 0.05 compared with control; ANOVA with Tukey post 
hoc test; n = 67 in control and n = 66 in TTX) and 107.9 ± 3.5 % in NS-1619 (P < 0.001 
compared with control; P = 0.56 compared with 30 μM TTX; ANOVA with Tukey post 
hoc test; n = 71). Therefore, in MDA-MB-231 cells, decreased active Rac1 levels at the 
leading edge caused by Vm hyperpolarisation may reduce lamellipodia formation, 







Figure 4.16. The expression of F-actin and active Rac1 in MDA-MB-231 cells after 
tetrodotoxin (TTX) and NS-1619 treatment. 
In a wound healing assay, MDA-MB-231 cells were allowed to migrate into the wound 
for 3 h in the presence/absence of TTX (30 μM) or NS-1619 (1 μM). Cells were then 
fixed with paraformaldehyde and labelled with mouse anti-active Rac1 antibody, 
followed by Alexa 488 conjugated goat anti mouse IgG secondary antibody. F-actin 
was labelled with Alexa 633-conjugated phalloidin. Cells were then mounted on 
microscope slides with DAPI and were examined using a Zeiss LSM 880 laser 
scanning confocal microscope. White arrows highlight active Rac1 staining at cell 







Figure 4.17. F-actin and active Rac1 signal intensity in the lamellipodium of MDA-MB-
231 cells. 
(a) Representative cell (in control condition) showing the quadrant mask as the region 
of interest for analysing F-actin and active Rac1 signal intensity at lamellipodia. (b) The 
signal density was measured across 20 arcs with various radii, in 0.28 μm increments, 
within the quadrant. (c) Normalised F-actin and (d) active Rac1 signal density across 
the arcs indicated in (b). (*) P < 0.05 comparing control and TTX (30 μM), and 
comparing control and NS-1619 (1 μM); ANOVA with Tukey post hoc test (n = 61, 62 





Taken together, data in this Chapter suggest that Vm hyperpolarisation does not 
significantly alter the [Ca2+]i in MDA-MB-231 cells. Activating BKCa channels with NS-
1619 mimicked TTX-induced Vm hyperpolarisation. Comparisons between cells treated 
with TTX and NS-1619 demonstrated that VGSC-induced Vm hyperpolarisation inhibits 
MDA-MB-231 cell motility, causes round cell morphology; reduces the proportion of 
cells with a lamellipodium, and decreases the level of active Rac1 at cell leading edge. 
In contrast, VGSCs appear to promote invasion independent of the Vm. 
 
4.3 Discussion 
4.3.1 Vm hyperpolarisation does not change [Ca2+]i in MDA-MB-231 cells 
Since Vm changes have been shown to regulate [Ca2+]i via Ca2+-permeable 
channels (Schwab et al., 2012), in the present study, it was hypothesised that Vm 
hyperpolarisation might change [Ca2+]i in MDA-MB-231 cells. However, replacing 
extracellular NaCl with ChoCl to hyperpolarise the Vm, or blocking VGSCs using TTX 
did not cause significant changes to the [Ca2+]i, nor the number of cells that exhibit Ca2+ 
spikes. Interestingly, unpublished data from Dr Scott Fraser (Imperial College London) 
presented at the 2015 Ion Channels, Transporters and Cancer meeting reported that at 
room temperature, MDA-MB-231 cells in ATP- and serum-free saline solution show 
spontaneous Ca2+ spikes, measured using Fluo-4 as the Ca2+ fluorescence indicator, 
and TTX reduced the occurrence and the magnitude of these Ca2+ spikes (Fraser et al., 
2015). Furthermore, high KCl application at the end of the experiment caused a large 
increase in [Ca2+]i. Several factors may contribute to the disagreement with the data in 
this Chapter. Firstly, in contrast to Fura-2, Fluo-4 is a non-ratiometric Ca2+ fluorescence 
indicator with a lower affinity (Kd = 300 nM) (Gee et al., 2000). Fluo-4 may be less 
sensitive than Fura-2 but does not chelate [Ca2+]i as strongly as Fura-2 (Takahashi et 




Ca2+ activities that depend on free cytosolic Ca2+, such as store-operated Ca2+ entry 
(SOCE) through Ca2+-release activated Ca2+ (CRAC) channels (Takahashi et al., 
1999). Future experiments should directly compare these Ca2+ fluorescence indicators. 
Secondly, the high KCl-induced Ca2+ increase reported by Dr Fraser suggests the 
presence of depolarisation-induced Ca2+ entry or release from stores. The machinery 
that carries the Ca2+ influx in MDA-MB-231 cells needs to be further investigated. In the 
present study, VGCCs were not detected in MDA-MB-231 cells. The scenario that the 
Ca2+ was released from the store is also unlikely, because as a low affinity Ca2+ 
indicator, Fluo-4 can bind to Ca2+ in organelles in the first place (Takahashi et al., 1999; 
Lambert, 2006), therefore, any Ca2+ release from the store/organelle should be 
reflected as redistribution rather than an increase of Fluo-4 signal intensity. Clearly, the 
link between VGSC/Vm and [Ca2+]i in MDA-MB-231 cells needs further investigation, 
using multiple Ca2+ indicators. 
 
4.3.2 BKCa channels hyperpolarise the Vm of MDA-MB-231 cells 
Experiments in this Chapter investigated whether the depolarised Vm per se is a 
functional factor in promoting cancer cell metastatic behaviours by modulating 
endogenous BKCa channels. Unexpectedly, while searching for a suitable protocol to 
record the BKCa current, a voltage-dependent persistent inward current was discovered 
in MDA-MB-231 cells when the [Ca2+]i was buffered at 7.8 μM. The current is not 
sensitive to VGCC blockers nifedipine and Cd2+, but is abolished by Ba2+, which inhibits 
BKCa channels. Other groups have also recorded similar inward current while studying 
BKCa channels by applying [Ca2+]i in the micromolar range (Cui et al., 1997; Xia et al., 
2002), and mutations in the BKCa intracellular regulator of the conductance of K+ (RCK) 
domain abolish this inward current (Xia et al., 2002). The persistent inward current may 




current and CRAC (Hartzell et al., 2005; Motiani et al., 2010). Future work is required to 
establish whether this inward current is a feature of endogenous BKCa channels, or is 
due to indirect activation of another type of channel, e.g. ClC3 (Habela et al., 2008). 
In whole-cell patch clamp mode, by buffering the [Ca2+] in the intracellular solution 
to 100 nM, which is close to the physiological [Ca2+]i reported in MDA-MB-231 cells 
(Sareen et al., 2007; Winnicka et al., 2008), BKCa current can be recorded from MDA-
MB-231 cells, in agreement with a previous study (Roger et al., 2004). However, the 
perforated patch clamp technique leaves the [Ca2+]i uncontaminated by components in 
the recording pipette, and this technique delivered better success rate in recording 
BKCa currents from MDA-MB-231 cells. The current-voltage relationship obtained is 
similar to that reported previously (Roger et al., 2004). Activating BKCa channels using 
NS-1619 at various concentrations hyperpolarised the Vm. Interestingly, activating BKCa 
channels in MDA-MB-231 cells using 40 μM NS-1619 yielded a Vm at ~-52 mV, similar 
to that in non-tumourigenic mammary epithelial MCF-10A cells where various types of 
K+ channels are present (Fraser et al., 2005). This suggests that the depolarised Vm (~-
10 mV) recorded from MDA-MB-231 cells should be attributed to the Na+ influx carried 
by VGSCs as well as the low activity of Vm-hyperpolarising K+ channels. 
 
4.3.3 Vm hyperpolarisation does not inhibit MDA-MB-231 cell proliferation 
Although Vm can function as an instructive signal in promoting cell cycle 
progression, previous reports have shown that blocking VGSCs with TTX or phenytoin 
does not affect cancer cell proliferation in vitro (Roger et al., 2003; Fraser et al., 2005; 
Yang et al., 2012; Aktas et al., 2015). In the present study, hyperpolarising the Vm 
using NS-1619 did not affect MDA-MB-231 cell proliferation. However, another study 
reported that NS-1619 at 50 μM reduced MDA-MB-231 cell growth by 40 % (Roger et 




different incubation period adopted [5 days in (Roger et al., 2004) vs. 1 day in the 
present study]. Since Vm hyperpolarisation inhibits MDA-MB-231 cell migration (Section 
4.2.7), the cell colonies may expand more slowly and therefore longer incubation leads 
to higher cell population density, which may induce contact inhibition of proliferation 
and locomotion, as well as apoptosis (Bates et al., 1994). Future work needs to 
determine whether in MDA-MB-231 cells, Vm regulates cell proliferation in a cell-density 
dependent manner.  
In rat cerebellar neurones, Vm-dependent cell cycle progression is partly 
dependent on promoting the activity of VGCCs that trigger downstream Ca2+ signalling 
by carrying Ca2+ influx upon Vm depolarisation (Borodinsky & Fiszman, 1998). 
However, in MDA-MB-231 cells, there is no evidence showing the presence of VGCCs. 
In addition, Ca2+ imaging data show that Vm hyperpolarisation, which is thought to be 
able to increase the driving force of Ca2+ entry, does not significantly alter the [Ca2+]i of 
MDA-MB-231 cells (Section 4.2.2), suggesting Vm may not play an important role in 
Ca2+-dependent proliferation of MDA-MB-231 cells. 
 
4.3.4 Vm hyperpolarisation reduces migration but not invasion 
In MDA-MB-231 cells, Vm depolarisation caused by VGSCs promotes cell motility, 
because TTX (30 μM) or NS-1619 (1 μM) hyperpolarised the Vm to a similar degree 
and decreased migration to comparable levels. Activating BKCa channels has been 
previously reported to reduce migration of glioma cells, although the molecular 
mechanism was unclear (Bordey et al., 2000; Kraft et al., 2003). However, another 
study using the same 1321N glioma cells as in Kraft et al., 2003 demonstrated that 
inhibiting BKCa channels reduced cell transwell migration (Weaver et al., 2004). The 
authors proposed that this is because BKCa channel activity is necessary for regulating 




important while the cells are migrating through the 8 μm-sized pores on the 
polyethylene terephthalate membrane. In this Chapter, ptychography was used to 
measure the change in MDA-MB-231 cell volume in wound healing assays, and 1 μM 
NS-1619 did not significantly alter the cell volume compared to control. Therefore, it is 
possible that the role of BKCa channels in controlling cell volume is more significant in 
transwell migration than in lateral migration. 
Interestingly, the inactivation of BKCa channels in MDA-MB-231 cells grown on 
monolayers of human brain microvasculature endothelial HCMEC/D3 cells reduced 
transendothelial migration (Khaitan et al., 2009). This suggests that the functionality of 
BKCa channels during MDA-MB-231 cell migration is dependent on the culture 
conditions and the extracellular environment. MDA-MB-231 cell invasion was not 
affected by hyperpolarising the Vm using NS-1619, however, TTX reduced invasion by 
~42 % (Section 4.2.8), consistent with previous reports (Fraser et al., 2005; 
Brackenbury et al., 2007). Thus, the data in this Chapter suggest that VGSCs control 
MDA-MB-231 cell migration and invasion via different pathways: VGSC-mediated Vm 
depolarisation promotes cell migration, whereas Na+ itself may lead to a more invasive 
phenotype in MDA-MB-231 cells, independent of regulating the Vm. Indeed, a model 
previously proposed by Dr Sebastien Roger’s group argues that Na+ allosterically 
regulates NHE1 at the MDA-MB-231 cell plasma membrane, which acidifies 
extracellular pH and therefore promotes cysteine cathepsin B and S proteolytic activity, 
leading to a more invasive phenotype (Gillet et al., 2009; Brisson et al., 2011).  
 
4.3.5 Vm hyperpolarisation reduces the active Rac1 level at the leading 
edge 
The relationship between VGSCs and small GTPase Rac1 was recently reported, 




[Ca2+]i via NCX and subsequently activated ERK and Rac1, which led to migration 
(Persson et al., 2014). However, data here show that in MDA-MB-231 cells, 
hyperpolarising the Vm using TTX and NS-1619 both reduced the active Rac1 level at 
the cell leading edge, but the [Ca2+]i did not significantly change after ChoCl or TTX 
treatment. This suggests that NCX activity may not be involved in the Vm-dependent 
[Ca2+]i regulation in the context of MDA-MB-231 cells, and Rac1 may be regulated by 
Vm/VGSCs but not Ca2+. 
The VGSC-Vm-Rac1 signalling axis fits well in a previously proposed model in 
MDA-MB-231 cells in which VGSCs potentiate the phosphorylation of src kinase and 
cortactin (Brisson et al., 2013). Src kinase can promote cortactin phosphorylation via 
Rac1 activation (Head et al., 2003; Servitja et al., 2003), which ultimately facilitates 
lamellipodia formation by activating the Arp2/3 complex (Miki et al., 1998; Krueger et 
al., 2003). Interestingly, it has been reported that VGSC activity caused the activation 
of the small GTPase Rap1B in SW620 cells (House et al., 2015). Further experiments 
should explore whether the activation of Rap1B is due to the Vm-depolarising role of 
VGSCs in these cells. 
The detailed mechanism by which Vm regulates Rac1 activation and/or 
distribution is not yet clear. Vm may regulate Rac1 activity via controlling GEFs, For 
example, GEF-H1 (a Rho GEF) is activated upon Vm depolarisation (Waheed et al., 
2010). In addition, the Vm depolarisation-induced activation of Ras and Rap1 has been 
reported in mouse cortical neurones (Baldassa et al., 2003). In PC12 cells, Vm 
depolarisation activates Ras in a PKA-dependent manner (Obara et al., 2007). Given 
that VGSCs activate PKA in MDA-MB-231 and Mat-LyLu cells (Brackenbury & 
Djamgoz, 2006; Chioni et al., 2010), activation of Rac1 may be through this pathway. 
More recently, a study has demonstrated that Vm depolarisation enhances 
phosphatidylserine and K-Ras nanoclustering in baby hamster kidney cells, and K-Ras 




al., 2015). Taken together, emerging data suggest that a depolarised Vm is a functional 
signal in activating small GTPases. It may consequently and/or concurrently promote 
the MAPK signalling pathway, which in turn controls key cellular behaviours including 
proliferation, differentiation and development (Shaul & Seger, 2007).  
 
4.4 Conclusion 
The data in this Chapter show that Vm hyperpolarisation and blockade of VGSC 
have no impact on [Ca2+]i of MDA-MB-231 cells. Modulating the Vm using TTX and NS-
1619 has revealed a role for Vm depolarisation in promoting migration but not invasion 
of MDA-MB-231 cells. TTX and NS-1619 both reduce lamellipodium formation and 
cause a round morphology in these cells, likely through reducing the active Rac1 level 
at the leading edge of lamellipodia (Figure 4.18). Further studies should elucidate the 












Figure 4.18. Depolarised membrane potential (Vm) increases MDA-MB-231 cell 
migration.  
This Chapter demonstrated that blocking voltage-gated Na+ channels (VGSCs) or 
hyperpolarising the Vm does not change intracellular Ca2+ concentration ([Ca2+]i, red 
cross). However, VGSC activity and depolarised Vm promotes lamellipodium formation 
and cell migration by increasing active Rac1 level at MDA-MB-231 cell leading edge (red 
arrow). Whether Na+/VGSC regulates Rac1 activity independent of Vm is not clear 




5 Chapter 5: Investigating the INa and Vm in tumour tissue slices 
5.1 Introduction 
Na+ accumulation in tumour cells was reported in the 1980s: X-ray microanalyses 
of freeze-dried tissue sections revealed that cancer cells have a higher [Na+]i: the mean 
[Na+]i of H6 mouse hepatoma, 7777 rat hepatoma, C3H mouse adenocarcinoma and 
13762 HF rat adenocarcinoma is 451 mmol/kg in freeze-dried tissue sections, which is 
significantly higher than that in their non-cancerous counterparts (138 mmol/kg) 
(Cameron et al., 1980). In addition, rapidly proliferating cells, including neonatal mouse 
cardiomyocytes and rat thymus cortex cells, have significantly higher [Na+]i (196 
mmol/kg) than slowly proliferating cells, such as rat thymus medulla and mouse/rat 
mammary epithelial cells (140 mmol/kg), but have significantly lower [Na+]i than cancer 
cells (Cameron et al., 1980). Electron probe X-ray analysis revealed that daily injection 
of amiloride to H6 hepatoma-bearing mice reduces intranuclear [Na+]i from 499 mmol/kg 
to 275 mmol/kg and significantly decreases tumour growth (Sparks et al., 1983). In 
Xenopus laevis, Na+ accumulation appears in regions where cells over-proliferate 
(Lobikin et al., 2012). Moreover, quantitative magnetic resonance imaging (MRI) has 
shown that the total tissue Na+ concentration in patients’ BCa lesions is 53 mmol/l, which 
is significantly elevated compared to benign lesions (26 mmol/l) (Ouwerkerk et al., 
2007). 
How Na+ accumulates in cancer cells is not clear. Recently, it is reported that 
VGSCs increase the [Na+]i in lung cancer cells: compared to VGSC-expressing H460 
NSCLC cells, the [Na+]i of VGSC-lacking normal NL-20 cells or non-invasive A549 cells 
is significantly lower (Roger et al., 2007; Campbell et al., 2013). Blocking VGSCs in 
H460 cells with TTX reduces the [Na+]i from 22.3 mM to 10.8 mM (Campbell et al., 




tumourigenesis (Pool et al., 1981; Sparks et al., 1983), it is possible that the high 
malignancy of MDA-MB-231 cells may be partly due to a high [Na+]i caused by VGSCs. 
Indeed, VGSCs increase MDA-MB-231 cell migration by depolarising the Vm, but Na+ per 
se may be important in potentiating cell invasion. Thus, it is likely that VGSCs may also 
regulate [Na+]i in MDA-MB-231 cells. 
In mouse BCa models, inhibiting Nav1.5 with phenytoin or ranolazine reduces 
tumour growth (Nelson et al., 2015a) and metastasis (Yildirim et al., 2012; Driffort et al., 
2014; Nelson et al., 2015a; Nelson et al., 2015b). Together with the in vitro data (Fraser 
et al., 2005; Brackenbury et al., 2007; Yang et al., 2012), these studies suggest that 
VGSCs may be potential therapeutic targets in cancer treatment. However, the 
functional activity of VGSCs in tumours in vivo has not been explored. In this Chapter, 
whole-cell slice recording, which has been frequently used to study neuronal activities in 
the brain (Blanton et al., 1989), was performed on BCa tissue slices to study the INa and 
Vm in cancer cells ex vivo. The whole-cell recording technique has been previously used 
in slices to investigate the electrophysiological properties of single cancer cells. For 
example, Cl- currents were recorded in human glioma cells in patient tissue slices 
(Ullrich et al., 1998), and action potentials were recorded from human oligodendroglioma 
and oligoastrocytoma cells in brain slices (Patt et al., 1996). However, VGSC activity in 
BCa cells in tissue slices has not been studied. 
A previous study used sharp electrode to measure the Vm of human breast cells in 
slices from biopsies and reported that the Vm is significantly more depolarised in biopsies 
from patients who are diagnosed with infiltrating ductal carcinoma compared to patients 
with benign breast disease (Marino et al., 1994). The same study also showed that in 
comparison to normal fibroblasts, chemically transformed fibroblasts have more 
depolarised Vm (Marino et al., 1994). In Xenopus laevis, Vm depolarisation can induce 
tumourigenesis in vivo (Lobikin et al., 2012). During development, melanocytes with 




including over-proliferation, arborized cell morphology and increased local invasion 
(Blackiston et al., 2011). It is proposed that depolarised Vm increases serotonin export at 
the melanocyte plasma membrane, resulting in an increase in serotonin concentration in 
the extracellular microenvironment. Serotonin receptors on nearby melanocytes and on 
pituitary melanotrope cells are then activated, increasing the expression of TFs, 
including Sox10 and Slug, ultimately resulting in cellular over-proliferation (Lobikin et al., 
2015).  
Given the functional expression of VGSCs in MDA-MB-231 cells in vitro, INa carried 
by VGSCs should also be present in MDA-MB-231 tumour xenografts in vivo. 
Additionally, since the depolarised Vm and Na+ influx have pro-migratory and pro-
invasive roles in vitro, cancer cells at the periphery of tumour tissue may have larger INa 
and/or more depolarised Vm during their invasion into surrounding non-tumour tissue. 
 
5.1.1 Hypotheses and aims 
The hypotheses in this Chapter were (1) VGSCs regulate [Na+]i in MDA-MB-231 
cells in vitro, and (2) VGSCs are functionally active in vivo. The aims in this Chapter 
were: 
(1) To use the Na+ reporting fluorescent probe SBFI to measure the steady-state 
[Na+]i of MDA-MB-231 cells. 
(2) To measure the [Na+]i after extracellular Na+ depletion, TTX or NS-1619 
treatment. 
(3) To record the INa and Vm across various regions of mouse MDA-MB-231 
primary tumour tissue. 







5.2.1 Measurement of [Na+]i in MDA-MB-231 cells in vitro 
Tumour cells have higher [Na+]i compared with normal cell types (Cameron et al., 
1980). VGSCs in MDA-MB-231 cells carry INa, but whether VGSCs regulate the [Na+]i of 
MDA-MB-231 cells has not been investigated. Here, SBFI was used as the intracellular 
Na+ fluorescent indicator to measure the [Na+]i. SBFI is a ratiometric Na+-selective dye 
with Kd for Na+ of 7.4 mM in the presence of K+ (Minta & Tsien, 1989). Upon Na+ binding, 
SBFI shows an increase in the ratio of energy absorbed at 340 nm and 380 nm (Minta & 
Tsien, 1989). MDA-MB-231 cells were labelled with 5 μM SBFI in DMEM supplemented 
with 5 % FBS at 37 °C in the dark before being transferred to standard PSS for 2 min 
(Figure 5.1a). SBFI was alternately excited at 340 and 380 nm and the fluorescence 
emission at 512 nm was monitored using a Nikon Eclipse TE200 epi-fluorescence 
microscope as described in Section 2.9 (Figure 5.1b, top panel). After the incubation 
with the standard extracellular PSS, cells were treated with extracellular solution 
containing 10 mM Na+ for 2 min in order to let the cells settle in a low [Na+]o environment, 
before being consecutively perfused with 10 mM Na+ extracellular solution plus 20 μM 
Na+ ionophore gramicidin for 12 min, and then extracellular solution containing 20 mM 
Na+ plus 20 μM gramicidin for a further 12 min (Figure 5.1a).  
As shown in Figure 5.1b, cells in the 20 mM Na+ PSS showed increased 340/380 
ratio compared to 10 mM Na+ PSS, indicating an increase of [Na+]i . Cells had higher 
340/380 ratio in standard PSS than in 10 mM Na+ PSS, but lower than in 20 mM Na+ 
PSS, suggesting that the [Na+]i in standard PSS is between 10 mM and 20 mM.  
The [Na+]i was determined for individual cells. Figure 5.1c shows the calculation of [Na+]i 
in a representative cell. The mean 340/380 ratios over the last 60 s of PSS, 10 mM and 
20 mM Na+ extracellular solution treatment were 1.31, 1.23 and 1.34, respectively. A 
linear relationship between 340/380 ratio and [Na+]i was derived by plotting [Na+]i at 10 








Figure 5.1. Measurement of intracellular Na+ concentration ([Na+]i) of MDA-MB-231 cells. 
(a) Na+ imaging experimental outline. (b) Representative SBFI fluorescence intensity at 
excitation = 340 nm and 380 nm when cells were perfused with standard PSS (top 
panel), extracellular solution containing 10 mM Na+ plus 20 μM gramicidin (middle panel) 
and extracellular solution containing 20 mM Na+ plus 20 μM gramicidin (bottom panel). 
(c) Relationship between SBFI fluorescence intensity (340/380 ratio) and [Na+]i in a 




340/380	𝑟𝑎𝑡𝑖𝑜 = 	0.01171	×	[𝑁𝑎4]t + 1.111	   (Equation 5.1) 
 
Hence, the [Na+]i of the cell in standard PSS was calculated as (1.31 – 1.111) ÷ 0.01171 
= 17.0 mM for this cell. Six technical repeats were performed. In each repeat, [Na+]i of 8 - 
20 cells was calculated individually and averaged in each of the experiment, giving a 
steady-state [Na+]i of MDA-MB-231 cells of 15.6 ± 0.7 mM (Figure 5.2b; n = 6). 
Next, the effect of replacing extracellular NaCl with NMDG on the [Na+]i of MDA-
MB-231 cells was investigated. After labelling the cells with SBFI (5 μM), cells were 
immediately transferred to NMDG saline solution where NaCl was replaced with 
equimolar NMDG. After 2 min, cells were consecutively perfused with 10 mM Na+ 
extracellular solution for 2 min, 10 mM Na+ extracellular solution plus 20 μM gramicidin 
for 12 min, and 20 mM Na+ extracellular solution plus 20 μM gramicidin for 12 min 
(Figure 5.2a). The 340/380 ratios were obtained, and the [Na+]i was calculated as 
described above. The steady-state [Na+]i of MDA-MB-231 cells after extracellular Na+ 
depletion was 7.6 ± 1.7 mM, which was significantly lower than in control (Figure 5.2; P < 
0.05; ANOVA with Tukey post hoc test; n = 6 in standard PSS and n = 3 in NMDG). 
The effect of VGSC activity on [Na+]i in MDA-MB-231 cells was also examined. 
Cells were pre-incubated with 30 μM TTX for 48 h before imaging. TTX was also present 
during the labelling the cells with SBFI and in the first 2 min after the cells were perfused 
with standard PSS. TTX was then washed out with 10 mM Na+ extracellular solution 
before 10 mM and 20 mM Na+ PSS plus gramicidin were consecutively applied. 
Compared with standard PSS, TTX significantly reduced the steady-state [Na+]i of MDA-
MB-231 cells from 15.6 ± 0.7 mM to 11.3 ± 0.5 mM (Figure 5.2b; P < 0.05; ANOVA with 
Tukey post hoc test; n = 6 in standard PSS and n = 3 in TTX). However, the [Na+]i of 
MDA-MB-231 cells was not significantly different comparing TTX and NMDG treatment 






   
 
Figure 5.2. Depletion of extracellular Na+ and tetrodotoxin (TTX) pre-treatment reduced 
the Na+ concentration ([Na+]i) of MDA-MB-231 cells. 
(a) Na+ imaging experimental outline. Cells were perfused with N-methyl-D-glucamine 
(NMDG)-containing extracellular solution or TTX (30 μM) for 2 min, before perfusion in 
10 mM Na+ extracellular solution and then gramicidin-containing extracellular solutions. 
For TTX, cells were pre-incubated with 30 μM TTX for 48 h. (b) The comparison of the 
steady-state [Na+]i in standard extracellular physiological saline solution (PSS), in NMDG 
extracellular solution, and after TTX (30 μM) treatment. (*) P < 0.05; (**) P < 0.01; 
ANOVA with Tukey post hoc test (n = 6 in standard PSS and n = 3 in NMDG and TTX). 




summary, extracellular Na+ depletion and incubation with TTX (30 μM) both reduced the 
[Na+]i. 
 
5.2.2 Suppressing Nav1.5 expression using shRNA reduces [Na+]i in MDA-
MB-231 cells 
The steady-state [Na+]i of Nav1.5-shRNA and shRNA control cells was measured 
as described in Section 5.2.1. The [Na+]i of shRNA control and Nav1.5-shRNA cells was 
13.5 ± 0.4 mM and 9.4 ± 0.7 mV (n = 3 in both conditions), respectively, showing a 
significant difference (Figure 5.3; P < 0.01; t-test; n = 3 in both conditions). Therefore, 
these data suggest that Nav1.5, by carrying a sustained Na+ influx, causes an increase in 
the steady-state [Na+]i in MDA-MB-231 cells. 
 
5.2.3 NS1619 (1 μM) does not significantly alter the [Na+]i in MDA-MB-231 
cells 
Both 30 μM TTX and 1 μM NS-1619 hyperpolarised the Vm of MDA-MB-231 cells 
to a similar degree, and Vm hyperpolarisation inhibited cell migration and reduced active 
Rac1 levels at cell leading edge (Section 4.3.5), suggesting that VGSCs potentiate 
MDA-MB-231 cell migration by depolarising the Vm. In order to investigate whether 1 μM 
NS-1619 hyperpolarises the Vm without altering [Na+]i, SBFI-labelled MDA-MB-231 cells 
were perfused with 1 μM NS-1619 for 5 min (Figure 5.4a). The mean [Na+]i both before 
and after NS-1619 treatment was 14.3 ± 1.0 mM (Figure 5.4b; P = 0.93; t-test; n = 22 
from three technical repeats). In summary, in MDA-MB-231 cells, depleting extracellular 
Na+ or blocking VGSCs reduced [Na+]i. Importantly, NS-1619 (1 μM) did not significantly 
change [Na+]i. Thus, the inhibitory role of NS-1619 (1 μM) on MDA-MB-231 cell 







Figure 5.3. The intracellular Na+ concentration ([Na+]i) of MDA-MB-231 cells is reduced 
when Nav1.5 expression is suppressed by shRNA. 
(a) Na+ imaging experimental outline. Cells were perfused with standard saline solution 
(PSS) for 2 min before settled in 10 mM Na+ extracellular solution and being perfused 
with gramicidin-containing extracellular solutions (b) The steady-state [Na+]i of MDA-MB-
231 cells where Nav1.5 expression was suppressed by shRNA (Nav1.5-shRNA), and the 
scrambled RNA control (shRNA control). (**) P < 0.01; t-test (n = 3 in both conditions). 







Figure 5.4. NS-1619 (1 μM) application does not change the intracellular Na+  
concentration ([Na+]i) in MDA-MB-231 cells. 
(a) Na+ imaging experimental outline. Cells were treated with standard PSS (2 min) 
followed by 1 μM NS-1619 (5 min), before perfusion with 10 mM Na+ extracellular 
solution and then gramicidin-containing extracellular solutions. (b) [Na+]i of individual 
MDA-MB-231 cells after NS-1619 (1 μM) treatment. n.s. not significant; t-test (n = 22 




5.2.4 Recording the INa and Vm from cells in tumour tissue slices 
Although many in vitro studies have recorded the INa carried by VGSCs from 
cancer cells with different tissue origins, functional VGSC activity has not been studied in 
intact tumour tissue before. Here, the whole-cell patch clamp technique was used to 
study the INa and Vm of shRNA control cells xenografted in mice. GFP-expressing shRNA 
control cells were mixed with Matrigel/PBS and were orthotopically injected in the fourth 
left inguinal fat pad (Section 2.3.3). Tumours were allowed to grow for 20–37 days 
before being removed following euthanisation (Figure 5.5a). The fur and surrounding 
muscle tissue were gently removed from the tumour using a blade (Figure 5.5b), and the 
processed tumour was fixed onto the pedestal of a vibratome using cyanoacrylate glue 
and was immersed in ice-cold standard extracellular PSS (Figure 5.5c). A 5 % agar 
block was fixed onto the pedestal to support the tumour (Figure 5.5c), and the tumour 
was sliced at 250 μm. Tumour slices were incubated in the standard extracellular PSS at 
room temperature for at least 20 min before being transferred into the electrophysiology 
recording chamber and tightly held using a slice anchor (Figure 5.5d). The slice was 
continuously perfused with standard PSS. The tumour slice was firstly examined at 10X 
(Figure 5.5e). Next, healthy, GFP-positive cells were located at 40X before they were 
sealed with recording pipette containing Cs+-free standard intracellular solution (Figure 
5.5f).  
Similar to shRNA control cells recorded in vitro, tumour cells showed fast inward 
INa ex vivo. The current-voltage relationship from a representative cell is shown in  
(Figure 5.6a and b). Among all the 60 cells recorded from 18 mice across six cages, 39 
cells (65 %) showed detectable INa. The current was inhibited by applying 30 μM TTX  
(Figure 5.6c; n = 3), and was recovered after subsequent washout using the standard 
extracellular PSS (Figure 5.6d; n = 3), suggesting that the fast inward current is carried 
by VGSCs. The current-voltage relationship of all the cells with INa is shown in Figure 






Figure 5.5. Performing electrophysiological study on mouse tumour tissue slices. 
Tumour tissue was processed, sliced and mounted on an electrophysiology recording 
chamber. (a) The primary tumour was dissected from a euthanised mouse. (b) The fur 
and surrounding muscle tissue were removed from the tumour using a blade. (c) The 
tumour was fixed onto the pedestal of vibratome and was immersed in ice-cold 
physiological saline solution (PSS). (d) Tumour was sliced and incubated with PSS in a 
holding chamber at room temperature at least 20 min before being transferred to the 
electrophysiology recording chamber, and held with a slice anchor. (e and f) Bright field 





fitted with Boltzmann functions (Figure 5.6f): the V1/2 and the k for the conductance curve 
were -27.2 ± 1.4 mV and 3.9 ± 0.5 mV (n = 39), respectively. For the availability curve, 
V1/2 was -87.4 ± 2.4 mV and the k was -0.7 ± 2.2 mV (n = 12).  
The relationship between peak INa density and the number of days following 
tumour implantation was also investigated (Figure 5.7a). The linear regression shows 
that the number of days after surgery did not correlate with size of the peak INa density 
(Figure 5.7a; Pearson r = 0.27; P = 0.09; n = 39). Moreover, the size of tumours did not 
correlate with peak INa density (Figure 5.7b; Pearson r = 0.11; P = 0.49; n = 39).  
Compared with recording shRNA control cells cultured in vitro, tumour cells in vivo 
had subtly different electrophysiological properties. To begin with, the whole-cell 
capacitance recorded from cells on tissue slices was 11.7 ± 0.5 pF, which is significantly 
less than that recorded in vitro (23.1 ± 2.0 pF; Figure 5.8a; P < 0.001; t-test; n = 8 in in 
vitro and n = 60 in ex vivo). Since whole-cell capacitance is determined by cell surface 
area (Hille, 2001), the data suggest that compared with in vitro 2D culture, the average 
size of cells was significantly smaller when growing in vivo. However, the peak INa 
density was not significantly different comparing in vitro and ex vivo (-14.9 ± 2.1 pA/pF 
vs. -11.8 ± 1.6 pA/pF; Figure 5.8b; P = 0.39; n = 8 in in vitro and 39 in ex vivo). 
Interestingly, the Vm of cells on tissue slices was more depolarised than for in vitro 
recordings (-7.8 ± 0.5 mV vs. -12.6 ± 0.9 mV; Figure 5.8c; P < 0.001; n = 16 in in vitro 
and 60 in ex vivo). 
 








Figure 5.6. Na+ current (INa) recorded from tumour tissue slices. 
(a) INa recorded from a representative cell from a tumour tissue slice. (b) The fast inward 
current was abolished by (c) TTX (30 μM) application, and (d) the current was recovered 
after subsequent washout. (e) The current-voltage relationship of INa recorded (n = 39; 
18 mice from six independent cages). (f) Normalised INa availability and conductance 
plotted against voltage. Data are fitted with Boltzmann functions (n = 39 in conductance 
and 14 in availability). For (a), (e) and activation in (f), cells were depolarised from a -120 
mV pre-pulse (250 ms) to voltages between -80 and 0 mV for 50 ms in 5 mV increments. 
For inactivation in (f), cells were held at various pre-pulses ranging from -120 mV to -10 






Figure 5.7. The relationship between tumour volume/stage and peak Na+ current (INa) 
density. 
(a) The relationship between peak INa density and the number of days after tumour 
implantation (n = 39). (b) The relationship between peak INa density and tumour volume 
(n = 39). Solid line shows linear regression and broken lines 95 % confidence intervals. 







Figure 5.8. Cell capacitance, Na+ current (INa) density and membrane potential (Vm) in 
vitro and ex vivo. 
The comparison of (a) cell capacitance, (b) peak INa density and (c) Vm recorded using 
whole cell patch clamp in vitro and ex vivo. (***) P < 0.001. n.s. not significant; t-test. (a) 
n = 8 in in vitro and n = 60 in ex vivo. (b) n = 8 in in vitro and n = 39 in ex vivo. (c) n = 16 
in in vitro and n = 60 in ex vivo. Liquid junction potential is compensated in (c). Data are 




5.2.5 Investigating the INa from cells across various regions of the tumour 
Previously published in vitro evidence shows that VGSCs potentiate local invasion 
of MDA-MB-231 cells by enhancing the activity of cysteine cathepsins B and S (Gillet et 
al., 2009; Brisson et al., 2013). Additionally, VGSCs increase MDA-MB-231 cell motility 
by depolarising the cell Vm (Section 4.2.7). Therefore, since INa/Vm lead to cancer cell 
migration and invasion, next, the INa and Vm were compared across central and 
peripheral regions of orthotopic primary tumours of shRNA control cells. 
Slices from primary tumours were categorised into three regions, namely 
periphery, intermediate region and centre, according to distance from the edge of the 
tumour. The distance between recorded cells and the tumour edge was determined 
using an eyepiece reticule. Cells that were ≤ 1 mm from the edge were categorised as in 
the periphery; those > 1mm and ≤ 1.5 mm as in the intermediate region; and those ≥ 1.5 
mm as in the centre (Figure 5.9a). The whole-cell capacitance was 11.8 ± 0.6 pF, 11.4 ± 
0.9 pF and 12.1 ± 1.1 pF in periphery, intermediate region and centre, respectively, 
showing no statistically significant difference across regions (Figure 5.9b; P = 0.87; 
ANOVA with Tukey post hoc test; n = 25, 20 and 15, respectively). Moreover, the peak 
INa density in the periphery was -11.44 ± 1.3 pA/pF, which was not different from that in 
the intermediate region (-12.44 ± 4.3 pA/pF) or in the centre (-10.9 ± 1.8 pA/pF; P = 
0.93; ANOVA with Tukey post hoc test; n = 20, 12 and 7, respectively).  
The INa conductance and availability in the periphery (Figure 5.10a; n = 20 in 
activation and n = 3 in inactivation), the intermediate region (Figure 5.10b; n = 12 in 
activation and n = 3 in inactivation) and centre (Figure 5.10c; n = 7 in activation and n = 
3 in inactivation) were analysed by plotting the normalised INa or conductance against 
voltage. The activation/inactivation V1/2 and slope factor k did not differ across tumour 
regions (Table 5.1; ANOVA with Tukey post hoc test; conductance: n = 20, 12 and 7 in 








Figure 5.9. Na+ current (INa) density across various regions of tumour tissue slices. 
(a) Diagram showing the definition of the periphery (≤ 1 mm from the edge of tumour 
tissue slice), intermediate region (> 1 and ≤ 1.5 mm from the edge of tissue slice) and 
centre (> 1.5 mm from the edge) regions of the tumour. (b) Comparison of whole-cell 
capacitance and (c) peak INa density across the periphery, intermediate region and 
centre of tumour. ANOVA with Tukey post hoc test. n = 25, 20 and 15 in periphery, 







Figure 5.10. Na+ current (INa) availability and conductance across various regions of 
tumour tissue slices. 
The normalised INa availability and conductance in the (a) periphery, (b) intermediate 
region and the (c) centre plotted against voltage. Data are fitted with Boltzmann 
functions. (a) n = 20 in conductance and 3 in availability. (b) n = 12 in conductance and 3 
in availability. (c) n = 7 in conductance and n = 3 in availability. For activation, cells were 
depolarised from a -120 mV pre-pulse (250 ms) to voltages between -80 mV and +30 
mV for 50 ms in 5 mV increments. For inactivation, cells were held at various voltages 
ranging from -120 mV to -10 mV for 250 ms before depolarisation to -10 mV for 50 ms. 







Table 5.1 Characteristics of Na+ current recorded in various tumour regions. 
 Periphery Intermediate region Centre P 
Va (mV) -31.0 ± 1.8 -27.9 ± 3.1 -27.9 ± 0.4 0.55 
Vp (mV) 9.8 ± 1.9 10.0 ± 3.4 9.3 ± 3.2 0.99 
Tp at 0 mV (ms) 1.41 ± 0.11 1.51 ± 0.41 1.01 ± 0.11 0.56 
Activation V1/2 
(mV) -27.3 ± 0.9 -26.9 ± 1.8 -26.2 ± 1.8 0.88 
Activation k 
(mV) 7.1 ± 0.8 7.0 ± 1.5 5.7 ± 1.5 0.74 
Inactivation V1/2 
(mV) -85.6 ± 6.1 -90.0 ± 1.0 -89.1 ± 1.5 0.69 
Inactivation k 
(mV) -13.0 ± 5.1 -4.5 ± 1.0 -5.9 ± 1.3 0.20 
Va, activation voltage; Vp voltage at current peak; Tp time to peak; V1/2, half activation 
or inactivation voltage; k: slope factor. Periphery: ≤ 1 mm from tumour edge; 
intermediate region: > 1 mm and ≤ 1.5 mm from the edge; centre: > 1.5 mm from the 




Other INa characteristics including the activation voltage Va, voltage at peak current Vp 
and time to peak Tp at 0 mV were not significantly different across the three tumour 
regions (Table 5.1; ANOVA with Tukey post hoc test; n = 20, 12 and 7 in periphery, 
intermediate and centre). Finally, the proportion of cells that had INa was not significantly 
different across the three regions (Table 5.2; Fisher’s exact tests with Bonferroni 
corrections). In summary, the data suggest that the whole-cell capacitance, peak INa 
density, as well as the INa characteristics, were not significantly different across various 
tumour regions. 
 
5.2.6 Investigating the Vm from cells across various regions of mouse 
primary tumour 
The Vm recorded from cells in orthotopic tumours is significantly more depolarised 
than cells cultured in vitro (Section 5.2.4). Next, the Vm across the tumour periphery, 
intermediate region and centre was analysed. The Vm was highly consistent across the 
three regions: cells in the periphery had a Vm of -7.6 ± 0.6 mV (n = 26), and the Vm of 
cells in the intermediate region and centre was -8.8 ± 1.3 mV (n = 18) and -7.2 ± 0.3 mV 
(n = 10), respectively (Figure 5.11; P = 0.53; ANOVA with Tukey post hoc test). The data 
suggest that in tumour tissues, the level of cell Vm does not correlate with the position of 













Table 5.2. The proportion of cells with Na+ current (INa) across tumour regions. 
 Periphery Intermediate region Centre 
Number of cells 
with INa 
20 12 7 
Number of cells 
without INa 
6 6 9 
Total 26 18 16 
Periphery: ≤ 1 mm from tumour edge; intermediate region: > 1 mm and ≤ 1.5 mm from 
the edge; centre: > 1.5 mm from the edge. No statistical difference in the proportions 






Figure 5.11. The tumour cell membrane potential (Vm) at various regions across 
orthotopic tumours. 
The Vm was measured using whole-cell patch clamp. Periphery: ≤ 1 mm from tumour 
edge; intermediate region: > 1 mm and ≤ 1.5 mm from the edge; centre: > 1.5 mm from 
the edge. ANOVA with Tukey post hoc test. n = 26, 18 and 10 in periphery, intermediate 




5.2.7 Nav1.5-shRNA cells showed reduced tumour growth in mice 
Blocking VGSCs decreases cancer cell migration and invasion in vitro 
(Brackenbury, 2012; Roger et al., 2015). Recently, an increasing number of in vivo 
studies has demonstrated the potential therapeutic value of VGSCs in cancer treatment. 
For example, we have previously reported that using an orthotopic BCa model where 
MDA-MB-231 cells were implanted into mouse mammary fat pads, daily intraperitoneal 
injection of phenytoin reduced primary tumour growth and invasion and inhibited 
metastasis to lungs, liver and spleen (Nelson et al., 2015a). Here, the effect of Nav1.5 on 
tumour growth was investigated. The dimensions of the tumour (length and width) were 
determined using calliper measurement, and the volume of the tumour was calculated 
using Equation 2.2. 
Mice developed palpable tumours typically 8–9 days after the surgery. As shown in 
Figure 5.12, two weeks following tumour cell implantation, the primary tumour 
development in Nav1.5-shRNA cell-bearing mice was significantly less than in mice 
implanted with shRNA control cells. At the end of the experiment (typically 28 days after 
surgery), the tumour volume was 327.0 ± 21.2 mm3 in mice with shRNA control cells and 
155.3 ± 18.4 mm3 in mice bearing Nav1.5-shRNA cells (Figure 5.12; P < 0.001; t-test; n = 
13 for shRNA control and n = 16 for Nav1.5-shRNA cells). Therefore, Nav1.5 promotes 












Figure 5.12. Suppressing Nav1.5 expression using shRNA reduces primary tumour 
growth in vivo. 
Nav1.5-shRNA or shRNA control MDA-MB-231 cells (5 × 105) were orthotopically 
implanted under the fourth left inguinal fat pad in immunodeficient mice. The dimensions 
of the tumour were measured using callipers, and the tumour volume was calculated as 
volume = 0.5 × (length × width2). (*) P < 0.05; (**) P < 0.01; (***) P < 0.001; t-test (n = 13 





5.3.1 VGSCs increase [Na+]i in MDA-MB-231 cells 
Cancer cells are reported to have higher [Na+]i compared to normal cells (Cone & 
Tongier, 1973; Smith et al., 1978; Cameron et al., 1980), and the implication of high 
[Na+]i in tumourigenesis and/or mitogenesis has been reported since the late 1970’s 
(Smith et al., 1978; Pool et al., 1981; Sparks et al., 1983). Recently, quantitative Na+ MRI 
has shown that the total tissue Na+ concentration is higher in malignant BCa tissues than 
in benign lesions (Ouwerkerk et al., 2007). In this Chapter, pre-incubation with 30 μM 
TTX for 48 h, or Nav1.5 knockdown with shRNA both showed a similar reduction in [Na+]i 
compared to controls, suggesting that VGSCs result in Na+ accumulation in MDA-MB-
231 cells. The result agrees with other studies on H460 NSCLC cells where VGSCs are 
expressed (Roger et al., 2007; Campbell et al., 2013). MDA-MB-231 cells treated with 
NMDG showed further but not statistically significant [Na+]i reduction than reported in the 
TTX and Nav1.5-shRNA experiment, suggesting that VGSCs are the predominant 
pathway that causes Na+ accumulation in MDA-MB-231 cells. Future experiments should 
investigate how other Na+ transporters, such as NHE1 (Brisson et al., 2011), regulate 
[Na+]i, and whether or not leak INa or ENaC are present in MDA-MB-231 cells and 
increase [Na+]i (Kellenberger & Schild, 2002). 
According to the Goldman-Hodgkin-Katz equation (Equation 1.1), increased [Na+]i 
is an important factor that contributes to the depolarised Vm in MDA-MB-231 cells. A 
calculation using the Nernst equation predicts that the reduced [Na+]i (from 15.6 mM to 
7.6 mM) after NMDG treatment would lead to a hyperpolarising shift in the Na+ 
equilibrium potential of -18.3 mV, which is close to the Vm hyperpolarisation (~-15 mV) 
recorded using whole-cell patch clamp technique (Section 3.2.1). However, the 
calculated Vm hyperpolarisation based on the decreased [Na+]i in TTX-treated cells and 
shRNA control cells is -8.2 mV and -12.8 mV, respectively, which is more than 2-fold 




due to the limited resolution of SBFI and/or epi-fluorescence microscopy when 
determining changes in [Na+]i at a few mV. Future experiments should address this 
discrepancy by using alternative Na+-sensitive fluorescent indicator, using a confocal 
microscope, or using methods that are more sensitive to small changes in the [Na+]i, 
such as the intracellular ion-selective microelectrode (ISME) technique (Shattock & Bers, 
1989). 
A recent study showed that Na+ accumulated at the “regeneration bud” during tail 
regeneration in Xenopus laevis (Tseng et al., 2010). In the tadpole tail amputation 
model, application of the Na+ ionophore monensin with Na+ gluconate increased the level 
of MSX-1, a regenerative marker, at the wound, and eventually facilitated the regrowth of 
limbs at the amputation site (Tseng & Levin, 2013). Using the same animal model, high 
local [Na+] can be indicative of tumourigenesis in vivo (Lobikin et al., 2012). Together, 
the evidence suggests a role for [Na+]i in intracellular signalling. Indeed, data in Section 
4.2.7 suggest that it was the Na+ ions, rather than Vm, that increased the invasiveness of 
MDA-MB-231 cells in vitro. This agrees with the previously proposed Nav1.5-Na+-NHE1-
cathepsin pathway in MDA-MB-231 cell invasion (Gillet et al., 2009; Brisson et al., 2011). 
Furthermore, Na+ carried by VGSCs can also enhance the activity of NCX in microglia, 
which ultimately leads to [Ca2+]i increase and ERK activation (Pappalardo et al., 2014b; 
Persson et al., 2014). In THP-1 macrophages, activating Nav1.6 with veratridine 
increases Na+ release from cationic vesicular compartments, which then increases 
mitochondrial Ca2+ release via NCX (Carrithers et al., 2009). Finally, how the increased 
[Na+]i regulates the activity of other Na+-related ion transporters and exchangers remains 
unclear in cancer cells. For example, in rat kidney tubules, [Na+]i increases Na+-K+ 
ATPase activity and cell surface expression in a PKA-dependent manner (Vinciguerra et 
al., 2003). Future experiments should address the potential Na+-dependent regulation of 
transmembrane transportation of various types of ions and their role in downstream 




Considering the role of the depolarised Vm in promoting cancer cell migration 
(Section 4.2.7) and the role of Na+ in inducing tumourigenesis and cancer cell invasion, 
further experiments should explore whether combining Vm hyperpolarisation with [Na+]i 
reduction can reduce the malignancy of cancer cells both in vitro and in vivo. Data in 
Section 3.2.1 and Section 5.2.1 demonstrated the impact of the extracellular 
environment on [Na+]i and Vm: MDA-MB-231 cells in a Na+-free environment displayed 
significant [Na+]i reduction as well as hyperpolarised Vm. The clinical value of reducing 
[Na+]o in patient tumour tissue during cancer treatment should be investigated in the 
future.  
 
5.3.2 Recording the INa in tumour tissue 
An increasing number of reports demonstrate the presence of VGSCs in various 
types of cancer cell lines and biopsies. Since 2012, the therapeutic potential of VGSCs 
in cancer treatment has been investigated in vivo. Application of VGSC blockers such as 
TTX (Yildirim et al., 2012), ranolazine (Driffort et al., 2014) and phenytoin (Nelson et al., 
2015a) reduced tumour progression in vivo. Agreeing with these previous reports, 
Section 5.2.7 showed that Nav1.5-shRNA significantly decreased primary tumour growth 
compared to shRNA control cells. Nav1.5/INa increased the tumour growth probably by 
reducing cell apoptosis, since the density of activated caspase 3+ apoptotic cells was 
significantly lower in shRNA control tumours (Nelson et al., 2015b). Additionally, Nav1.5-
shRNA cell-bearing mice showed reduced metastases to lungs, liver and spleen (Nelson 
et al., 2015b), which is similar to the effects caused by phenytoin (Nelson et al., 2015a). 
In spite of all the data showing the clinical relevance of targeting VGSCs in cancer 
treatment, until now, the INa in cells in tumour tissue had not been studied. In the present 
study, by performing whole-cell patch clamp recording on tumour tissue slices, data in 




tumour tissue. The tumour slice recording technique may have value when applied to 
recording INa on tumour tissues from cancer patients in the future. 
Compared to most mammalian tissues that exist at 2–9 % O2 (Hockel & Vaupel, 
2001; Bertout et al., 2008), cells in solid tumours are thought to experience sustained 
hypoxia (defined as ≤ 2 % O2) due to the restrained O2 delivery (Hockel & Vaupel, 2001), 
which is the result of the structural abnormalities of tumour microvessels and disrupted 
microcirculation (Vaupel et al., 1989). Surgical specimens of cervical tumours showed 
that compared to well-oxygenated tumours, hypoxic tumours exhibit a more invasive 
phenotype and more frequent parametrial spread, resulting in a worse survival rate 
(Hockel et al., 1996). Hypoxia can modulate the function of VGSCs. In rat ventricular 
myocytes, hypoxia augmented the persistent INa (Ju et al., 1996); in rat glomus cells in 
the carotid body, chronic hypoxia for 1–2 weeks increased transient INa; and Nav1.5-
expressing HEK293 cells showed increased persistent INa under acute hypoxia (Fearon 
& Brown, 2004). In MDA-MB-231 cells, acute hypoxia (2 % O2) increases persistent INa, 
and 24 h hypoxic treatment increases Matrigel invasion (Djamgoz & Onkal, 2013). In the 
present study, the tumour tissue was divided into three regions, namely periphery, 
intermediate region and centre, and the characteristics of INa were consistent across 
these regions. However, it was not possible to resolve hypoxia and/or distance from 
vasculature in this model. In a future experiment, transgenic mice with GFP-tagged 
VEGF (Kishimoto et al., 2000), which serves as an angiogenesis marker (Hoeben et al., 
2004), could be used to study the INa from tumour cells from regions with different blood 
vessel densities.  
 
5.3.3 The unvarying Vm across the tumour tissue  
Given the pro-migratory role of the depolarised Vm in MDA-MB-231 cell in vitro, it is 
logical to hypothesise that the Vm of tumour cells at the edge of tumour tissue would be 




Future experiments should perfuse the slices with TTX and test whether or not VGSCs 
regulate the Vm in cells in tumour tissue. On the other hand, gap junctions are able to 
regulate Vm at long-range (Chernet & Levin, 2014), and they may cause a unified Vm 
across the cells in tumour tissue via transporting ions intercellularly. However, a group 
has performed dye injection experiments using Lucifer Yellow on MDA-MB-231 cell 
monolayers cultured in vitro (Qin et al., 2002), where they found that the diffusion of dye 
was inefficient, given that only 6 % of cells exhibited dye transfer (Qin et al., 2002), 
suggesting a limited role for gap junctions in intercellular communication in this cell line. 
Interestingly, although exogenously expressing Cx43 in MDA-MB-231 cells increased 
the proportion of cells with dye transfer to 37 % (Qin et al., 2002), MDA-MB-231 cells 
over-expressing Cx43 did not form gap junctions in vivo (Qin et al., 2002). Future 
experiments should block Cx43 connexon using pharmacological agents such as 
mefloquine (Juszczak & Swiergiel, 2009) or perform juxtapositional recordings on cells in 
tumour tissue to further investigate whether the Vm of a target cell can be affected by 
artificially controlling the Vm in its adjacent cell, and whether the depolarised, unvarying 
Vm across tumour tissue is caused by the in vivo tumour microenvironment. 
 
5.4 Conclusion 
This Chapter has demonstrated that VGSCs not only depolarise the Vm of MDA-
MB-231 cells in vitro, but also cause Na+ accumulation in these cells. Suppressing 
Nav1.5 expression with shRNA significantly reduced tumour growth in vivo, supporting 
the value of targeting VGSCs in cancer treatment. For the first time, INa carried by 
VGSCs has been recorded in tumour tissue slices, indicating the role of VGSCs in 
regulating Na+ influx in vivo and suggesting that Vm of tumour cells in vivo may not be 
intrinsically regulated. Future experiments should record INa from tumour tissue samples 





6 Chapter 6: Discussion 
6.1 The knowledge gap in understanding VGSC-dependent metastasis 
Cancer is a leading cause of death, given that 8.2 million cancer deaths occurred 
globally in 2012 (Torre et al., 2015). Recently, an increasing number of ion channels and 
transporters have been identified in cancer cells and biopsies from patient tumours 
(Prevarskaya et al., 2010; Lastraioli et al., 2015; Stock & Schwab, 2015), where they 
regulate metastasis-related activities such as proliferation, apoptosis, adhesion, 
migration, invasion and gene expression (Brackenbury, 2012; Roger et al., 2015; Stock 
& Schwab, 2015). Excitingly, studies have highlighted the therapeutic potential of ion 
channels as novel targets in cancer treatment (Prevarskaya et al., 2011; Brackenbury, 
2012; Huang & Jan, 2014; Turner & Sontheimer, 2014).  
VGSCs were previously thought to be expressed only in excitable cells, such as 
neurones, skeletal muscle cells and cardiomyocytes, where they initiate the firing of 
action potentials (Catterall, 2000). VGSCs are also expressed predominantly in cancer 
cells with strong migration and/or invasion potential (Brackenbury, 2012; Roger et al., 
2015). Compared to less malignant cancer cells, highly metastatic or multidrug-resistant 
cancer cells exhibit INa together with reduced outward IK (Yamashita et al., 1987; Lee et 
al., 1988; Fraser et al., 2005; Fulgenzi et al., 2006). Moreover, inhibiting VGSCs with 
pharmacological agents or shRNA/siRNA reduces proliferation and metastasis in vivo 
(Yildirim et al., 2012; Driffort et al., 2014; Nelson et al., 2015a; Nelson et al., 2015b), and 
cell metastatic behaviour in vitro (Roger et al., 2003; Fraser et al., 2005; Brackenbury et 
al., 2007; Roger et al., 2007; House et al., 2010; Yang et al., 2012; Campbell et al., 
2013; Xing et al., 2014; House et al., 2015). However, the detailed molecular 





As in excitable cells, Na+ influx carried by VGSCs through the cancer cell plasma 
membrane may cause two main physiological changes to the cell: increased [Na+]i and 
depolarised Vm. It was reported over 30 years ago that cancer cells possess higher [Na+]i 
compared to cells derived from healthy tissue (Smith et al., 1978; Cameron et al., 1980; 
Pool et al., 1981), and reducing [Na+]i in tumour cells slows tumour growth in vivo 
(Sparks et al., 1983), suggesting the role of intracellular Na+ in tumourigenesis. 
However, according to the Nernst equation (Equation 2.6), the increase of the [Na+]i will 
also inevitably depolarise the Vm of cells under physiological conditions.  
Vm is more than an epi-phenomenon that only indicates the difference of ionic 
concentration across cell plasma membrane. An increasing amount of evidence has 
shown that Vm is a functional signal per se (Sundelacruz et al., 2009; Yang & 
Brackenbury, 2013; Lobikin et al., 2015; Zhou et al., 2015). During cell proliferation, a 
depolarised Vm is necessary for G1/S transition in the cell cycle (Cone & Tongier, 1971), 
whereas a hyperpolarised Vm is required at the G2/M border (Habela et al., 2008). Vm 
depolarisation is able to induce mitogenesis/tumourigenesis both in vitro and in vivo. 
Sustained Vm depolarisation (1–3 h) induces mitotic activity in terminally differentiated 
neurones (Stillwell et al., 1973; Cone & Cone, 1976). In Xenopus laevis and Dugesia 
japonica planaria, Vm depolarisation facilitates the regeneration of amputated tissues 
(Beane et al., 2011; Beane et al., 2013; Tseng & Levin, 2013). Artificially depolarising 
the Vm in Xenopus laevis embryos induces tumour formation (Blackiston et al., 2011; 
Lobikin et al., 2012). Taken together, this evidence suggests a powerful role for a 
depolarised Vm in promoting tumourigenesis. Therefore, it is not surprising that cancer 
cells generally display a depolarised Vm, and that the cells from cancer tissue possess a 
more depolarised Vm compared to those from normal tissue of the same origin (Binggeli 
& Weinstein, 1986; Yang & Brackenbury, 2013). 
Given the importance of Vm in regulating cellular behaviours, this PhD Thesis 




MDA-MB-231 cells and investigate whether VGSC-mediated cell migration/invasion is 
also dependent on the Vm in these cells.  
 
6.2 VGSCs depolarise the Vm and therefore increase cell motility in vitro 
Before this study, there was no evidence showing whether VGSCs potentiate 
cancer cell migration and/or invasion due to Na+ per se or via their possible role in 
altering the Vm. The involvement of VGSCs in Vm regulation was examined in MDA-MB-
231 cells. Blocking VGSCs using phenytoin or TTX causes a 3–4 mV Vm 
hyperpolarisation. Nav1.5-shRNA cells are 3.4 mV more hyperpolarised than control 
cells, suggesting that Nav1.5 causes a steady-state Vm depolarisation, and that the 
depolarised Vm caused by Nav1.5 is not compensated by other ion-permeable pathways 
when the Na+ conductance through Nav1.5 is shut down. Since the Vm of MDA-MB-231 
cells is at approximately -10 mV, blocking Nav1.5 leads to a 40 % increase in the 
transmembrane voltage. Extracellular Na+ depletion causes a much larger Vm 
hyperpolarisation of 10–15 mV, which points to other Na+ permeable pathways in MDA-
MB-231 cells that contribute to the depolarised Vm, in addition to VGSCs. Future 
experiments should address the involvement of Na+-K+ ATPase (Winnicka et al., 2008) 
and NHE1 (Brisson et al., 2011) in Na+ -dependent Vm regulation in MDA-MB-231 cells. 
Additionally, the presence of other Na+ -permeable ion channels/ transporters, such as 
ENaC, NCX and Na+-K+-2Cl- co-transporter, has not been reported in MDA-MB-231 
cells, and whether or not they contribute to Na+-dependent Vm regulation should be 
investigated in future studies. Another study showed that blocking Nav1.7 in H460 non-
small cell lung cancer cells hyperpolarises the Vm by 10 mV (Campbell et al., 2013). 
Taken together, VGSCs are now known to cause Vm depolarisation not only in excitable 
cells during action potential firing, but also in non-excitable cancer cells.  
In order to study the role of Vm without interfering with [Na+]i, subsequent 




cells (Section 0). The activity of BKCa channels is weak in MDA-MB-231 cells (Section 0), 
probably because the [Ca2+]i is not sufficiently high to fully activate the channel (Barrett 
et al., 1982). Activating BKCa channels in MDA-MB-231 cells using 40 μM NS-1619 
yielded a Vm of -52 mV, similar to that in MCF-10A cells where various types of K+ 
channels are present (Fraser et al., 2005). A previous report showed that suppressing 
hEAG1 channels in MDA-MB-231 cells depolarises the Vm by 18 mV (Hammadi et al., 
2012). Therefore, the depolarised Vm (~-10 mV) recorded from MDA-MB-231 cells 
should be attributed to the increased permeability to Na+ via VGSCs as well as the weak 
activity of Vm-hyperpolarising K+ channels.  
NS-1619 at 1 μM hyperpolarised the steady-state Vm of MDA-MB-231 cells by 
approximately 4 mV, replicating the effect of 30 μM TTX in these cells. Importantly, 1 μM 
NS-1619 did not significantly alter the [Na+]i (Section 5.2.3). In a wound healing assay, 
NS-1619 (1 μM) and TTX (30 μM) reduced cell migration in vitro to a strikingly similar 
extent (Section 4.2.7). However, while 30 μM TTX showed a strong inhibitory effect on 
invasion through Matrigel, NS-1619, at both 1 μM and 40 μM, did not have any effect 
(Section 4.2.7). These data suggest that VGSC-mediated Vm depolarisation leads to 
increased cell migration, whilst VGSC-dependent cell invasion is Na+- but not Vm-
dependent. Na+ may promote cell invasion via the previously proposed Nav1.5-NHE1-
cathepsins pathway (Gillet et al., 2009; Brisson et al., 2011; Brisson et al., 2013). For the 
first time, data presented in this Thesis show that Nav1.5 potentiates cancer cell 
migration and invasion via different mechanisms. 
 
6.3 Vm and [Ca2+]i regulation 
Vm is a double-edged sword in regulating [Ca2+]i (Schwab et al., 2012; Yang & 
Brackenbury, 2013). On one hand, a depolarised Vm can activate VGCCs, which then 
causes Ca2+ influx (Borodinsky & Fiszman, 1998). On the other hand, a hyperpolarised 




independent channels (Prevarskaya et al., 2011; Schwab et al., 2012). For example, in 
MDA-MB-231 cells, hEAG1 channels cause a hyperpolarised Vm, and blocking these 
channels reduces Ca2+ entry via Orai1 (Hammadi et al., 2012), suggesting that Vm-
hyperpolarisation increases [Ca2+]i in MDA-MB-231 cells. However, in the present study, 
replacing extracellular NaCl with ChoCl or blocking VGSCs with TTX, both 
hyperpolarising the Vm (Section 3.2.1), did not significantly alter the [Ca2+]i in MDA-MB-
231 cells. It is possible that hEAG1-induced Ca2+ entry requires a hEAG1-Orai1 
interaction, whereas the hyperpolarised Vm is not necessary. Indeed, ion channels can 
regulate intracellular signalling without conducting ions. For example, 3T3 fibroblasts 
transfected with Drosophila EAG channels show increased p38 MAPK activity and 
proliferation, which is independent of ion flux through the expressed EAG channels but 
depends on the position of the channel voltage sensor domain (Hegle et al., 2006).  
VGSCs are present in THP-1 macrophages (Carrithers et al., 2009), rat cortical 
astrocytes (Pappalardo et al., 2014b) and microglia (Persson et al., 2014), where they 
play a role in [Ca2+]i regulation by collaborating with NCX on the mitochondrial or plasma 
membrane. In human umbilical vein endothelial cells, Ca2+ influx through NCX is 
required for VEGF-induced ERK1/2 activation, which requires Na+ carried by VGSCs 
(Andrikopoulos et al., 2011a; Andrikopoulos et al., 2011b). In mouse cardiomyocytes, INa 
potentiates Ca2+ influx in wildtype but not NCX-knockout mice (Larbig et al., 2010). It is 
noteworthy that the mode of action of NCX is Vm-dependent (Blaustein & Lederer, 1999): 
when the Vm is more depolarised than the Vrev of NCX, the exchanger works in its 
reverse mode, importing Ca2+. Therefore, whether or not VGSCs potentiate NCX activity 
and then causes an increase of [Ca2+]i in these cells should be studied in the future. 
 
6.4 Vm and the small GTPases 
Work presented in this Thesis examined the possible underlying mechanism by 




proportion of cells with lamellipodia in NS-1619- and TTX-treated MDA-MB-231 cells 
was reduced; the cells had a less elongated morphology after treatment with either of 
the drugs, suggesting Vm hyperpolarisation causes alterations in cytoskeletal 
components (Section 4.2.9). Active Rac1 at cell leading edge was reduced to a similar 
degree by TTX (30 μM) and NS-1619 (1 μM) treatment (Section 4.2.11). Therefore, the 
results suggest a functional role for the depolarised Vm in increasing active Rac1 levels 
at the leading edge. However, whether this is due to the redistribution of active Rac1 in 
the cell body, or increased Rac1 activation at cell leading edge is not clear. Future 
experiments should examine the protein level of total Rac1 and active Rac1 upon Vm 
depolarisation.  
The relationship between VGSC activity and the small GTPase Rac1 was recently 
investigated in microglia, where VGSCs increase [Ca2+]i via NCX and subsequently 
activate ERK and Rac1, which leads to migration in an ATP-dependent manner 
(Persson et al., 2014). Since the [Ca2+]i does not change after Vm hyperpolarisation or 
blocking VGSCs in MDA-MB-231 cells (Section 0), the activation of Rac1 may be 
dependent on the depolarised Vm per se.  
A depolarised Vm can activate small GTPases in both a Ca2+-dependent and 
independent manner. For example, in mouse cortical neurones, Vm depolarisation 
activates Ras and Rap1 via PKA and calmodulin, which subsequently induces ERK 
activation (Baldassa et al., 2003). Similarly, Vm depolarisation in PC12 cells induces c-
fos expression via PKA and MAPK, and the process requires the Ca2+-sensitive proline-
rich tyrosine kinase 2 (Park et al., 2000). In rat caudal arterial smooth muscle cells, the 
depolarised Vm activates ROCK and downstream MLCK in a VGCC- dependent manner 
and ultimately leads to muscle contraction (Mita et al., 2002; Mita et al., 2013). On the 
other hand, in LLC-PK1 kidney tubule epithelial cells, Vm depolarisation induces MLC 
phosphorylation via a Rho- and ROCK-dependent but Ca2+-independent pathway 




GEFs upon Vm depolarisation (Waheed et al., 2010). More recently, a study has 
demonstrated that Vm depolarisation enhances phosphatidylserine and K-Ras 
nanoclustering in baby hamster kidney cells, and K-Ras nanoclustering upon Vm 
depolarisation activates MAPK signalling (Zhou et al., 2015). Taken together, 
depolarised Vm is emerging as a functional signal in activating small GTPases. These 
activated small GTPases can then increase the assembly of cytoskeletal components, or 
promote the MAPK signalling pathway, which controls key cellular behaviours including 
proliferation, differentiation and development (Shaul & Seger, 2007). 
Interestingly, Nav1.5 activity activates Rap1B in SW620 cells (House et al., 2015). 
Given the capability of a depolarised Vm in activating small GTPases, future experiments 
should explore whether the activation of Rap1B is due to the Vm-depolarising role of 
Nav1.5 in SW620 cells. In order to fully understand the Vm-dependent small GTPase 
activation pathways in cancer cells, future experiments should also investigate the up-
stream effectors of Rac1 that lead to its activation, such as GEFs, upon Vm 
depolarisation. Moreover, since the activation of small GTPases may increase cancer 
malignancy by promoting cancer cell migration/invasion (Sahai & Marshall, 2002; 
Downward, 2003; Yamazaki et al., 2005), how VGSCs/Vm regulate other small GTPases 
in cancer cells should be further examined. Recently, it was reported that the Nav1.5 
level in MDA-MB-231 cells positively correlates to that of RhoA (Dulong et al., 2014). In 
the future, one may expect that the relationships between VGSC/Vm and other cancer-
related small GTPases such as Rab (Cheng et al., 2004), Ras (von Lintig et al., 2000; 
Eckert et al., 2004) and Arf (Hashimoto et al., 2004) will be revealed. 
 
6.5 The roles of VGSCs in cancer cells: an updated view 
In MDA-MB-231 cells, the Nav1.5-Vm-Rac1 signalling axis fits well in a previously 
proposed model that shows Nav1.5 potentiates the phosphorylation of src kinase, 




phosphorylation by increasing Rac1 activity (Servitja et al., 2003), and active Rac1 can 
potentiate cortactin phosphorylation (Head et al., 2003), which ultimately facilitates 
lamellipodia formation by activating the Arp2/3 complex (Miki et al., 1998; Krueger et al., 
2003). 
Together with other previously published data, more detail showing the 
downstream signals initiated by VGSC activity has been revealed (Figure 6.1). In Mat-
LyLu PCa and MDA-MB-231 cells, Na+ influx through Nav1.7 or Nav1.5 activates PKA, 
which consequently increases Nav1.7/Nav1.5 mRNA level and increases the trafficking of 
VGSC α subunit protein to the plasma membrane (Brackenbury & Djamgoz, 2006; 
Chioni et al., 2010). Additionally, Na+ influx carried by Nav1.5 allosterically potentiates the 
activity of NHE1 in MDA-MB-231 cells, which leads to an acidic extracellular 
environment, favouring the pH-dependent proteolytic activity of cysteine cathepsins B 
and S (Gillet et al., 2009; Brisson et al., 2011; Brisson et al., 2013).  
Moreover, Nav1.5 positively regulates the expression of the metastasis-promoting 
CD44 protein in MDA-MB-231 and SW620 cells (House et al., 2015; Nelson et al., 
2015b), which may lead to the activation of src kinase (Bourguignon et al., 2001; Lee et 
al., 2008). Given that CD44 promotes invasion by up-regulating the cortactin mRNA level 
(Hill et al., 2006), taken together, these data suggest that the CD44-src-cortactin axis is 
regulated by Nav1.5 in cancer cells.  
In BCa cell lines, the expression of VGSCs appears to be associated with ER 
status: VGSCs are expressed in ER— MDA-MB-231 cells but not in ER+ MCF-7 cells. 
Interestingly, down-regulation of ER in MCF-7 cells induced functional expression of 
VGSCs, likely Nav1.5 (Section 3.2.7) (Mohammed et al., 2015).  Although microarray 
data show that Nav1.5 mRNA levels do not correlate with ER status in BCa patient 
samples (Yang et al., 2012), ER down-regulation may increase functional channel 
activity and/or channel trafficking to plasma membrane of BCa cells, independent of 









Figure 6.1. The roles of voltage-gated Na+ channels in different cancer cells.  
In MDA-MB-231 cells, Nav1.5 carries Na+ influx, which depolarises the Vm, increasing 
Rac1 activity (Section 4.2.11). VGSC activity also activates src kinase (Brisson et al., 
2013). Rac1 and src kinase control cytoskeletal modification by regulating the Arp2/3 
complex and phosphorylation of cortactin and cofilin (Pollard, 2007; Stock & Schwab, 
2015). Nav1.5 positively regulates the expression of CD44 (Nelson et al., 2015b), which 
may lead to src activation (Lee et al., 2008). Na+ also increases H+ efflux through NHE1, 
which enhances cathepsin protease activity (Brisson et al., 2011; Brisson et al., 2013; 
Pardo & Stuhmer, 2014). In SW620 colon cancer cells, Nav1.5 transcriptionally up-
regulates invasion-related genes via an ERK signalling pathway (Schwab et al., 2012; 
House et al., 2015; Roger et al., 2015). In MDA-MB-231 and Mat-LyLu prostate cells, 
Na+ influx potentiates VGSC synthesis at transcription level and increases VGSC 
trafficking to the plasma membrane in a PKA-dependent manner (Brackenbury & 
Djamgoz, 2006; Chioni et al., 2010). In addition, in MDA-MB-231 cells, ER down-
regulation induces functional Nav1.5 expression (Section 3.2.7). The auxiliary β1 subunit 
increases cancer cell process outgrowth via fyn kinase (Nelson et al., 2014). β1 also 
increases INa density in MDA-MB-231 cells (Chioni et al., 2009). Red lines indicate the 





In SW620 colon cancer cells, Nav1.5 activity leads to persistent MAPK activation in 
a Rap1-dependent manner (House et al., 2015), and it also transcriptionally activates the 
expression of invasion-related genes via an ERK/c-Jun pathway (House et al., 2010; 
House et al., 2015). Finally, the auxiliary β1 subunit can potentiate Na+ influx through 
Nav1.5 in MDA-MB-231 cells (Chioni et al., 2009), and can also facilitate neurite-like 
process outgrowth on BCa cells in vitro in a fyn kinase-dependent manner, where Na+ 
conductance through the α subunits is also required (Nelson et al., 2014). In conclusion, 
a number of models have shown distinct downstream signalling pathways initiated by 
VGSCs in different cancer cells. Future studies should investigate whether these 
mechanisms are applicable to all cancers where VGSCs are present, or whether they 
are dependent on the cancer type or VGSC isoform. 
 
6.6 Na+ and tumourigenesis  
In Xenopus laevis, Na+ accumulation appears in regions where cells over-
proliferate (Lobikin et al., 2012). High [Na+]i correlates with tumourigenesis in mammalian 
cell types (Cameron et al., 1980; Pool et al., 1981; Sparks et al., 1983). Therefore, this 
study also investigated whether VGSCs regulate [Na+]i in MDA-MB-231 cells. TTX and 
Nav1.5-shRNA reduced [Na+]i , suggesting that Nav1.5 not only depolarises the Vm but 
also cause Na+ accumulation in MDA-MB-231 cells (Section 0). This result agrees with 
another study using H460 NSCLC cells where Nav1.7 is expressed, showing that 
blocking Nav1.7 using TTX reduces [Na+]i (Campbell et al., 2013). However, how Na+ per 
se contributes to tumourigenesis is less understood. As discussed above, Na+ increases 
MDA-MB-231 cell invasion by allosterically regulating NHE1 (Gillet et al., 2009; Brisson 
et al., 2011; Brisson et al., 2013), but how Na+ regulates other ion channels/transporters 
in cancer is less studied. Increased [Na+]i enhances the activity and cell surface 
expression of Na+-K+ ATPase in rat kidney cortical collecting duct cells and opossum 




Na+ influx via VGSCs may increase [Ca2+]i through NCX in human umbilical vein 
endothelial cells and mouse cardiomyocytes (Larbig et al., 2010; Andrikopoulos et al., 
2011a; Andrikopoulos et al., 2011b). Future work should investigate whether or not 
increased Na+-K+ ATPase and/or NCX activity leads to tumourigenesis.  
 
6.7 Recording INa and Vm on cells from tumour tissue slices  
In spite of all the in vivo evidence showing that suppressing VGSC expression or 
blocking VGSC activity reduces tumour growth and metastasis (Yildirim et al., 2012; 
Driffort et al., 2014; Nelson et al., 2015a; Nelson et al., 2015b), the INa on cells in tumour 
tissue had not been previously studied. By performing whole-cell patch clamp recording 
on tumour tissue slices, this study provides direct evidence showing INa carried by 
VGSCs in primary tumour tissue. The INa characteristics did not differ across the tissue, 
suggesting that VGSCs are homogeneously expressed in orthotopically implanted 
tumours. In vitro, hypoxia increases persistent INa in MDA-MB-231 cells (Djamgoz & 
Onkal, 2013), but VGSC activity in hypoxic regions of tumour tissue was not 
investigated. Future experiments using Tie2-promoter driven GFP in transgenic mice 
(Schlaeger et al., 1997; Motoike et al., 2000), where endothelial cells of vasculature are 
labelled with GFP, in order to study whether or not INa differs in tumour regions with 
various blood vessel densities.  
The Vm recorded ex vivo was more depolarised than in cells cultured in vitro 
(Section 5.2.4), and the Vm across tumour tissue did not vary. It is possible that the Vm of 
cells in tumour tissue is regulated at a tissue-scale via gap junctions (Chernet et al., 
2014; Chernet & Levin, 2014). Cx43 is expressed in MDA-MB-231 cells (Qin et al., 
2002), and future experiments can apply Cx43 blockers such as mefloquine (Juszczak & 
Swiergiel, 2009) on tumour tissue and investigate whether or not inhibiting gap junctional 





6.8 Clinical relevance 
Using an orthotopic mouse model, suppressing Nav1.5 expression using shRNA 
reduced tumour growth (Section 5.2.7) and metastasis to liver, lungs and spleen in mice 
(Nelson et al., 2015b). Moreover, phenytoin, an FDA-approved anticonvulsant, reduces 
tumour growth in mice bearing MDA-MB-231 cells, possibly by increasing cancer cell 
apoptosis (Nelson et al., 2015a). In addition, phenytoin also reduced cancer cell invasion 
and metastasis to liver, lungs and spleen (Nelson et al., 2015a). Additionally, ranolazine, 
another FDA-approved antiarrhythmic, reduces lung metastasis after injection of MDA-
MB-231 cells into the tail vein (Driffort et al., 2014). Similarly, subcutaneously implanted 
Mat-LyLu cells show reduced lung metastasis in rats following local injection with TTX 
(Yildirim et al., 2012). In summary, using various tumour implantation models, inhibiting 
VGSCs results in reduced primary tumour growth and/or metastasis, suggesting the 
significance of repurposing VGSC-targeting antiarrhythmic antiepileptic drugs as a 
potential new cancer treatment. Further studies should investigate combining VGSC-
blocking anti-arrhythmics with chemotherapy, radiation therapy and/or hormone therapy 
during cancer treatment in order to inhibit metastasis. 
 
6.9 Future directions 
Given the data presented in this study, a number of future experiments should be 
done to better illustrate the relationships between VGSC/Vm and tumour progression 
both in vitro and in vivo.  
To begin with, whether VGSCs regulate Vm in other cancer cell types and thereby 
potentiate cancer cell migration by activating Rac1 should be studied. On the other 
hand, Rac1 may not be the only small GTPase that is activated upon Vm depolarisation 
in cancer cells, and the activity of other cancer-related small GTPases should be 
investigated in response to changes in Vm. More importantly, how exactly a depolarised 




One of the limitations of the present study is that Vm was determined in individual 
cells using the whole-cell patch clamp technique. In spite of their limited accuracy, Vm-
sensitive fluorescent indicators are becoming popular in studying tissue-scale, temporal 
and spatial Vm change in vivo (Adams & Levin, 2012). Future studies can combine Vm- 
and Na+-/Ca2+-sensitive fluorophores to investigate dynamics between [Na+]i, Vm and 
[Ca2+]i.  
The effector(s) of increased [Na+]i in tumours is not completely clear. However, 
considering the pro-invasive role of intracellular Na+ and the pro-migratory role of 
depolarised Vm, reducing [Na+]o may have therapeutic value in cancer treatment, since 
replacement of extracellular NaCl with NMDG both hyperpolarises the Vm and reduces 
[Na+]i. Future experiments should test this hypothesis both in vitro and in vivo. 
Polyoma middle T oncoprotein-expressing (PyMT) mice can develop BCa and 
lung-metastasis spontaneously (Lin et al., 2003; Fantozzi & Christofori, 2006). 
Interestingly, the BCa progression in PyMT mice accompanies loss of ER (Lin et al., 
2003). Given that suppressing ER expression leads to functional VGSC expression in 
MCF-7 cells (Section 3.2.7), the PyMT mouse is an ideal model to investigate how 
VGSCs are up-regulated during cancer progression.  
In conclusion, given the significance of VGSC/Na+/depolarised Vm in promoting 
cancer progression both in vitro and in vivo, one may expect further elucidation of the 
VGSC-dependent metastasis pathways, as well as their potential exploration as 
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